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Abstract 
 
Pharmaceutical drugs are widely used, yet their consequences and longevity in the 
environment following consumption are rarely discussed. Knowledge on the fate of 
these compounds within different matrices in the environment is inadequate and needs 
to be further improved in order to determine their concentrations and associated risks.  
The determination and quantification of these compounds in water samples is already 
widely conducted using filtration, solid-phase extraction (SPE) and nitrogen blow-down 
followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). However, 
a method with a high degree of accuracy and reproducibility is yet to be obtained for 
sediment samples due to matrix complexity.  Using strategically planned spot-sampling 
and the development of a new and optimized determination and quantification method, 
the analysis of sediments from the River Ouse (Sussex, UK) and River Medway (Kent, 
UK), allowed for the simultaneous quantification of nine target pharmaceutical 
compounds using ultrasonication followed by SPE, nitrogen blow-down and LC-
MS/MS. Variables investigated were extraction method, solvent, sample mass and 
clean-up procedure; these allowed for the optimization of method development. 
Following these, spatial and temporal reports were concluded. Monitoring the River 
Medway between December 2009 and June 2010 showed stable yet high levels of 
pharmaceuticals in comparison to studies conducted globally. Concentrations increased 
the further through the year with June 2009 being the overall highest.  
The method was further applied to biological matrices with excellent results. The 
determination of pharmaceutical compounds was extended to environmental samples 
from China as part of a collaboration project. It is expected that the method will be 
successfully used for future experimentation and analysis. Diclofenac and meclofenamic 
acid is overall the compound with the highest concentrations, compared to 
sulfamethaxazole and thioridazine which are the lowest.  
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Chapter 1 - Pharmaceuticals in the Aquatic Environment 
 
1.1 Introduction 
When attempting to understand the effects of pollution, it is critical to have an 
understanding of both the pathways through which contaminants enter the system, and 
their subsequent lifecycle. To do this accurate measurements of the presence of 
contaminants in the environment are needed. This work will focus on attempting to 
develop a novel method for measuring a group of pollutants known as Pharmaceutical 
and Personal Care Products (PPCPs), which have until now proven difficult to measure. 
Consequently, it is unsure how much is known about current contamination levels and 
the long-term impacts of this pollutant. Due to the large quantity of PPCPs in daily use 
and their unknown lifecycle, current contamination levels may be significant, and may 
potentially cause unforeseen and widespread impacts to future society. 
For the purpose of this thesis, the term pollution will specifically refer to a group of 
selected PPCPs in aquatic ecosystems. PPCPs are continuously released into the 
environment at an unknown rate by anthropogenic activities. Although little is known 
about the long-term impacts of these compounds, evidence indicates that they may have 
serious impacts on exposed organisms, leading to sex change, organ failure and cancer 
(Daughton and Ternes, 1999). Data concerning accumulation rate, and lifetime of 
PPCPs in the environment is available, but rarely discussed. Consequently, further 
investigation into this area is needed to determine the potential long-term threat to 
human and ecological health.   
Currently, no method exists to retrieve multiple PPCP compounds from sediment 
matrices with a high degree of accuracy. Simultaneous recovery of multiple PPCPs is 
needed due to the vast number of different compounds released in to the environment 
(>100,000 [(Giger et al., 2002)]), which makes non-simultaneous methods  both time-
intensive and costly (Zhang and Zhou, 2007, Zhou et al., 2009, Besse and Garric, 2008). 
Selecting particular compounds out of such a high number available, will give an 
insight into the wider significance through dependent sampling. Compounds will be 
selected based on their (assumed) environmental abundance, use and consumption, 
subsequent release into the environment, and coverage in recent literature and related 
investigations. The compounds selected will represent specific groups of compounds. It 
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will be assumed that the similar compounds out of the same class, will behave in a 
similar way and therefore logical assumptions can be made about wider importance. 
Such issues have made accurately gauging PPCP pollution levels in the environment 
difficult (Sanchez-Prado et al., 2010). A useful approach to overcome such issues may 
be through the use of trial and error procedures during method development to 
determine the accurate simultaneous recovery (Angus et al., 1998). 
During method development, the possibility of low concentrations of PPCPs in samples 
must not be mistaken for poor recoveries. Variability in the results will primarily result 
from experimental methodology, not from the sample, and will therefore maximise 
accurate measuring capabilities. It is important to not mistake low recoveries for poor 
analytical methods (high variability), because detecting this correctly is not easy. 
Calculating precision and bias of results will help to identify these factors. To ensure 
that a poor recovery is not mistaken by a low concentration of target PPCPs in the solid 
matrix, a high initial concentration is key in limiting variance in results from sample 
variations. Methods will test a sample matrix where there is a predicted high initial 
concentration. 
It is important to understand the entries and pathways of target PPCPs into the 
environment. These are discussed in more detail with supporting diagrams in the 
literature review. They indicate their introduction, pathways through and lifecycle of 
PPCPs in an ecosystem. 
The compounds selected for testing will be carefully chosen from those which have 
previously come under investigation in the field, in order to maximise analysis and 
background information on the compounds, and provide a basis for comparison of 
recovery results. The choice of compounds and the number to be analysed 
simultaneously is stated in assessment of relevant literature.  
A busy, heavily polluted and actively industrialised sampling location will be 
considered for analysis to meet the necessary criterion. For the purpose of this study a 
stretch of river water meeting those criteria has been chosen and which is also easily 
accessible and in constant use. The importance of using a ‘busy’ river or estuary is that 
it has a high boat and vessel concentration and thus high sewage outflow (which is a 
common source of PPCPs in the aquatic environments) should subsequently maximise 
the chances of attaining high PPCP concentrations in the sediment on the river bed; this 
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point is discussed in more detail during literature analysis. Another important 
consideration is that there are both Water Treatment Works (WTWs) and Sewage 
Treatment Works (STWs) along the banks of this river, and so an increased likelihood 
that chosen compounds will be present in the sampling area. This minimises the chance 
of low concentrations being mistaken by low recovery. This is of course secondary to 
the method development process, where a standard (compound) only solution will be 
tested for recovery. A high compound concentration is essential for testing the solid 
sample to minimise the likelihood of aforementioned conclusions and to also better 
identify a matrix effect.  
The River Medway in Kent is a busy estuary catering for the South and South East of 
England, as well as being a tributary to the River Thames Estuary, which is highly 
industrialised and in constant use. This is the busiest River and Estuary in the United 
Kingdom, and meets all of the above criteria. It is important to remember that 
concentrations found on analysis may not be representative of other rivers locally. It 
will be used as an insight into concentrations in this stretch of water with the purpose of 
high initial concentration. This estuary also proves to be easily accessible and sampling 
certainly attainable without causing difficult or incurring unnecessary expenses due to 
exposed public perimeters and walkways. A method will be devised and optimised 
using established validation techniques, before being tested under controlled conditions. 
These methods will be applied to samples in the field to determine the quantification 
and deposition of target PPCPs in the environment.  
After initial testing and method development, sampling will be conducted for method 
validation. The sediment samples will also be compared to water samples from 
concentrations in the same locations to assess the relationship between matrices, as the 
concentration of PPCPs in the water column may not relate to the sedimentation in a 
direct way.  
A group of PPCPs will be selected for testing and method development application in 
this investigation which represent different therapeutic classes over a broad range of 
uses. They will possess different chemical attributes and most importantly, are heavily 
prescribed and consumed today. It is important that simultaneous quantification covers 
a broad compound range to maximise its potential relevance and application to other 
samples.  
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Following the development of suitable recovery methods, the analysis of other matrices 
including vegetation and biological samples will be analysed. This will not only give an 
indication of the dynamic behaviour and relationship of such compounds in this 
environment, especially those which have undergone long-term exposure to such 
contaminated environments as in Beausse, but also highlight if the method can be 
applied to different matrices (Beausse, 2004). This will also highlight if the compounds 
are present in these different matrices and in what level of concentrations. The 
possibility of success through a tried and tested method to measure and quantify 
contamination of such pollutants, their unknown environmental impacts are to become 
clearer. It is not definite that a successful method will be identified at this stage; only 
through laboratory experimentation will this become clear.  
Following this introduction and identification of aims and objectives of this research, a 
relevant review of the literature will be given. This literature will be assessed and 
discussed in terms of critically assessing the methods already in place, limitations of 
existing methods, data already collected from relevant studies and other such topics 
such as PPCPs in the media and the law. Then the process of method development will 
begin, eliminating and drawing in analytical methods suitable for this simultaneous 
quantification of pharmaceutical compounds. Method validation and application will 
follow, leading to conclusions of the research and intentions for future work.  
 
1.2 Aims and Objectives 
1.2.1 Aim 1 – Pharmaceutical analysis and monitoring 
This work will attempt to improve existing methods in novel ways currently used for 
the analysis of PPCPs and successfully apply this to sediment samples with good 
recoveries and high reproducibility. Current methods have either a low recovery and 
high variability, or high recovery and either high or unstated variability for the 
quantification of pharmaceuticals in sediment, giving inaccurate conclusions. Therefore 
an improved method is to be developed. Investigations will be conducted using 
microwave-assisted extraction (MAE), ultrasonication (U), solid phase extraction (SPE) 
and liquid chromatography tandem-mass spectrometry (LC-MS/MS) to simultaneously 
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determine the concentrations of nine selected pharmaceuticals from a range of sediment 
samples for environmental analysis and quantification.  
This method will have an increased recovery and decreased variability of the selected 
pharmaceuticals in comparison to existing methods currently used in literature. 
Once established, it will be used to determine the levels of pharmaceuticals in UK river 
sediment; the River Ouse, East Sussex. Several hypotheses will arise regarding the 
targeted chemical compounds, in particular which will be found in high and low 
concentrations and their effects on aquatic life. It is expected that carbamazepine (Carb), 
diclofenac (Diclo) and meclofenamic acid (Meclo) will be found in high concentrations 
throughout the samples due to the large amounts discharged into the aquatic 
environment and previous high quantification from studies. The PPCPs investigated 
also enter a river system through sewage treatment works (STWs), water treatment 
works (WTWs) and runoff from agricultural land.  
1.2.1.1 Objective 1 – Extraction and clean-up method 
To identify the best extraction and clean-up method of pharmaceutical compounds from 
the sample matrix. This will elucidate the solvent used during extraction which achieves 
the greatest recovery of the target compounds, along with sample size, extraction 
conditions and clean-up columns.  
1.2.1.2 Objective 2 – LC-MS/MS method 
To develop and refine a confident LC-MS/MS method for the simultaneous extraction, 
separation and quantitative analysis of a group of nine pharmaceutical compounds from 
river sediment samples.  
1.2.1.3 Objective 3 – Environmental samples 
To use the new method developed in Objective 1 and 2 to quantify the concentration of 
the target pharmaceuticals in the Rivers Ouse (Sussex, UK) and Medway (Kent, UK), 
and to determine their concentrations spatially across the sample sites identified. The 
new method will also be used to conduct a temporal and spatial variability report of 
pharmaceuticals from the River Medway, Kent, UK, and finally be applied to samples 
from China for analysis. 
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1.2.2 Aim 2 – Assessing the quality of analysis 
The second aim of this thesis is to maximize the precision and reliability of the 
developed method in Aim 1, with a reduced variability and increased recovery. As with 
any analytical technique, data and sample analysis at any stage is open to a degree of 
variability. It is essential that this is minimized and so a set of experiments were 
designed to do so.  
Considering the high number of variables used for the developed method, there is 
potentially a high degree of variability in results obtained from analysis. Quantitative 
results are not statistically significant unless they are accompanied by calculated errors 
associated with the data. 
During this research a number of variables illustrating these changes were demonstrated 
and significant conclusions can be drawn from observations identified. With this aim 
complete, it can confidently be concluded that and data obtained as a result is to the 
highest degree of accuracy possible.  
1.2.2.1 Objective 4 – Precision and bias of sampling 
To identify the precision of sample recovery through triplicate sampling, including 
inter- and intra-day variability of the LC-MS/MS, and to show variability of bias on 
increasing number of replicates.  
1.2.2.2 Objective 5 –  Analysis of blank samples 
To analyse the concentration of target compounds identified in blank samples and if this 
has any significant effect on concentration of target compounds in samples, and to 
identify background concentration of target compounds. 
1.2.2.3 Objective 6 – Sample storage 
Identify the best possible way to store samples to identify any significant difference.   
1.2.2.4 Objective 7 – Matrix effect 
To determine the matrix effect on sample analysis. Conclude the most suitable 
extraction method as a result.  
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1.2.3 Aim 3 – Applications of the developed method 
Using the analytical method developed in Aim 1 to consider applications to a wider 
variety of sample matrices. Aside from simultaneously determining the quantification of 
PPCPs from sediment samples, it will be beneficial to investigate the application of this 
method to water samples and a variety of different sample matrices, both biological and 
vegetation. This will provide an insight into the suitability of the developed method to a 
wider range of environmental samples, without jeopardizing the recovery and reliability 
of the method.  
1.2.3.1 Objective 8 – Biological samples 
Obtain a variety of biological samples from the River Medway, UK, and determine 
recovery of pharmaceuticals following spiking experiments.  
1.2.3.2 Objective 9 – Water samples 
Analyse water samples from the River Medway, UK, for target pharmaceutical 
compounds and determine the successful application of the developed method used for 
sediment sample analysis. 
1.2.3.3 Objective 10 – Geochemistry of contaminants 
Determine pH, salinity (‰) and dissolved Oxygen (DO) content from water samples 
used in Objective 22 to identify a correlation between any of the nine selected 
pharmaceutical compound concentrations.  
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1.3 Summary  
To summarise, this work will aim to; 
 Develop an analytical method for the determination of a select group of PPCP 
compounds in river sediment. This method aims to have good high recoveries 
and low variability.  
 Apply this tried and tested method to real environmental sediment samples.  
 Use the same method to analyse water samples from the same location.  
 Test this method on other environmental sample matrices; vegetation and 
biological.  
 Test method variables such as sample storage, analysis of a blank and the matrix 
effect.  
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Chapter 2 - Literature Review 
 
2.1  Introduction 
Over the last twenty years interest in the environmental impact of pharmaceutical and 
personal care products (PPCPs) has greatly increased. This is apparent in an increased 
number of studies relating to such compounds. Publications have attempted to better 
understand their origin, fate and impact, but the need remains for sound and reliable 
method for the detection and quantification of PPCPs, with improved sensitivity, 
reproducibility and ruggedness. This literature review summarises the current 
understanding into the environmental impacts of PPCPs, but more importantly existing 
methods for quantification following detection, assessing their success and reliability. 
This will give insight into further development of a simultaneous and reliable method 
for this investigation of PPCP compounds in river sediments.  
The compounds under investigation in this work are propanolol (Pro), sulfamethaxazole 
(Sulf), mebeverine (Meb), thioridazine (Thio), carbamezapine (Carb), tamoxifen 
(Tamo), indomethacine (Indo), diclofenac (Diclo), meclofenamic acid (Meclo). They 
were chosen because they are representative of PPCP classes (discussed later), and their 
documented abundance in the environment, rendering it relatively easy to collect 
accurate data with a new method.  
 
2.2  Scientific Reviews in Literature 
There have been countless attempts to consolidate and conclude research into PPCPs. 
However, popular topics discussed, scientific laboratory procedures, results and 
conclusions are so broad, that authors can only make those; reviews. Selected reviews in 
ascending date order follow, and their key conclusions are discussed.  
 
There have been many reviews concerning the identification, source, fate and toxicity of 
PPCPs in the environment across recent decades. With each report there is an improved 
understanding of PPCPs in general, and in most cases, an increased environmental 
assessment which in turn increases a global understanding of, and builds on collected 
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data and information. There is also on-going improvement into methods relating to the 
detection and quantification of PPCPs. Later reviews still cover the same topics as 
earlier examples, highlighting widely unaddressed issues, not through lack of trials. 
This poses a big problem; that there is still much speculation as well as the 
aforementioned unknowns regarding PPCPs. 
 
An older review by Halling-Sorensen et al. concentrate on pharmaceutical occurrence, 
fate and effects in the environment (Halling-Sorensen et al., 1998). Although this 
publication is now a little dated, it deems no less important and still provides a good and 
interesting insight into the field of research in question as the issues remain 
unaddressed. At the time, pharmaceutical research was a newly popular and interesting 
focus for investigation. They highlight exposure routes into the ecosystem, which 
covers both aquatic and terrestrial environments (Figure 1). It gives insight into what 
was then (and still current) legislation of the topic as well as knowledge of the 
occurrence, fate and environmental effects. They also highlight the still important issue 
of determining the exact sources of such contaminants, as if the output from the source 
can be minimised, eventual concentration will be lowered. The report gives awareness 
into toxic effects of contaminants to micro-organisms, phytoplankton, plants, 
crustaceans and insects, but the information is not relevant as no compound data were 
reported.  
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Figure 1 Anticipated exposure routes of both veterinary and human medicinal 
substances in the environment (Halling-Sorensen et al., 1998). 
 
Giger et al.highlight that over 100,000 different chemical compounds are recorded in 
the Europeon Union (EU) alone, with over a third released in quantities over one tonne, 
which is significantly high (Giger et al., 2002). Pharmaceutical compounds are a major 
concern as they are presenting themselves as emerging, persistent contaminants. This is 
becoming an issue not only in scientific research, but also a public concern as reported 
by Donn et al. in The Associated Press news article;  
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“A recent poll indicated millions of consumers were ‘very’ concerned that their water 
supplies may be contaminated with trace amounts of pharmaceuticals” (Donn et al., 
2008). 
This comes under scrutiny due to a lack of statistics to support the claims, as with most 
media attention in this research area attracts, discussed in more detail later.  
 
Once again highlighting concerns of pharmaceutical residues in the aquatic 
environment, is a review by Heberer (Heberer, 2002). He calls upon papers which have 
recognised the importance of issues raised with concern to this environment, including 
Stan and Herber and Halling-Sorensen et al.(Stan and Heberer, 1997, Halling-Sorensen 
et al., 1998) They discuss how unused medication being disposed of through the water 
and sewage system being of little importance in comparison to the wider and complex 
issue of excretion through the human body (through the consumption of medication) 
due to the compounds not being fully broken down and eliminated. Following 
excretion, Zweiner et al.  also highlight how pharmaceutical substances are not 
completely eliminated during WWT due to inefficient techniques, and remain in the 
environment as they are not biodegradable (Zweiner. et al., 2000). This leads to 
concerns regarding bioaccumulation. This and other negative knock on effects pose 
huge implications, discussed later. Heberer has his own diagram illustrating possible 
pathways and sources of pharmaceutical compounds into an aquatic environment 
(Figure 2). He also evaluates the occurrence of chosen PPCPs in different aquatic 
environments, concluding that compounds are not only widespread, but also abundant, 
which raises cause for further concern. In particular, those detected at trace level 
concentrations in drinking water pose a concern, as only a few are removed completely. 
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Figure 2 Scheme showing possible sources and pathways for the occurrence of 
pharmaceutical residues in the aquatic environment (Heberer, 2002).  
 
In 2004, Beausse published a review of target drugs in solid matrices regarding their 
determination, occurrence and properties (Beausse, 2004). Beausse immediately 
highlighted knowledge that a considerate quantity of an original substrate leaves the 
body untouched, and that recent developments have made it easier for compounds to be 
quantified to a higher degree, to parts per billion (ppb) concentration level. This gives a 
better insight into environmental concern due to increased accuracy. He also addressed 
the complex issue of how it is difficult to determine what happens in solid matrices, 
which is what the article focuses on. This is just one example of the documentation of 
the complexity of investigation a solid rather than an aqueous sample matrix, and the 
problems faced in doing so. 
 
Turning focus to aqueous samples, Doerr-MacEwen and Haight gave a report on the 
effects of human PPCPs, as opposed to those used in agriculture or on animals for 
veterinary uses (Doerr-MacEwen and Haight, 2006). A figure by Doerr-MacEwen and 
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Haight show routes through which human pharmaceuticals reach water and groundwater 
(Figure 3). There still remains a high degree of uncertainty over the matter of the effects 
of human PPCPs, as Cleuvers discusses (Cleuvers, 2003). Focusing on human PPCPs 
draws on a reader’s emotional connection to the subject of which importance is 
discussed later. They identify the potential threat to aquatic organisms as well as human 
health and how they are poorly understood. A different approach concerning expert 
stakeholders’ adds another dimension to the complex issue; in total they consider 27 
different opinions from the government, academia and pharmaceutical companies and 
give a range of assessments into PPCPs. Although those interviewed identified a 
concern for human health, they were even more concerned with the effect on organisms 
in the aquatic environment. This is possibly due to magnification through 
bioaccumulation through the food chain, but this is not stated. While the interviewees 
remain anonymous, it gives insight into a broad professional view on the issue. It was 
reported that the subjects were unanimous in believing a combination of strategies 
including improved water treatment strategies, education into the issue and a secondary 
wastewater treatment plant (WWTP) system, is the answer to reducing the impacts of 
PPCPs. However, this is not easily achievable, and interviewees may have had their 
opinions biased from the interviewer from question phrasing and direction, leaving 
them no room for their own opinions. These may have been given, but they are most 
certainly not portrayed in the review.  
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Figure 3 Some routes through which human pharmaceuticals enter surface water and 
groundwater. The main route of entry is through WWTPs after consumption and 
excretion (Doerr-MacEwen and Haight, 2006). 
 
Although not proven to pose a threat to human health Cunningham et al. there have 
been many studies proving that pharmaceutical products contribute reports of high 
toxicity levels, as seen in Muñoz’s findings (Cunningham et al., 2009, Muñoz et al., 
2008). It is important to note the naivety of the general public to this growing issue, 
despite broad sweeping statements as mentioned previously. When asked in a study 
what they do with unused or expired medication, the answer was that they are disposed 
of in rubbish, or more concerning, washed down the sink or flushed down the toilet 
(Kotchen et al., 2009). It seems a greater need for education and increased knowledge to 
the general public would be beneficial in reducing concentration of PPCPs in the 
environment.  
 
A recent review by Caliman and Gavrilescu summarised PPCPs and endocrine 
disrupting chemicals[/agents] (EDCs) in the environment (Caliman and Gavrilescu, 
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2009b). Focusing on PPCPs for the sake of this research project, they interestingly 
report that many were unknown in terms of their impact on natural ecosystems. Many of 
these substances are yet to be tested for negative environmental properties, as Ingerslev 
et al. discuss (Ingerslev et al., 2003). It is important to remember that these chemicals 
are synthetic in nature which makes them less biodegradable, and are used intensively in 
large volumes, further augmenting the problem. Their inability to be easily biodegraded, 
also raises concerns as this will lead to accumulation in any environment. This bio-
accumulation is a separate issue and discussed later. Due to a lack of global regulation, 
it is difficult to determine widespread and long term impact of PPCPs. 
  
2.3  Media Attention 
It is already known that the fate of pharmaceuticals in the environment has attracted 
media attention. Ghosh wrote a short article on the negative impact of antibiotics (and 
PPCPs) on the environment (Ghosh, 2008). He supports Petrovic et al.’s argument that 
the fate of these antibiotic residues on entering the environment is widely unknown, and 
raises cause for concern (Petrovic et al., 2005). In 2009, the U.S.News & World Report 
released a press article written by Donn concerning the release of pharmaceutical drugs 
into water in the United States, and claim the release of at least 271 million pounds 
(Donn, 2009). This of course is going to cause concern with the general public, but 
there is no indication of timescale of this statistic or its reliability, jeopardising the 
validity of the claim. Donn soon points out that consumers (the general public) are the 
biggest contributors to the contamination in question and so it lies in their hands to 
reduce this shocking figure. He talks of researchers and what they have found, but 
includes no direct reference links and so his claims go unsupported and untraced. There 
are no statistics or referenced material to support his writing and so is only assumed to 
be correct.  
In February 2010, local newspaper Kent Messenger reported a serious environmental 
incident concerning the target sampling location under investigation. Alan Watkins 
(journalist), reported (Watkins, 2010). With this in mind, results around and after this 
time will pose particular interest; 
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“Medway faces a major environmental crisis after millions of gallons of sewage was 
discovered leaking for several days prior to discovery, due to a main sewage pipe 
rupture. The area is that of natural conservation, and as a result the Environment 
Agency will declare a Category One disaster. This is the second time this has happened, 
and evidence is currently being collected” 
 
It can be concluded that the presence of PPCPs and related issues in the media increases 
public awareness, which in turn leads to an increased public concern and demand for a 
change in the industry, namely the decrease of PPCPs in the natural environment. The 
problem is, that this is a fashionable media trend, and there will soon be something else 
which takes its place and becomes popular with the public. At this time, PPCP attention 
will be abandoned, almost overnight.  
 
2.4  Pharmaceuticals in the aquatic environment; environmental considerations 
There has been a lot of investigation into substrates of this nature in aquatic 
environments. Reports globally include those from Spain, Italy, China, USA, UK, 
Canada and Germany, to name a few which implies the magnitude of the research topic 
in hand. Some of these reports are detailed below.  
 
There are many ways in which PPCPs enter the natural environment, highlighted again 
by Caliman and Gavrilescu (2003), and in Figure 1, Figure 2 and Figure 3; 
1. Direct and indirect effluents from wastewater treatment plants (WWTPs), 
hospitals and pharmaceutical manufacturing 
2. Direct and indirect leakage from septic tanks or landfill sites 
3. Direct and indirect surface water runoff 
4. Direct discharge into waters.  
 
Human pharmaceuticals are added to the environment (be it aquatic or terrestrial) 
through consumption followed by excretion (Farré et al., 2008), often as different 
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forms; a mixture of, unchanged or conjured with other chemicals (Rang and Dale, 
1991). These authors also state that between 30 to 90% of known prescribed doses to 
both humans and animals is excreted in urine, still as an active and unchanged 
substance. If this remains after WTW’s, there is a big problem on our hands due to 
subsequent environmental effects. It is very common for such compounds to be used in 
farming, in particular fisheries, mainly to promote growth. Authors discuss how up to 
80% of drugs used in such aquaculture end up in the environment, and are often also 
found in sediment accumulated beneath the farms. Other authors also found antibiotics 
in the sediment beneath fish farms, including Björklund et al. (H.V. Björklund et al., 
1991).  
 
Highlighting the environmental risk of PPCPs in both aquatic and solid environments, 
Hernando et al. conclude that there is a high risk in particular to sewage treatment plant 
(STP) effluents for many identified target compounds, as well as in surface waters and 
sediments, whereas those not in question such as steroids, pose a low risk level 
(Hernando et al., 2006). They report that further assessment combined with longer-term 
exposure is required for a more accurate assessment and better risk considerations.  
 
Using Oasis HLB (Solid Phase Extraction) SPE cartridges and Methanol as the solvent, 
followed by GC-MS, Weigel et al. contributed a paper regarding the simultaneous 
determination of pharmaceuticals from water samples including Prop, Carb and Diclo 
(Weigel et al., 2004). Seven different SPE sorbents were investigated, with a 70 to 
100% recovery for some. Oasis HLB was chosen to continue the method development 
process further and on combination with GC-MS for analysis, gave good results of even 
trace amounts. In particular, Diclo was found to have a relative recovery rate of 87%, 
with a relative standard deviation (RSD) and regression coefficient (r
2
) value of 1 
during experimental stages. On the testing of Oasis HLB cartridges, Carb, Pro and Diclo 
had relative recovery rates of 101, 98 and 102% respectively, with very good variability 
(RSD) of 2, 4 and 2 (again, respectively). During the analysis of real surface water 
samples, 7 different locations were sampled, with concentrations between 26 and 67 
ng/l. No indication of variability was noted with these results, so it is assumed that they 
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are as good as previously documented in laboratorial trials without real environmental 
samples.  
 
The assessment of PPCPs in WWTPs is not a new approach when addressing the 
subject. When Lee et al. tested for pharmaceuticals in sewage effluent samples, they 
were first able to assess similar studies (Lee et al., 2003). They focused on the 
methodology and stability of such methodologies (ie their variability and recovery 
rates). Employing the use of Oasis HLB SPE cartridges, 11 pharmaceuticals (including 
diclo and indo) were subject to recovery testing, which gave results over 80%, which 
supports other studies in the field aforementioned, after being analysed using GC-MS. 
They also tested the stability of such samples in storage conditions at 4°C for a week, 
and results concluded that over 75% of the known quantity in the samples was 
recovered. For practicality reasons, it is often important for a method to still be 
applicable even if samples have been stored for a period of time, as analysis cannot be 
carried out on site, amongst other reasons researchers commonly face such as machine 
downtime and batch sample processing.  
 
A similar study by Gomez et al. also employed the use of Oasis HLB SPE, but followed 
sample preparation using LC-MS/MS for analysis (Gomez et al., 2006). They were also 
testing water effluent samples, this time for 16 different pharmaceutical compounds 
including carb, indo, diclo and pro. Pharmaceutical recoveries of over 75% were 
recorded, and the matrix effect of these samples assessed. It is known that the LC-
MS/MS signal can be supressed by the matrix of a sample (due to complexities and 
impurities of a matrix), and this is greater in a solid sample as opposed to liquid sample, 
but is still necessary to be considered, as Choi et al. demonstrates (Choi et al., 
2001).There are many reasons for signal suppression in this instance, which Choi et al. 
illustrate, along with Renew & Huang  and Sorensen & Elbaek (Renew and Huang, 
2004, Sorensen and Elbaek, 2005). They state; 
1. Pharmaceuticals can sorb to organic matter making target compounds more 
difficult to detect as the concentration of free pharmaceuticals is lower. This is 
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why remobilization (traditionally using Microwave Assisted Extraction [MAE] 
or ultrasonification [U]) is important. 
2. Other contaminants in the matrix may raise analyte peaks, leaving the real 
concentrations to be underestimated or mistaken as noise.  
3. Contaminants in a solid matrix can reduce the efficiency of ionisation of 
analytes as they can inhibit charged sites on electrospray droplets.  
 
Therefore, importantly, Gomez et al. test for signal suppression, with the majority of 
target compounds showing signal suppression (Gomez et al., 2006). It becomes more 
apparent towards the end of the chromatographic separation, with suppression up to 
91%. This was also noted by Hernando et al., who have extensively investigated such 
matrix effects (Hernando et al., 2004).  Choi et al. have approached this and offer a 
solution to compensate for such effects through the use of internal standards in the 
sample solution (Choi et al., 2001). They investigated the effect of LC separation on 
LC-MS/MS signal response for compounds in a complex (solid) matrix. It was noted 
that signal suppression was given. Comparisons to an internal standard-only sample, 
and relating this to the same level of standard spiked into samples gives a simple and 
effective compensatory calculation to determine loss on analysis through the matrix 
effect. Although timely, the process of identifying a suitable internal standard leads to 
benefits for final results and increases experimental accuracy and confidence in figures.  
  
Gros et al. developed, optimised and validated an offline SPE filtration method 
combined with LC-MS/MS, for the detection of PPCPs in surface waters (Gros et al., 
2006). Recoveries of over 60% were achieved, with a variability of less than 15%.  The 
method would be improved by increasing recovery and decreasing variability through 
further laboratory experimentation using trial and error. This is one of the best examples 
yet of a reliable recovery method. A justifying internal standard (IS) was used for the 
simultaneous determination of a very large number of PPCPs; 29. The internal standard 
is a known quantity of a selected compound spiked to the sample to test the percentage 
recovery obtained following experimental procedure. Ideally, the higher the recovery 
the better. The high number of compounds tested in this investigation makes the 
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recovery and variability even more impressive. These included Pro and Carb which 
were among the most frequently and highly detected compounds. Other compounds 
investigated which are of interest to this study are Diclo, Indo, Meclo, Sulf and 
Phenacetin (Phen). Their method proves to be robust and reproducible, which gives a 
high degree of reliability in a field where such methods have come under high criticism.  
 
2.5  Methods for quantifying PPCPs 
Many methods have already been aforementioned in the previous section when 
assessing PPCPs in water. After conducting research into the field, it appears there is 
one important factor in method development concerning the determination and 
quantification of such substances; simultaneousness. There are many reasons for this, as 
highlighted in research. A paper closely related to my investigations is that of Zhang 
and Zhou who investigated the simultaneous determination of pharmaceutical 
compounds in water (Zhang and Zhou, 2007). Method development often begins by 
selecting a good reagent, followed by a suitable extraction method. As previously 
mentioned, determination of compounds in water is common, as opposed to the 
complexities faced in method development of a more solid (soil) matrix. The early 
experimental stage of this method development began with testing 6 different reagents 
and 12 different solid-phase extraction methods, followed by LC-MS/MS analysis.  
 
Zhang and Zhou concluded that the optimum method for determining simultaneous 
pharmaceutical compounds in water samples, was to use an Oasis HLB SPE cartridge 
using Methanol as the eluting solvent (Zhang and Zhou, 2007). They then used a LC-
MS/MS method for the detection and quantification of target compounds. Their results 
broadly agreed with Liu et al. and Zhang et al. (Liu et al., 2004, Zhang et al., 2006). 
Their method proved successful with high recoveries; over 80% for most 
pharmaceutical compounds, of which 11 were tested. Results showed good recoveries 
and variability for almost all samples in both river water and sewage effluent, however 
none were relevant to this study. Their methods were interesting to note and bear in 
mind for further method development, especially variations around different methods of 
derivatisation (Figure 4).  
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With particular reference and interest to drinking water, Mompelat et al. consider the 
occurrence of PPCPs in this resource (Mompelat et al., 2009). They comment on how 
popular documentation is for wastewater, but less common for drinking water and water 
resources even though drinking water has a more popular interest to the general public. 
Fent et al. are correct when stating that the quantity of PPCPs consumed and released 
into the environment is difficult to identify what is happening between the two; between 
human (or animal) intake and subsequent discharge into the environment (Fent et al., 
2006). To date, there is very little data available for a full assessment for 
pharmaceuticals in drinking water globally and so this review concluded little more than 
that there is simply ‘some threat’ of pharmaceuticals in drinking water and water 
resources. It still remains that there is no rapid or on-site identification and 
quantification of target pharmaceutical compounds. Young offers a solution regarding 
rapidity, although it is still a laboratory-based procedure (Young, 2009). He used Oasis 
hydrophile-lipophile balance (HLB) discs, as consistent with other authors, followed by 
ultra performance liquid chromatography mass spectrometry (UPLC-MS). The HLB 
system is particularly useful to identify surfactants for oil and water emulsification, and 
has been widely used in this type of investigation. The UPLC-MS is a highly 
sophisticated, state of the art analytical instrument which allows the selective and 
sensitive analysis of chemical compounds in a wide range of sample matrices. He 
reported a good success in his method, but did not go into detail of quantities found, 
recovery data or variability. This leads the readers to assume that the method has a high 
recovery and low variability, as one would assume that the method is successful and so 
both of these elements satisfactory. In fact, he proceeds further in the reader’s 
assumptions, and notes significant advantages of the HLB disc format, again supporting 
his method, which includes that the disc rather than the cartridge can be used for the 
extraction of water samples containing a significant amount of particulate matter. This 
is particularly useful when analysing ‘dirty’ samples without the need for prior 
filtration.  
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Figure 4 Schematic diagram of different derivatisation protocols (A – D) for Endocrine 
Disrupting Chemicals (EDC) analysis (Zhang et al., 2006). 
 
Following the relatively simple, low-cost sample collection process, comes the more 
complex part of compound determination and quantification. A mass spectrometry piece 
of equipment is usually employed to determine compounds and then assess their 
quantity, namely GC-MS, or LC-MS/MS. These techniques however pose their own 
disadvantages; 
1. Difficult to use- often require specialist training (incurring further costs) 
2. Time consuming 
3. Very expensive 
4. Need specific procedures for complex samples 
5. Require a large volume of the sample  
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Ternes et al. and Sacher et al. also adopt the use of LC-MS/MS and GC-MS 
(respectively) to detect pharmaceuticals in water samples (Ternes et al., 1998a, Sacher 
et al., 2001). Detection limits were down to 10ng/l in Ternes’ investigations, even for 
organically highly contaminated waters like sewage treatment plant effluents. Recovery 
rates almost exceeded 70% for most of the compounds tested, however the 
determination of some compounds (including Carb) was disturbed by organic 
particulates in the real environmental samples; a seemingly common problem. Table 1 
is a copy of the two compounds of the most interest from Ternes’ 1998a study, where 
recoveries are both high. However the limit of detection (lowest possible detectable 
level) (LOD) is also high, possibly biasing results as lower concentrations could not be 
detected accurately. Results for Carb using LC-MS/MS rather than GC-MS prove to 
have a poor recovery, but a better LOD.  
 
  
Recovery 
(%) 
RSD 
(%) 
LOD in drinking water 
and rivers (ng/l) 
LOD in STP 
effluents (ng/l) 
Propranolol 91 11 5 25 
Carbemazepine 99 (92) 8 (1) 20 (10) 100 (10) 
 
Table 1 Mean recoveries (n=5) of compounds at 1µg/l and detection limits achieved by 
using GC-MS after using SPE. Results in brackets indicate results from LC-MS/MS 
detection (n=3) (Ternes et al., 1998a) 
 
Sacher et al. analysed pharmaceuticals from groundwater in Germany, a seemingly 
popular sample location across many papers; it is unclear why this is, however it does 
not seem important, simply logistical. They analyse 60 different pharmaceutical 
compounds in aqueous samples. Their methods used SPE followed by GC-MS or HPLC 
mass spectrometry for analysis and separation. Pharmaceuticals under investigation 
which are relevant to this thesis are Diclo, Indo, Carb, Pro and Sulf. Table 2 highlights 
data for these compounds in question; all have a good r-value, as well as recovery in 
both tap and surface water, excluding Sulf for recovery values.  
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  r-value 
Recovery from 
tap water (%) 
Recovery from 
surface water (%) 
LOD (ng/l) 
Diclofenac 0.979 70 70 8.7 
Indomethacine 0.990 86 114 5.4 
Carbemazepine 0.796 80 74 9.6 
Propranolol 0.993 84 48 4.6 
Sulfamethaxozole 0.999 23 21 1.8 
 
Table 2 Correlation coefficient, recovery in tap water and surface water (%) and limit of 
detection for relevant pharmaceuticals (Sacher et al., 2001). 
 
The maximum concentration detected for Diclo, Carb and Sulf were 590, 900 and 410 
ng/l respectively; all relatively high values. Interestingly, these three compounds were 
the only ones to be detected at least 3 times in all 105 groundwater samples with high 
values.  
 
Ternes also identified concentrations above the µg/l level for Diclo and Carb, which are 
of particular interest in this investigation (Ternes, 1998b) (Table 3). In a paper 
investigating 32 compounds in German Sewage Treatment Plants (STPs) and rivers, he 
documented a high 6.2 µg/l for Carb in the sewage outflow, therefore leading to river 
contamination. Taken from his 1998b paper, Table 3 indicated a good low LOD, but 
low concentrations at the µg/l level. These data once again give no indication of 
variability, or at least not documented in the results published. Ternes also gives a 
diagram of the main fate of drugs in the environment, after their application. It is 
interesting to compare this to others in literature (Figure 5).  
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All conc.'s in µg/l 
STP Effluents Rivers and Streams 
LOD 
Median 
conc 
Max 
conc 
LOD 
Median 
conc 
Max 
conc 
Diclofenac 0.05 0.81 2.10 0.01 0.15 1.20 
Indomethacine 0.05 0.27 0.60 0.01 0.04 0.20 
Meclofenamic Acid 0.05 0.00 0.00 0.01 0.00 0.00 
Propralolol 0.25 0.17 0.23 0.01 0.02 0.59 
Carbemazepine 0.05 2.10 3.70 0.03 0.25 1.10 
 
Table 3 Concentrations of relevant compounds tested at both STP effluents, and rivers 
and streams (Ternes, 1998b). 
 
 
Figure 5 Scheme for the main fates of drugs in the environment after application (STP) 
(Ternes, 1998b). 
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Using a different approach entirely, Angus et al. developed a method for pharmaceutical 
analysis using capillary electro-chromatography (CEC), combining both capillary 
electrophoresis with HPLC technology (Angus et al., 1998). Although having promising 
potential, this method seems short-lived in pharmaceutical testing due to lack of 
continued use of this method, assumed from no follow-up papers or investigations; there 
are very little papers using CEC in method development and subsequent continuation. 
Angus et al. used a previously validated HPLC analytical method, and so this provided 
a good basis for CEC investigative parameters. Their investigations at the time of 
publication were still on-going, although offering promising results. However, no 
recovery data were presented;.  
 
Löffler and Ternes adopted the use of ultrasonication using acetone followed by ethyl 
acetate for the extraction of acidic pharmaceuticals from solid soil matrices, with a good 
limit of quantification (LOQ) of 0.4 ng/g (Löffler and Ternes, 2003). The mobile phase 
during LC-MS/MS analysis for this investigation comprises water/acetonitrile mixed 
with acetone. Three compounds of interest are highlighted from this paper; Diclo, Indo 
and Sulf. All showed very good recoveries between 65 and 116%, however recoveries 
were often high (Table 4).  
 
 
LOQ SPE (1ug/l) Sediment (20ng/g) Sediment (3ng/g) 
ng/g 
Absolute 
Recovery 
(%) 
Relative 
Recovery 
(%) 
Absolute 
Recovery 
(%) 
Relative 
Recovery 
(%) 
Absolute 
Recovery 
(%) 
Relative 
Recovery 
(%) 
Diclofenac 8 116±25 115±25 81±18 57±12 125±85 92±48 
Indomethacin 0.4 94±5 94±5 80±17 57±5 123±45 91±18 
Sulfamethoxazole 20 94±7 108±6 65±8 99±22 75±41 113±93 
 
Table 4 LOQ’s, and recovery rates of three selected pharmaceuticals for SPE and 
sediment analysis at 2 spiking levels (Löffler and Ternes, 2003). 
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Prior to sample quantification, PPCPs are subjected to filtration and pre-concentration 
procedures due to the small level of which they are found in such samples. Methods 
often used are SPE or solid phase micro-extraction (SPME). In documenting LC-
MS/MS methods for quantifying pharmaceutical compounds in solid matrices, Kim and 
Carlson identified SPE filtration as the most reliable process (Kim and Carlson, 2005).  
These authors have reported on advantages of such procedures as; 
1. Simple to use 
2. Cost effective 
3. Solvent free (less impact on the natural environment and lowers cost further) 
4. Can be combined with GC-MS for a variety of compounds 
5. Rapid and sensitive process.  
 
However, this method is labour intensive when a large quantity of compounds need to 
be analysed, especially when trying to improve accuracy. Peck discusses further 
extraction methods including liquid-liquid extraction (LLE) and pressurized fluid 
extraction (PFE), however these are not discussed further. He simply gives the general 
recovery methods for the methods used in relation to the composition of the matrix ie 
river water or sludge (Peck, 2006).  
 
Following the use of SPE followed by GC-MS, a third matrix has been considered by 
Scheytt et al., in the determination of pharmaceutical compounds in sandy sediments. 
The porous nature of such a matrix offers its own complexities; does it initially retain 
compounds, and can the same methods as tested for aqueous and solid soil matrices be 
applied (Scheytt et al., 2005). Of the three compounds tested, of particular interest in 
this investigation are Carb and Diclo. Recovers between 80 and 120% were presented 
for each respectively, and it was determined that sorption to a sandy sediment of these 
compounds is relatively low. Recoveries of over 100% were identified due to the 
samples being from real locations which may have contained the compounds in 
question prior to spiking with a known amount. If a compound is successfully sorbed 
into the matrix being tested, it makes it less available to surrounding environments ie in 
surrounding water. However, it then leaves the sediment environment (ie earthworms in 
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river sediment) more readily exposed to bioaccumulation. And to assess the 
concentration of compounds readily sorbed sediments proves difficult.  
 
Sampling procedures in relation to sample collection are questionable and possess many 
faults. This is due to the high instability and remobilization of the compounds, which 
through traditional sampling procedures would disrupt the natural concentration of 
target compounds in question. The traditional method is through spot-sampling; using 
pre-cleaned bottles to take a one-off, on the spot sample of water which are then treated 
in the laboratory prior to investigation. However this has come under criticism due to its 
ineffectiveness to show concentration over time with daily fluctuations. A more recent 
approach is to use a passive sampling technique; Polar Organic Chemical Integrative 
Samplers (POCIS), developed by Alvarez, Petty and Huckins in 2002, when they also 
filed a U.S. patent (Alvarez et al., 2002). It is designed to sample water-soluble organic 
chemicals from aqueous environments, which can provide time-weighted average 
concentrations of chemicals over deployment periods ranging from weeks to months. 
As it is a passive sampler, it requires no moving parts or power supervision during use. 
The sorbent material are removed and set intervals, each giving an accumulative 
representation of the sampling period at the designated location. A photograph clearly 
shows the components in Figure 6. They offer a more representative alternative to 
traditional sample collection. When compared to traditional grab samples taken 
concurrently, the values identified using the POCIS were in good agreement (Alvarez, 
Petty, Huckins et al, 2004, Development of a passive, in situ, integrative sampler for 
hydrophilic organic contaminants in aquatic environments, Environmental Chemistry 
23, 7, p 1640 – 1648).  
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Figure 6 Four POCIS are shown mounted in a stainless steel deployment canister. There 
is a white plastic outer protective canister which was removed for this photograph. 
(Alvarez et al., 2002) 
 
Zhang and Zhou provide an analysis of the same 9 PPCP compounds in this work using 
water samples (sewage effluent and river water). They assess the difference between 
spot and passive sampling both in the laboratory and in the field. There was a good 
agreement between the pharmaceutical concentrations obtained using spot sampling and 
those from passive sampling, with the POCIS obtaining good results (Zhang et al., 
2008).  
 
Due to the complexity of chemical bonding and structure of pharmaceutical compounds 
present in solid (soil) matrices, it is essential to remobilize these as part of the 
experimental laboratory process, prior to sample filtration. Chen et al. (2008) identify 
the complexity of solid matrices, and agree that sample pre-treatment are required to 
extract and isolate target compounds. A method commonly used to remobilize and 
transfer said compounds from the sample matrix into the chosen solvent, is Microwave 
Assisted Extraction (MAE). The use of MAE for sample preparation was seen as early 
as the 70’s however there was great progress in the late 80’s when Gedye et al. 
describes the use of MAE for the rapid assessment of organic compounds (Gedye et al., 
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1986). Even then they document how important time minimising is in such experiments, 
and also highlight the low running costs of the method. Although this technique has 
been around for decades, in 1994, Renoe highlighted the advantages of such technology 
in analytical chemistry applications, and its success in compound extraction from a solid 
matrix sample into the chosen liquid elute, ready for filtration (Renoe, 1994). Supported 
by Letellier and Budzinsky, the main advantages include (Budzinski et al., 1999); 
1. Reduction of required solvent 
2. Low waste generation 
3. Short extraction and preparation time 
4. Small sample size required 
5. Low cost and time implications 
 
Recently, Sanchez-Prado et al. assessed the use of well established MAE to determine 
pollutants in a solid matrix, which gives a useful insight into methods already in place 
(Sanchez-Prado et al., 2010). In comparison to other extraction techniques, Sanchez-
Prado commented on the fact that due to a relatively low number of parameters, it is 
relatively straightforward to optimize MAE procedures. Other advantages of MAE 
extraction are that multiple samples can be extracted at one time, and so offers a good 
alternative to other methods available, and encompasses the importance of 
simultaneousness. Sanchez-Pedro et al. document the methods of different authors’ with 
relation to simultaneous pharmaceutical extraction from a solid matrix. Of particular 
interest is Rice and Mitra who developed a method for 8 very diverse PPCPs in such 
matrices, who used MAE followed by GC-MS as their successful extraction process 
(Rice and Mitra, 2007). Although no specific compounds related to these investigations 
are relevant, the authors note that the “concentration of PPCPs in natural solids 
remains largely unknown, due to a lack of methods permitting the simultaneous 
detection of diverse, low-level contaminants present in these complex matrices”. 
Recoveries gave results as high as 89% for some compounds, but as low as 25% for 
others, highlighting the difficulties in simultaneously determining complex 
pharmaceuticals. Variability was up to almost 3% for some compounds, which is still a 
good result. The laboratory based recovery tests without a matrix present presented 
much higher and stable results compared to when target compounds were attempted to 
be detected in natural sediment samples. They report that matrix effects are the most 
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likely cause for low recoveries, which is an important factor to consider in further 
investigation.   
Cueva-Mestanza et al. also targeted 8 diverse compounds (including propranolol and 
carbemazepine) using MAE (dried sediment mass of 2g), followed by SPE for clean-up 
and pre-concentration, before finally using HPLC for analysis in several types of solid 
sample matrices (Cueva-mestanza et al., 2008a) (Table 5). Recoveries were above 70% 
and RSD under 11%, with detection limits between 4 and 167ng/g
-1 
obtained, however 
no ‘real’ contaminated samples were evaluated. Of the 8 compounds investigated, only 
two were relevant to this work; Carb and Pro. Their results from analytical testing are 
located in Table 5. These publications are important, as pharmaceuticals presents 
themselves as very difficult to extract and analyse from a solid matrix due to their 
complexity and chemical bonding. At present, there are few publications, some with 
low recovery rates, and so a further optimized method is needed.  
 
  Recovery (%) RSD LOD (ng/g) LOQ (ng/g) 
Carbemazepine 78 10 15 48 
Propranolol 78 11 19 62 
 
Table 5 Analytical parameters of the proposed method result (n=6) (Cueva-mestanza et 
al., 2008a) 
 
Cueva-Mestanza et al. continued their experiments to different solid matrices, including 
molluscs (dried and homogenised 1g sample mass) (Cueva-mestanza et al., 2008b). 
They tested for 6 compounds using the same method as before, and achieved recovery 
rates over 85%. The method showed satisfactory linear results and reproducibility of 
between 3 and 15%, as well as good detection limits between 30 and 220 ng/g, and 
applied successfully to the determination of PPCPs in mollusc samples. This gives a 
promising insight into method application to other solid matrices. The diagram below 
demonstrates the method used for the procedure to analyse mollusc samples (Figure 7); 
a useful insight for work later in this thesis. However out of the 6 compounds tested, 
61 
 
only one (Carb) is of particular interest here. At a spiking level of 0.8 and 3 µg/g (n=6), 
Carb produced recoveries of 98 and 90% respectively, and a RSD of 15 and 5% 
respectively. A LOD and LOQ were determined as 0.22 and 0.73% respectively. All 
indicating good stable results from the tried method.  
 
Figure 7 Scheme of Microwave Assisted Micellar Extraction (MAME) and SPE 
procedure in mollusc samples (Cueva-mestanza et al., 2008b) 
 
Antonic & Heath tested a group of 4 pharmaceuticals (including Diclo), and after using 
MAE for the extraction process went on to use GC-MS for sample analysis (Antonic 
and Heath, 2007). The paper reported recoveries over 80%. Anatonic & Heath were 
using dried (crushed and sieved) 5g river sediment (a relatively large sample mass). 
High variability and room for error is normally expected from a sample of this size.  
 
As previously mentioned, Liu et al. analysed river sediment samples for EDCs using 
GC-MS (Liu et al., 2004). They used MAE as the extraction technique, with spiking 
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experiment recoveries over the 60% level, with good reproducibility. Although this 
method is for use on EDCs, it offers an interesting insight to method application and 
could potentially prove successful on pharmaceutical determination trials. Their 
preliminary results proved promising, however when applied to real environmental 
samples, proved less so, with recoveries regularly below the LOQ. However, some 
concentrations of up to 12 ng/g were detected at sewage outfall sampling locations on 2 
instances. All environmental samples gave good standard deviations using a sample 
number of 3. Popular methods for PPCP analysis now encompass the use of MAE, SPE 
and MS technology, whether it be GC-MS, or LC-MS/MS.  
 
 
2.6  Effects on the environment and human health 
There are growing concerns over the eventual fate and consequences of named 
pollutants in the natural environment, and more recently, their effects on human health. 
Studies quantifying such compounds are vast in comparison to those determining the 
subsequent consequences to the natural environment or human health.  
 
There is wide dispute over the effects of PPCPs to human health, however one thing is 
known; there is some cause for concern due to existing speculation and studies on 
fauna, but extent to this concern is unknown. PPCPs cover a wide variety of everyday 
household products, again highlighting the importance of their uncontrolled release into 
the environment; antibiotics, antioxidants, lipid regulators, psychiatric drugs, hormones, 
x-ray contrast media, antimicrobial compounds, insect repellents, and the list goes on 
(Caliman & Gavrilescu, 2003). Potential EDC and PPCPs are displayed by the authors 
in Figure 8. Of particular interest to this work are Tamo and Diclo which you probably 
at some point would have had in your home as they are common household prescription 
drugs.  
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Figure 8 Scheme of the potential endocrine disruption PPCPs (Caliman and Gavrilescu, 
2009a) 
 
Although no specific pharmaceuticals to this work were discussed, Henschel et al. gave 
a strong report of common pharmaceutical compounds and their hazard on the natural 
environment (Henschel et al., 1997). Their biological degradability and toxic effects to 
common algae were investigated, which are both important considerations relating to 
this topic. They concluded that there was no significant bioaccumulation of the four 
tested compounds in the algae, however there were significant effects following 
ecotoxicology tests, to cell structures. The extent of these concerns is however unclear.  
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A recent review by Crane et al. highlights aquatic risks of human pharmaceutical 
exposure (Crane et al., 2006). They review current information in the field and assess 
the aquatic toxicology of human pharmaceuticals with relation to how it should be 
measured. For a long time such compounds have been detected in the environment, and 
more recently their associated potential risks have been of great concern, supported by 
Jorgensen and Halling-Sorensen when they discussed a wide variety of drugs in the 
environment (Jorgensen and Halling-Sorensen, 2000). There have been many water 
assessments globally where pharmaceutical compounds have been successfully 
quantified, as previously discussed. Crane et al. assess ecotoxicology from different 
sources in micro-organisms, algae, invertebrates and fish, and conclude that human 
pharmaceuticals pose an enormous potential threat to aquatic organisms. They highlight 
the need for a universal matrix method for identification and quantification, rather than 
different methods being used for different samples (ie algae, fish etc), as the variables 
between methods is too broad. This relates to the investigation preceding this review as 
after method development, I will go on to test application to different matrices.  
 
There have been many other investigations into the harmful effects of pharmaceutical 
drugs to life forms in both aquatic and terrestrial ecosystems, and Stranchan et al. 
highlight the importance that during WWTPs, a significant proportion of the waste 
which includes pharmaceutical compounds, ends up in solid form, and eventually be 
transferred to biosoils (Stranchan et al., 1983). Small terrestrial organisms within these 
environments can therefore act as good indicators to the wider significance of the issue 
and offer an insight into what could happen when infiltrated to the human body. A study 
focusing on earthworms found in pre-treated agricultural soil assessed the 
bioaccumulation of pharmaceuticals (Kinney et al., 2008). Both the earthworms and the 
soil they were found in were assessed, and unexpectedly, over 20 compounds were 
identified in earthworms which were also in the soil samples. Interestingly, 28 of the 
detected compounds identified in the earthworms were below detectable levels in the 
corresponding soil samples, which highlights the bigger issue of bioaccumulation. 
There remains an unanswered question, of how this affects human and ecological 
health. Although earthworms are at the bottom of the food chain, they soon become 
prey and eventually work their way through the food chain until they reach us (humans), 
and so the problem is rapidly magnified through bioaccumulation. Further studies are 
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needed to assess the effects of bioaccumulation before human impact can be assessed. A 
globally important issue has been addressed by the aforementioned authors and their 
publications.  
 
It is clear that at present, there is not enough strong statistical evaluation of the toxic 
effects of compounds in question to human health due to the lack of information from 
solid matrices, highlighting the importance of method development (Brooks et al., 
2003). This is critical because the effect on human health are of the upmost importance 
with relation to scientific investigation of this kind, and may result in a dramatic change 
in manufacture, disposal, prescription and use of PPCPs. However once again, 
evaluations in the aquatic environment are present, and studies indicate that effects at 
trace levels as found are rare. 
 
 
2.7  The Law 
Halling-Sorensen  report on the legislation relating to drugs of this nature (Halling-
Sorensen et al., 1998). It states that; 
“In Europe legislation was first initiated in the early 90’s and it distinguishes medical 
substances into two groups; those which contain Genetically Modified Organisms 
(GMOs) and those which do not. These are then further divided into veterinary, and 
human medicinal products.” 
There is now an environmental dimension to the equation, which now means that the 
environmental impact is now also considered. It is still unclear why there is a separation 
between veterinary and human impact of such compounds, as in most cases they are 
considered equally as important (Irwin, 1994). 
At present, pharmacies, doctors and others in the medical profession are largely 
unaware of the eventual environmental fate of the drugs (PPCPs), or at least they have 
no choice to act upon this knowledge if to the contrary, otherwise the situation would be 
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different. No limiting dispensary limitations are in place to minimise this problem. It 
will require an alteration in the law to enforce such a change.  
 
2.8  Conclusions 
In light of discussing the relevant literature, it can be concluded that PPCPs are 
currently concerning emerging pollutants in the natural environment. It is known that 
they pose a threat to the environment, be it aquatic or terrestrial, however the extent of 
this threat is largely unknown. Concerns to these environments in question raises greater 
concerns to the effects on human health; something which is rapidly changing.  
 
Investigations regarding method development leading to detection and quantification of 
the target pharmaceuticals are unanimous in efforts to determine an effective (regarding 
both cost and time), sensitive method which yields good recoveries of multiple 
compounds. A further consideration is to whether this method is applicable to aqueous, 
solid, and biological samples with good, reliable recoveries and low variability.  
 
The preferred techniques involve SPE for filtration, having prior chosen a suitable 
solvent for elution. It has been widely accepted that an effective method is now in place 
for water samples following literature discussed perviously, however methods for solid 
matrices are still ineffective and vary greatly between investigations, with the same 
method for water currently not applicable. A variety of MS techniques have been 
employed to effectively quantify compounds, including GC-MS, and LC-MS/MS, and 
conclude that for the nature of pharmaceuticals, LC-MS/MS is by far the most effective.  
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Chapter 3 - Development of an LC-MS/MS method for the extraction of 
Pharmaceutical compounds from sediment samples. 
 
3.1 Introduction 
Research into PPCPs as environmental pollutants has grown significantly as advances in 
analytical procedures have allowed their measurement, increasing our understanding of 
their occurrence and persistence (Maskaoui et al., 2007). Prior to 1990, the major focus 
of research was on so-called ‘traditional’ pollutants, such as POPs and heavy metals, 
and very little attention was given to PPCPs (Ellis, 2006). However, since PPCPs are 
used and discharged continuously, leading to pseudo-persistent occurrence and chronic 
exposure in the environment, they have become a focus of scientific research and 
attracted attention worldwide (Nikolaou et al., 2007). Currently there are over 4,000 
pharmaceutically-active compounds consumed by humans and animals, of which 
approximately only 160 have already been studied to any extent in the natural 
environment (Mompelat 2004).  
Knowledge of the environmental concentrations and behaviour of various 
pharmaceuticals is essential to understanding their fate and risk as they have been 
shown to have deleterious impacts on the environment. Currently, there is limited data 
available on their occurrence or toxicity. One study highlighted the harmful nature of 
exposure to a popular human and veterinary pharmaceutical, Diclo. It was found that 
vultures feeding on dead livestock that were treated with Diclo in Pakistan were 
suffering renal failure which resulted in significant decreases in the population. It was 
also observed that the reduction in the population of vultures caused an expansion in 
other species, including those which carry human-communicable disease such as rabies, 
thus posing a secondary threat to the local human population (Green et al., 2004). 
Another potential health risk is the levels of antibiotics in water due the increased 
occurrence of antibiotic resistant biofilm in hospital and municipal wastewater, as well 
as drinking water (Schwartz et al., 2003). To summarise, the concern about potential 
harm that these compounds may impose on humans and wildlife are based on their 
being biologically active by definition. Little is scientifically proven about the 
occurrence or health risks posed by each pharmaceutically-active compound and 
moreover, a mixture of pharmaceuticals may pose  a greater potential health risk 
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compared to exposure to single compounds, since certain combinations of drugs can 
interact; however those effects have not been quantified or confirmed (Caliman and 
Gavrilescu, 2009, Jones et al., 2006). 
Due to emerging evidence that pharmaceuticals can have negative effects on the 
environment, several methods have been proposed to measure their presence. The 
majority of studies have focused on analysis of water samples, leaving sediment 
analyses largely neglected (Nikolaou et al., 2007, Loffler et al., 2005).  However, owing 
to the large range in the properties of pharmaceutically-active compounds, it is possible 
that sediment may act as a significant sink for some or all of these compounds. 
Sedimentary analyses may also prove more useful as they provide an understanding of 
the longer-term occurrence of the pharmaceuticals rather than the snapshot obtained 
with spot-samples of water (Antonic and Heath, 2007). Previously, methods such as U 
(Spongberg and Witter, 2008, Xu et al., 2008, Löffler and Ternes, 2003), soxhlet 
extraction (Buyuksonmez and Sekeroglu, 2005), PLE (Nieto et al., 2009, Jacobsen et 
al., 2004, Schlusener et al., 2003, Gobel et al., 2005), SFE, and MAE (Raich-Montiu et 
al., 2007, Rice and Mitra, 2007) have been used for the extraction of PPCPs from 
sediment (Antonic and Heath, 2007). In one study, all of these methods were compared 
using non-steroidal anti-inflammatory drugs (NSAIDs) and MAE was chosen to be the 
best method even though PLE and SFE produced higher efficiencies given that they are 
time-intensive and employ the use of large volumes of toxic solvents (Antonic and 
Heath, 2007). MAE has also been shown to be useful for endocrine disrupting 
chemicals (Liu et al., 2004), although to date, there are no published techniques for the 
simultaneous extraction of a range of pharmaceutical classes from sediment. Thus, a 
method is been developed here to measure nine pharmaceuticals covering three 
chemical classes using MAE, SPE, and LC-ESI-MS-MS in positive ionization (PI) 
modes. The compounds were selected so as to represent differences in pharmaceutical 
class, physicochemical properties, and occurrence in the environment (Liu et al., 2004).
 
The technique was optimised by assessing different factors such as sample mass, 
extraction solvent, microwave temperature and subsequently validated with 
environmental sediment samples from the River Ouse, UK.  
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3.2 Experimental 
3.2.1 Chemicals and Standards 
All of the solvents used, including methanol, ethyl-acetate, acetonitrile and hexane 
(Rathburns, UK) were of distilled glass grade. Pro, Sulf, Meb, Thio, Carb, Tamo, Indo, 
Diclo and Meclo were purchased from Sigma, UK. Internal standards (diuron-d6 and 
13
C-phenacetin were purchased from Cambridge Isotope Laboratories, USA. Diuron-d6 
and 
13
C-phenacetin were used following considerable existing literature reviews which 
used these standards for the same or similar groups of pharmaceuticals used in 
laboratory experimentation. Separate stock solutions (1000 mg/l) were prepared for 
individual compounds and internal standards by dissolving an appropriate amount of 
substance in methanol, then further diluted before using. From these standards, a 
mixture containing each compound (20 mg/l) was prepared weekly and used to spike 
the sediment samples. All standards and IS stock solutions were stored at -18 °C prior to 
use.  
3.2.2 Microwave-Assisted Extraction (MAE) 
Sediment samples from the River Ouse, East Sussex, UK were used for spiking 
experiments. First, sediment samples were extracted to determine the concentrations of 
target compounds in the matrix. Sediment samples were firstly frozen for 24 hours and 
then dried for 24 hours using a freeze-dry machine and were subsequently homogenized 
and sieved. Dry sediment samples (2 ± 0.2 g) were weighed into PTFE-lined extraction 
vessels and spiked with 200 ng each of the pharmaceutical standard. The samples were 
covered and allowed to stand for one hour in the MAE vessels at ~24 °C to allow 
sorption processes to occur before the solvent or solvent mixtures were added. 
Extraction solvents being studied included methanol, ethyl acetate, acetonitrile, hexane 
and ethyl acetate: hexane (1:1). Extractions were performed by a MARS-X laboratory 
microwave (CEM Corp., USA) at 30, 60, 90, 100, 110, 120 and 130 °C for 15 minutes 
(following 7 minute temperature ramp) with 100 % power or 600 W and 200 psi (1378 
kPa) with 15 ml of solvent or solvent mixture (Liu et al., 2004). Following the 
extraction, samples were cooled to room temperature for 1 hour before they were 
opened to ensure the glass vessel would not break with temperature change and the 
sample lost. The supernatants were transferred to round-bottomed flasks (250 ml) and 
the sediments were washed with 3 x 15 ml rinses of the same solvent or solvent mixture. 
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The supernatants were combined, then evaporated to nearly 1ml by rotary evaporation. 
Each sample was then subjected to cleanup procedure, discussed in 1.2.4.  
 
3.2.3 Ultrasonication Extraction of Sediment Samples 
For comparison with MAE, dry sediment samples (2 g) from the River Ouse were 
spiked with 200 ng each of the pharmaceutical standard, allowed to stand for one hour 
to fully interact with sediment, and extracted using an ultrasonication bath (Decon 
Laboratories, UK). The samples were sonicated for 30 minutes three times using 15ml 
of methanol and were subsequently centrifuged at 2500 rpm for 5 minutes. Due to the 
absence of pressure as with the MAE, a run time of 30 minutes was used to ensure 
fairness when compared with MAR. The supernatants were collected in 250 ml round-
bottomed flasks and rotary evaporated to about 1 ml. Each sample was then subjected to 
cleanup procedure (see 1.2.4).  
3.2.4 Clean-Up Procedure 
Due to the complexity of sediment matrix, it was necessary to develop a cleanup 
procedure to remove interfering substances from sediment extracts in order to improve 
compound separation in HPLC. A variety of approaches were tested including silica, 
alumina and solid-phase extraction columns. The different procedures were tested and 
are detailed below.  
3.2.4.1 Preparation of silica gel and alumina oxide column and cleanup of extracts 
The silica gel and alumina oxide were heated overnight in an oven at 500 °C (>18 hrs) 
and cooled to room temperature. Glass wool (pre-ashed at 500 °C for 3 hours) was 
inserted into the bottom of 5 ml graduated pipette to which the solid phase (silica, 
alumina, 50:50 silica alumina, 25:75 silica:alumina, 75:25 silica:alumina) was added to 
the 5 ml mark. Another piece of glass wool was inserted in the top of the column and it 
was conditioned with the extraction solvent of choice. Once the columns were ready, 
the sediment extracts were quantitatively transferred to the columns using a Pasteur 
pipette. The columns were then eluted with 20 ml of a solvent or solvent mixture, with 
the elutions finally blown down to 0.1 ml under a gentle N2 flow. 
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3.2.4.2 Solid-phase extraction 
For comparison with alumina and silica columns, SPE cartridges were also used as a 
cleanup procedure following previous work by Zhang and Zhou (Zhang and Zhou, 
2007). Briefly, SPE cartridges from Waters (HLB Oasis) and Supelco (DSC-18) were 
pre-conditioned with methanol (2 x 5 ml) and subsequently ultrapure water (2 x 5 ml). 
The sediment extracts (1 ml) were transferred to amber glass bottles (1 l), rinsed with 
methanol (3 x 5 ml), and diluted with 500 ml of ultrapure water. Two 5ml methanol and 
ultrapure rinses were used due to previous successful trials of this method by Zhou et al. 
(2009). This is also the case for the dilution with 500ml of ultrapure water. The diluted 
sediment/water solutions were subsequently extracted by SPE. Once completed, the 
SPE cartridges were dried under vacuum for 30 minutes, from which the target 
compounds were eluted by methanol (15 ml) before LC-MS/MS. The solvent extracts 
were reduced to approximately 0.1 ml under a gentle N2 flow. (Zhou et al., 2009).  
3.2.4.3 Microfugation 
The sediment extracts (1 ml) were pipette into 0.2 µm VectaSpin Micro centrifuge 
filters and spun at 8000 rpm in a Beckman Microfuge 1l until all of the solvent had 
passed through the filter. 
3.2.5 LC-MS/MS analysis 
Quantitative analysis of sediment extracts by LC-MS/MS was completed following a 
previously developed method using a Waters 2695 HPLC separation module (Milford, 
MA, USA) and a Waters Symmetry C18 column (4.6 mm x 75 mm, particle size 3.5 
µm) (Zhang and Zhou, 2007). All samples were spiked with 200 ng of internal 
standards prior to analysis. The mobile phase was composed of eluent A (0.1 % formic 
acid in ultrapure water), eluent B (acetonitrile) and eluent C (methanol) and flowed at a 
rate of 0.2 ml/min. The sample injection volume was 10 µl.  
A Micromass Quattro triple-quadruple mass spectrometer was employed for tandem MS 
analysis using a Z-spray electrospray interface. All samples were analysed in positive-
ionisation mode. The temperatures for the electrospray source block and the desolvation 
were 100 and 300 ˚C, respectively. Nitrogen flowed at a rate of 25 and 550 l/h to 
function as a nebulising and desolvation gas, respectively. The mass spectrometer 
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operated in multiple reaction monitoring (MRM) mode in order to further validate the 
presence of the analytes. 
An example of a chromatogram produced by the LC-MS/MS to then analyse results is 
displayed in Figure 9.  
 
 
 
 
Table 6 LC–ESI-MS–MS conditions for the analysis of pharmaceuticals by MRM in 
positive ion modes 
Pro
Anti-
hypertensive
ES+ 9.95 259 20 260
116(100), 
183(56)
Sulf Antibiotic ES+ 11.2 253 15 254
92(100), 
108(65), 
156(16)
Meb Gastrointestinal ES+ 12.2 429 25 430
101(100), 
135(3)
Thio Anti-depressant ES+ 14.3 370 25 371
126(100), 
98(75)
Carb Anti-epileptic ES+ 14.8 236 20 237 194 (100)
Tamo Anti-cancer ES+ 16.8 371 25 372
72(100), 
208(1)
Indo
Analgesic/Antip
yretic
ES+ 22 357 25 358
139(100), 
141(20)
Diclo Anti-
inflammatory
ES+ 22.1 295 30 296 214 (100)
Precursor 
ion (m/z )
Product 
ion (m/z )
Meclo
Anti-
inflammatory
ES+ 24.1 295 25 296 243 (100)
Compound
Therapeutic 
class
Ionisation 
mode
Retention 
time (mins)
Molecular 
mass
Collision 
energy (eV)
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Figure 9 Chromatograms of each compound and their retention times. 
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3.2.6 Analysis of Environmental Samples 
Once validated, the method was used for the analysis of environmental samples. 
Sediment samples were collected using a Van Veen sediment grab at the sewage outfall 
at Sheffield Park STP in the River Ouse, UK, between July 2009 and June 2010. In 
addition, sediment samples were collected at 500 m and 10 m upstream, as well as 100 
m downstream, of the STP, to assess the impact of STP on river water quality. The top 
oxic fraction of all sediment samples was removed with a stainless steel spoon and 
stored in pre-cleaned glass jars. The sediment samples were frozen at -18 ˚C, then 
freeze-dried and homogenised. The dry sediment samples were then subjected to 
extraction, cleanup and finally analysis using LC-MS/MS.  
 
3.3 Method Development Stage 1 – Preliminary investigations 
3.3.1 The effect of changing cleanup method on extraction 
To enhance the sensitivity and overall quality of analysis for pharmaceuticals, sample 
cleanup is often essential prior to chromatographic separation. The clean-up method can 
have a significant effect on the recovery of desired compounds due to their unique 
physicochemical properties, therefore it was the first experimental factor tested. 
Currently different cleanup methods have been used for this purpose, the most widely 
used being SPE cartridges and silica gel-packed columns (Antonic and Heath, 2007, Liu 
et al., 2004). The full method is given in section 3.2.4.2.  
In this work, sediment extracts from MAE were purified by a range of cleanup 
techniques, and the recoveries for each compound over different methods were as 
follows: Pro 4.7 - 70 %, Sulf 0.1 - 88.2 %, Meb 3.9 - 73.7 %, Thio 1 - 51.9 %, Carb 14.4 
– 98 %, Tamo 3.1 - 71.7 %, Indo 0.2 - 57.2 %, Diclo 0.1 - 82.4 %, and Meclo 1.7 - 61.7 
%, indicating very different performances from different cleanup methods (Table 6). 
Similar results were obtained from the cleanup of sediment extracts by employing U. 
Overall, it was observed that SPE on Water Oasis cartridges was the method that 
produced the best recoveries (between 52 – 98 %) for the target compounds under the 
chosen conditions and variables, of which 6 compounds showed a recovery >70 % 
(
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Figure 10). It is important to note that these recoveries may not be as desirable if other 
conditions are investigated. The results are consistent with those by Zhang and Zhou 
who showed Waters SPE to be the most effective sorbent during extraction of the 
pharmaceuticals from water samples (Zhang and Zhou, 2007). This method was 
favoured over a method that produced the best recovery for a single compound, since 
the goal of this research was to test multiple classes of pharmaceuticals. Aside from 
microfugation, none of the other methods showed recoveries for all compounds. 
Microfugation is not a desirable method because it does not completely remove 
interfering compounds from samples, which may reduce sensitivity therefore SPE was 
preferred. 
 
 Pro Sul Meb Thio Carb Tamo Indo Diclo Meclo 
Silica 11.01 13.17 9.89 1.48 7.10 14.27 21.24 22.60 29.43 
Alumina 20.53 1.02 72.94 8.85 48.27 12.08 0.22 1.4 1.72 
1:1 4.65 0.10 25.08 3.36 35.14 67.34 1.05 4.60 2.32 
1:3 13.63 12.83 22.62 4.85 18.05 9.44 20.87 2.04 7.81 
3:1 9.30 9.03 14.02 1.04 28.30 3.09 0.62 0.69 4.85 
SPE Oasis HLB 70.00 88.20 73.72 51.92 98.35 71.67 50.99 82.38 61.65 
SPE Silica C18 9.73 10.69 17.99 20.01 14.37 50.12 57.21 21.56 16.75 
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Table 7 Recovery of pharmaceuticals (%) with different cleanup methods tested (ratios 
are using silica and alumina respectively ie 3:1 silica:alumina) 
 
 
Figure 10 Comparison of different clean up methods on recovery of pharmaceutical 
compounds (n=3) 
Another interesting finding that resulted from testing cleanup method was the 
relationship between silica/alumina columns and SPE products. Specifically, when SPE 
(Waters) and silica/alumina columns were compared, the SPE outperformed the 
silica/alumina columns with higher recoveries. Pharmaceuticals could have possibly 
interacted with the silica/alumina columns and the SPE sorbent differently, leading to a 
disparity between recoveries. An explination for this could be adsorption. In theory, 
there is no scientific reason as to why the silica columns are any less efficient at 
recovery of compounds than the manufactured SPE silica column, however this seems 
to be the case in these experiments. The poor recovery of pharmaceuticals from silica 
gel is in contrast to very high recovery of EDCs such as estrone (E1), 17-estradiol (E2) 
and 17-ethynylestradiol (EE2) from the same column obtained by Liu et al. (Liu et al., 
2004). The difference is expected to be due to higher polarity of pharmaceuticals than 
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EDCs. There were also unexpected trends in the recoveries of various types of column 
material being used. It was expected that a mixture of silica and alumina would produce 
better recoveries than alumina or silica alone, because the mixture would interact more 
effectively with a greater range of chemicals with different polarity; however the 
alumina/silica mixture columns showed poorer recoveries for several compounds than 
alumina alone. The pure silica and alumina columns produced superior recoveries to the 
mixtures and each effectively eluted different compounds. This suggests that the 
pharmaceuticals interacted with the glass in the column and the plastic in the cartridge 
differently, leading to a disparity between recoveries. In this instance adsorption is a 
plausible conclusion. To summarise, the findings support the conclusion that SPE on 
Waters Oasis cartridges is the preferred method of cleanup for multiple classes of 
pharmaceuticals because it produced the best recoveries for most.  
 
3.3.2 The effect of changing MAE temperature on extraction 
A variety of extraction temperatures in MAE were investigated for suitable recovery of 
the target compounds (Figure 11). Overall optimum conditions for the suite of 
compounds was MAE at 110 °C for 15 min using methanol. Recovery was calculated at 
the end of the experimentation process as with all considerations in this chapter; 
therefore all results from samples treated fairly. High recoveries (>50%) for most 
compounds including Pro (84.6 %), Sulf (50.4 %), Carb (76 %), Tamo (71.3 %), Diclo 
(69.1 %) and Meclo (74.1 %) were obtained, although it was not as effective for other 
compounds, notably Thio with a recovery of only 4.5 %. All of the remaining extraction 
temperatures tested showed poorer recoveries for most compounds, in particular Thio 
and Tamo with recoveries of only 0.1 - 0.8 % and 0.5 - 10.1 % respectively. The higher 
recoveries at 110 °C may be explained by the favourable condition for the efficient 
extraction as well as relative stability of the target compounds. At temperatures higher 
than 110 °C, some of the compounds e.g. Meb and Tamo may have become degraded. 
At lower temperatures, the release of pharmaceuticals from sediment matrix may 
become retarded. 
Also shown in Figure 11 are recovery results from the U method; 30 minutes at room 
temperature. In comparison to MAE, U produced overall higher recoveries of between 
19.3 % and 97.6 %, with seven compounds achieving a recovery above 60 %, leaving 
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only two compounds with low recoveries (Meb at 43.9 % and Thio at 19.3 %). Hence, 
U is an effective method, in comparison to MAE at varying temperatures. 
 
 
Figure 11 Comparison of different extraction techniques (MAE temperatures and 
Ultrasonication) on recovery of selected pharmaceutical compounds (n=3) 
 
3.3.2.1 Considerations of a matrix effect on method development 
Recovery of individual compounds may be affected by properties of the sediment 
matrix, inducing disparities in results. The matrix effect was investigated using the two 
different extraction techniques, in comparison to a solvent only blank. Matrix effect of 
samples on recovery of Diclo and Pro are illustrated in Figure 12 and Figure 13 as 
examples, and it can be concluded that there is no significant matrix effect from U, with 
MAE extracts showing significant interference in the response of the compounds. 
Similar results were found for the other compounds, suggesting that MAE is more 
destructive than U in causing dislodging of sediment components. It can therefore be 
concluded that U is more suited for the extraction of pharmaceutical compounds from 
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aquatic sediments. However due to other variables and considerations, U was not taken 
further in the investigation.   
 
Figure 12 Effect of sediment matrix on the respoinse from LC-MS/MS analysis of Diclo 
(n=3) 
 
80 
 
 
Figure 13 Effect of sediment matrix on the respoinse from LC-MS/MS analysis of Pro 
(n=3) 
3.3.3 The effect of changing sample mass on extraction 
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Figure 14 Comparison of three different sample masses on the recovery of 9 selected 
pharmaceutical compounds (n=3) 
It is not evident from Figure 14 that the preferred sample mass is 2 g, however there are 
recoveries of almost 80 % for some target compounds. An improved analysis is 
displayed as a box plot, where it is clearly identified (Figure 15). Although some lower 
recoveries, overall this sample mass provided the highest compared to other masses 
tested. Recovery range was as follows; 0.01 – 58.37 % for 1 g, 4.54 – 78.28 % for 2 g 
and 0.02 – 25.30 % for 5 g.   
Interestingly, a sample mass of 5 g produced lower recoveries of target compounds 
compared to 2 g, with no single compounds producing a good result. A sample mass of 
1 g proved effective, but had a much lower recovery range than a sample mass of 2 g. It 
was expected to find the compound recovery increased with an increased sample size, 
which the results did not show. This is possibly due to the fact that a higher sample 
mass is required to extract a sufficient concentration of pharmaceutical compounds and 
a mass greater or equal to 5 g causes retention of compounds due to chemical bonding.  
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Figure 15 A box plot of three tested sample masses recovery results (n=3) 
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3.3.4 The effect of changing solvent on extraction 
 
Figure 16 Comparison of 5 different solvents used for the extraction of selected 
pharmaceutical compounds (n=3) 
 
A range of solvents were tested for the extraction process, to cater for compounds of 
different polarity. With over 70 % recovery for four compounds, methanol is clearly the 
best solvent to be used for the extraction of these compounds from sediment samples 
(Figure 16). Overall, methanol produced the highest recoveries of between 23.2 % for 
Indo and 84.6 % for Pro. This excludes the anomalously low recovery of 4.5 % for 
Thio, which despite its relatively low recovery, is surprisingly still the highest in 
comparison to all other solvents used. Hexane gave the lowest recoveries of between <1 
% for Thio and 6.7 % for Meclo. Ethyl acetate and acetonitrile produced recoveries of 
between 0.1 % for Thio and 59.8 % for Diclo, and between 0.1 % for Thio and 61.8 % 
for Carb, respectively. Of all the compounds, Thio was the most difficult compound to 
be extracted. Again, as a bar chart it is not easy to identify the best solvent for 
extraction, however it can be hazardous in assumption that Methanol provides best 
overall results (Figure 16).  
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Further testing with a mixture of solvents (hexane:ethyl acetate, 1:1) did not 
significantly increase percentage recovery, with recoveries between 0.1 % and 49.5 %. 
For some compounds e.g. Diclo, their recovery was significantly reduced compared to 
ethyl acetate alone, while for others e.g. Sulf, their recovery was significantly enhanced.  
A study by Liu et al. (Liu et al., 2004) also found that methanol was the best solvent for 
the extraction of EDCs, in particular for polar compounds such as EE2, from sediment 
samples. For other EDCs such as E1 and E2, the difference in recovery between 
different solvents such as ethyl acetate and methanol was insignificant. The findings 
further suggest that the polarity of extraction solvents should match as much as possible 
that of the compounds to be extracted, in order to ensure a more satisfactory extraction 
from sediments. Figure 17 not only clearly displays that Methanol is the most effective 
solvent to use, with the highest overall recovery compared to any other, but also that the 
mean recovery is the only over 50 % (also, over 60 %). The combination of 
hexane:ethyl acetate has very high outlier recoveries, which suggest anomalous results, 
probably for Carb as shown in Figure 16 as it has the highest recoveries for this solvent 
tested.  
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Figure 17 A box plot demonstrating the five different solvents (n=3) 
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3.4 Method development progress 
It can be concluded from method development in sections 3.2 to 3.3.4 that the best 
developed method is as follows; 
To firstly use a prepared sample mass of 2 g (dry weight). This, combined with using 
Methanol as the extraction solvent and SPE Oasis as the filtration stage, and finally 
using MAE at 110 °C for 15 minutes, proves to be the best parameters for a high 
recovery Figure 18.  
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Flow diagram to illustrate the new method for analysis of pharmaceuticals 
 
Other variables must now be tested in order to fully conclude the best parameters and 
variables for the quantification of pharmaceutical compounds in sediment.  
Sample Mass 
Solvent 
Extraction 
Clean-Up 
Reduction using N2 
blow-down 
Analysis with LC-
MS/MS 
1g, 2g, 5g 
Methanol, Hexane, Acetonitrile, Ethyl 
Acetate, Hexane:Ethyl Acetate 
Ultrasonication, Microfuge, MAE (30, 60, 90, 
100, 110, 120, 130°C) 
Hand made column (Silica, Alumina, 
Mixtures), SPE (Waters Oasis HLB, Supelco 
C18) 
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3.5 Method Development Stage 2 – Method refinement 
To ensure that the developed method is as accurate and optimal as possible, different 
variables were considered to further refine the method. These are detailed throughout 
section 3.4, and the optimal conditions applied to the developed method.  
3.5.1 Triple injection 
 
Figure 19 Comparison of variability of recoveries using triple samples (n=3) 
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
SPE Supelco 19.30 83.57 73.30 1.08 13.20 1.85 36.10 17.00 17.30 
SPE Supelco 2 17.10 78.00 23.40 0.64 28.10 3.19 30.12 25.30 12.10 
SPE Supelco 3 15.20 62.10 69.90 3.29 17.30 2.15 29.10 20.10 56.10 
Average 17.20 74.56 55.53 1.67 19.53 2.40 31.77 20.80 28.50 
stdev 1.68 9.10 22.76 1.16 6.28 0.57 3.09 3.42 19.63 
rsd 9.74 12.20 40.99 69.37 32.17 23.89 9.71 16.46 68.88 
Table 8 Recoveries for nine selected pharmaceuticals for triplicate recovery 
 
It is clearly illustrated in Figure 19 that there is a degree of variability from what is 
essentially the same sample tested. A stock solution was prepared and three sub samples 
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taken for the use of a triplicate experiment in the laboratory. Results shown in Table 8 
clearly highlight the variability between samples with statistical analysis. It is also 
useful to use triplicate samples as this experiment shows, is to identify outliers which 
may bias results. It can be seen that the third (SPE Supelco 3) sample for Meclo is an 
anomalous result with a recovery of 56.10 % compared to the others of 12.10 % and 
17.30 %, and therefore if not identified and removed, will subsequently increase 
statistical bias as seen in the standard deviation and relative standard deviation. These 
values would be significantly lower and accepted if this was the case. There is also 
another outlier identified in the Meb trials from the second sample (SPE Supelco 2) of 
23.40 % compared to the others of 73.30 % and 69.90 %. Once again this affects 
statistical tests.  
 
3.5.2 The effect of removing MAE on IS Phenacetin recovery 
During sample data analysis for section 3.3, it can be concluded that Phenacetin was the 
better IS to use than Diuron. This is possibly due to a characteristic difference in the 
compounds such as melting or boiling point (Table 9) or other properties (Error! 
Reference source not found. and Table 10). If one has a higher or lower melting or 
boiling point than another it may me more susceptible to the MAE treatment and 
provide better results to use as an IS for the developed method. It was concluded that. 
An experiment was conducted using both Phenacetin and Diuron and how they 
performed with and without the use of MAE. The protocol used for this set of 
experiments followed that developed previously.   
 
 
Table 9 Pharmaceutical compounds and their physiochemical properties (USEPA EPI 
Suite 2009) 
 
 
89 
 
 
Compound log(Kow) log(Koc) 
Kd (soil 
water) 
Reference 
Pro 1.2-3.48 
2.45-
2.96 
9.6/37.6 
Zhang 2007, USEPA KOCWIN, 
Beausse 
Sulf 0.5 
1.54-
2.41 
0.22/1.8 
Zhang 2007, USEPA KOCWIN, 
Beausse 
Meb 3.82 
3.02-
5.31  
USEPA KOWWIN, KOCWIN 
Thio 5.9 
4.06-
5.09  
USEPA KOWWIN, KOCWIN 
Carb 2.45 
2.23-
3.12 
1.4/4.4 
Zhang 2007, USEPA KOCWIN, 
Beausse 
Tamo 6.3 4.4-6.42 
 
USEPA KOWWIN, KOCWIN 
Indo 4.27 
2.34-
2.90  
Zhang 2007, USEPA KOCWIN 
Diclo 4.5 
2.61-
2.66 
0.8/5.9 
Zhang 2007, USEPA KOCWIN, 
Beausse 
Meclo 5.12 
2.62-
3.44 
  Zhang 2007, USEPA KOCWIN 
 
Table 10 Physicochemical properties of pharmaceuticals analyzed in this study 
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Figure 20 Comparison of using internal standard Phenacetin with and without MAE 
(n=3) 
With the inclusion of MAE on sample compound extraction it is obvious that 
Phenacetin outperformed Diuron (Figure 20). Diuron produced much lower recovery of 
the selected compound, of which this was without the use of MAE (Figure 21). 
Therefore the use of Phenacetin (with MAE) was used in further uses of the developed 
method. This is not only for the reason of a greater recovery but also its similarity to 
analytes used for experimentation.  
 
Figure 21 Comparison of using internal standard Diuron with and without MAE (n=3) 
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3.5.3 Triple vs. quintuplicate LC-MS replicates to test variability of samples 
 
 
Figure 22 Comparison of using three and five replicates of the same sample on recovery 
(n=5) 
Experimentation for further method development required increasing duplicate number 
to improve overall accuracy of results. Standard practice in science concludes that there 
is increased accuracy with a higher number of duplicate samples tested. The method 
validation protocols and quality assurance is in line with EU protocols.  
 
Following the realisation that a subsample can vary upon laboratory analysis (3.4.1), it 
must also be considered that a subsample from each of these used during LC-MS/MS 
analysis may also vary significantly. To illustrate this, a sample from 3.4.1 was analysed 
5 times and the recoveries displayed in Figure 22. The number of replicates will 
inevitably give a discrepancy in results with even the same sample, as this highlights. 
To illustrate this, the minimum combination of the average of these replicates were 
taken as if only 3 were taken as opposed to 5, and the same done for the 3 maximum 
results. There is a considerable difference in results. This highlights that the more 
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replicates are taken, the more accurate results are and anomalous results more easily 
identified. Table 11 highlights all possible combinations (recovery averages %) of 
results with minimum and maximum results.   
 
Rep. No. 
Short 
I.D. 
Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
1,2,3 1 8.3 12.0 0.0 1.6 19.3 15.3 17.4 24.2 23.6 
2,3,4 2 12.2 16.4 0.0 1.0 25.8 12.8 28.7 30.3 27.3 
3,4,5 3 15.5 18.8 0.0 0.6 29.5 12.6 35.6 36.7 30.2 
4,5,1 4 10.7 15.5 0.0 1.3 24.8 6.1 42.0 34.3 27.8 
5,1,2 5 5.5 10.4 0.0 1.6 17.6 6.0 32.0 25.5 22.7 
1,3,5 6 11.5 14.4 0.0 1.2 23.0 15.2 24.2 30.6 26.5 
1,3,4 7 13.5 17.1 0.0 1.2 26.4 15.4 27.3 33.0 28.7 
2,4,5 8 9.4 14.8 0.0 1.0 24.1 3.4 43.4 31.6 26.4 
5,2,3 9 10.3 14.7 0.0 0.9 22.3 12.5 25.7 27.9 25.0 
4,1,2 10 7.4 12.2 0.0 1.7 21.1 6.2 35.1 27.9 24.9 
1,2,3,4,5 11 10.4 14.6 0.0 1.2 23.4 10.5 31.1 30.2 26.3 
Minimum 5.5 10.4 0.0 0.6 17.6 3.4 17.4 24.2 22.7 
Maximum 15.5 18.8 0.0 1.7 29.5 15.4 43.4 36.7 30.2 
Table 11 5 replicates with different combinations of 3 replicates to show variance and 
inaccuracy of low replicate number. Average percentage recovery 
 
 
3.5.4 Percentage recovery; the use of calibration curves as a measure of increased 
accuracy 
Following method development, the possibility of using calibration curves were 
considered for the analysis of results. This is due to the instability and uncertainty of 
using either Phenacetin or Diuron as an IS. There have been occasions where there are 
high discrepancies in results, and of other compounds in comparison being over 100 % 
(some instances of > 3000 %). This was because the IS compounds were not being 
recovered effectively in the first place which meant that in comparison, the rest of the 
compounds in samples were unreliable. Figure 23 illustrates the R squared (r
2
) values of 
results from using different concentrations (ng/l) of compounds for the use of 
calibration curves. All ten compounds (including Phenacetin) gave highest values (most 
accurate) at 200ng/l, excluding Sulf (500 ng/l) and Diclo (1000 ng/l), however their 
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values for 200 ng/l were still very acceptable and so 200 ng/l was used for all 
calibration curves.  
Figure 24 to 
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Figure 32 illustrate the calibration curves for all compounds. The dark line indicates 
average value of triplicate data points and crosses indicate each replicate value. The 
dashed line represents regression line, with r
2
 value on top left of graph.  
 
 
 
Figure 23 R squared values for calibration curve data 
Conc 
(ng/l) 
Pro Sulf Meb Thio Phen Carb Tamo Indo Diclo Meclo 
2000 0.81 0.9762 0.7355 0.0805 0.8566 0.8703 0.185 0.9104 0.9882 0.9388 
1500 0.7711 0.9752 0.5694 -0.2518 0.8498 0.8543 
-
0.2379 
0.7853 0.9918 0.9138 
1000 0.5986 0.9684 0.2363 -1.3318 0.7207 0.7202 
-
1.3521 
0.4226 0.9923 0.7234 
500 0.7735 0.9768 0.4006 -0.0949 0.8141 0.9127 
-
0.2417 
0.5553 0.9874 0.9483 
200 0.9917 0.8988 0.8438 0.5856 0.9885 0.9386 0.5912 0.9674 0.9404 0.9654 
100 0.9918 0.8186 0.7087 0.6463 0.9935 0.8277 0.3347 0.8389 0.8847 0.8505 
50 0.9982 0.9981 
-
1.3495 
-1.8065 0.9915 0.9965 
-
7.0842 
-8.73 0.3983 - 
10 1 1 - - - 1 - - - - 
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Figure 24 Calibration curve for Propanolol 
 
 
Figure 25 Calibration curve for Sulfamethaxazole 
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Figure 26 Calibration curve for Mebeverine 
 
 
Figure 27 Calibration curve for Thioridazine 
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Figure 28 Calibration curve for Carbemazepine 
 
 
Figure 29 Calibration curve for Tamoxifen 
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Figure 30 Calibration curve for Indomethacine 
 
 
Figure 31 Calibration curve for Diclofenac 
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Figure 32 Calibration curve for Meclofenamic Acid 
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3.5.5 Analysis of a blank 
 
Figure 33 Analysis of a blank for target compounds 
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Blank 1 0.00 0.00 0.79 0.00 0.02 0.00 0.00 0.00 0.00 
Blank 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Blank 3 0.11 0.00 0.00 0.00 0.05 0.03 0.00 0.00 0.00 
Average 0.04 0.00 0.26 0.00 0.02 0.01 0.00 0.00 0.00 
stdev 0.05 0.00 0.37 0.00 0.02 0.01 0.00 0.00 0.00 
rsd 141.42 0.00 141.42 141.42 93.48 141.42 0.00 0.00 0.00 
LOD 0.15 0.00 1.11 0.00 0.06 0.03 0.00 0.00 0.00 
Table 12 Data for concentration of target compounds found in analysis of a three blank 
samples 
 
It can be concluded that the analysis of a blank showed no significant background levels 
of any compound being investigated (Figure 33 and Table 12). Mebeverine has not only 
the highest concentration identified in a blank (0.79ng/l, table 8) (which in the scheme 
of this thesis is a very small scale amount), it also has the highest variability between 
replicates of the same sample, with a standard deviation of 0.37, which suggests this 
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could also be an anomalous recording of result. Mebeverine, Thioridazine, 
Indomethacine, Diclofenac and Meclofenamic acid all showed no background 
concentration in the blank sample. Remaining compounds had concentrations between 
0.01 and 005ng/l, which renders the data to be irrelevant in comparison to sample 
analysis.  
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3.5.6 Direct vs. indirect injection 
 
Figure 34 A comparison of all coumpounds using direct and indirect injection to SPE 
cartridge 
 
When performing SPE on sample analysis it was apparent that removing the process of 
diluting the sample in 500ml of deionized water would clearly hasten this stage of 
investigation. This would only affect results, so to prove this I tested direct and indirect 
injection to the SPE column. Direct injection was to add the standard pharmaceutical 
stock solution straight onto the SPE column and indirect injection involved the process 
of diluting this in 500ml water, and then to draw through a vacuum so compounds 
would be held in the SPE column. After elution with methanol and nitrogen blow down, 
samples were analysed using the tested LC-MS/MS method and recovery of target 
compounds quantified.  
Recoveries between 52 – 98 % (Thio and Carb respectively) illustrates that indirect 
injection outperformed direct injection, with between only 0 and 55% recovery (Figure 
34). Explanation for the discrepancy between injection recoveries indicates loss of 
compounds via evaporation between release from syringe and absorption to SPE 
cartridge or immediately after the solution is injected to the SPE column. Diluting the 
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target compounds in 500ml deionized water ensures retention of compounds so 
maximum recovery is produced from the SPE filtration process.  
Interestingly, Thioridazine produces the lowest recovery with indirect injection (52%) 
and maximum recovery for direct injection (55%). Surprisingly, direct injection 
outperforms indirect injection, and that the results are fairly similar. This suggests 
properties of Thioridazine prevents loss or retention of compounds in comparison to the 
two different techniques.  
 
 
3.5.7 Particle size 
Sample 
I.D. 
Sample 
Name 
Median 
Size (µm) 
Mean 
Size (µm) 
Average 
Median Size 
(µm) 
Average 
Mean Size 
(µm) 
StDev 
Median 
StDev 
Mean 
5up1 
500m 
Upstream 
11.12 28.50 
14.96 37.48 3.87 8.30 5up2 14.92 39.07 
5up3 18.85 44.88 
up1 
Upstream 
20.76 75.72 
18.86 78.45 4.75 39.57 up2 22.37 119.31 
up3 13.46 40.31 
effluent1 
Effluent 
7.78 19.37 
6.95 17.47 1.17 2.68 effluent2 6.13 15.58 
effluent3 439.16 430.47 
down1 
Downstream 
14.10 57.71 
13.56 42.20 2.56 15.92 down2 10.76 25.91 
down3 15.80 42.99 
Table 13 Particle size analysis data for River Ouse sampling locations 
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Figure 35 Analysis of paricle size statistics from the River Ouse (µm) 
 
 
Particle size analysis was conducted using a HORIBA Partica LA-950 for Windows 
[Wet] Ver3.50 (Laser Scattering Particle Size Distribution Analyzer) for each sample, 
including replicates, for the River Ouse sediment analysis. The average median size of 
particles ranged between 6.95 – 18.86µm and the average mean size of particles ranged 
between 17.47 – 78.45µm (Table 13). Figure 35 clearly demonstrates that the Upstream 
location had the largest particle size, with a mean of 78.45µm. 500 meters upstream 
from the effluent size the average particle size was 37.48µm, effluent site was the 
lowest observed mean particle size of 17.47µm. Downstream from the effluent site, a 
mean particle size of 42.40µm was observed. Where the maximum particle size was 
observed, there was a high variability between sample replicates, with a standard 
deviation of 39.57. The effluent site had the best standard deviation of 2.68, which 
suggests that there are strict regulations made by the sewage treatment works at this 
location. There is an anomalous result the effluent site (effluent 3) which was not 
included in the analysis of results and has been discarded for further analysis. It is most 
likely a cause of larger particle filtrating to the sample on pre-treatment for the particle 
size analyzer.  
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Full particle size analysis data output from the HORIBA can be seen in Appendix 1.  
 
3.5.8 Sample stability testing 
Over a period of six weeks the stability of standard pharmaceutical stock solutions 
(200ppm) were monitored for loss of compounds and stability of samples. Stored under 
4 different conditions (room temperature covered, room temperature uncovered, fridge 
temperature covered and freezer temperature covered), a triplicate sub sample was taken 
on a weekly basis and analyzed for concentration of pharmaceutical compounds (Figure 
36, 37 and 38). Full data for these are found in Appendix 2 and 3.  
 
Figure 36 Temperature data for three different storage options 
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Figure 37 Relative Humidity (%RH) of the three storage solutions 
 
 
 
Figure 38 Sample volume losses (g) during stability testing 
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Figure 39 Stability of Propanolol over 10 weeks under different storage conditions 
 
 
Figure 40 Stability of Sulfamethaxazole over 10 weeks under different storage 
conditions 
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Figure 41 Stability of Mebeverine over 10 weeks under different storage conditions 
 
 
Figure 42 Stability of Thioridazine over 10 weeks under different storage conditions 
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Figure 43 Stability of Carbemazepine over 10 weeks under different storage conditions 
 
Figure 44 Stability of Tamoxifen over 10 weeks under different storage conditions 
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Figure 45 Stability of Indomethacine over 10 weeks under different storage conditions 
 
 
Figure 46 Stability of Diclofenac over 10 weeks under different storage conditions 
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Figure 47 Stability of Meclofenamic Acid over 10 weeks under different storage 
conditions 
 
After three weeks (day 3), all compounds in the 200ppm standard stock solutions had 
evaporated from uncovered samples at room temperature, as was the case after four 
weeks (day 4) for those stored at room temperature with a cover (Figure 39 - 47). The 
sample loss may have occurred between reading 2 and 3 or 3 and 4 for some 
compounds, however it is unknown the exact time due to weekly readings. To identify 
when exactly this happened, hourly readings would need to be considered. The covered 
sample may have allowed a small volume of the solvent matrix to be evaporated even 
though to the human eye a sufficient seal had been created. These samples were also 
exposed to light unlike the remaining two storage methods. All compounds in the 
uncovered sample increased after the second week of sample extraction. Exposure to 
surrounding air may have meant that the sample was contaminated with those 
compounds already present in the atmosphere which would increase existing levels in 
the sample. Target pharmaceutical compounds were also relatively volatile and so the 
uncovered sample rapidly lost those compounds under investigation.  
It is observed that between the two remaining storage solutions in the fridge and freezer 
that overall, the fridge temperature sample produced the highest amount (peak area) of 
all target compounds excluding Indomethacine. As only one compound would be 
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compromised with this storage method, sample storage at fridge temperature is 
observed to be the most preferable. However it must be noted that this result is possibly 
due to errors in analytical protocols, despite the preferred storage conditions being given 
as a result. As there are no error bars provided in the discussed figures, it is difficult to 
comment on the results and so results are in this case assumptions based on available 
data.  
 
3.5.9 Matrix Effect 
It was important to consider the effect of the matrix on sample recovery and compound 
quantification as if a significant amount of known spiked compound was lost purely 
owing to a selected extraction method, it may affect results and give lower false 
amounts.  
Firstly a sample containing no matrix, ie solvent and spiked compounds only, was 
analysed at 8 different concentrations on the LC-MS/MS to determine absolute 
optimum recovery (100%). The no matrix solution is simply a standard solution as a 
comparison to samples containing a matrix to assess the matrix effect. These 8 
concentrations (10, 50, 100, 200, 500, 1000, 1500 and 2000ppm) were then analysed 
using three different extraction techniques; ultrasonication, microfugation and MAE. It 
was expected that with the addition of the matrix that compounds would be readily 
retained in the sediment sample. For these experiments a tested clean sediment sample 
was used to minimise background concentrations of target compounds. These 
concentrations were subtracted from the final result. Thioridazine, carbemazepine and 
Tamoxifen always obtained highest concentration recovery irrelevant of extraction 
technique. Results are displayed in Figure 48 – 51. 
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Figure 48 No matrix 
 
 
Figure 49 The effect of Ultrasonication on matrix effect 
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Figure 50 The effect of Microfugation on matrix effect 
 
 
Figure 51 The effect of MAE on matrix effect 
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3.5.9.1 Compound by compound 
 
Figure 52 Different conditions affecting the matrix effect of Propanolol 
 
 
Figure 53 Different conditions affecting the matrix effect of Sulfamethaxazole 
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Figure 54 Different conditions affecting the matrix effect of Mebeverine 
 
Figure 55 Different conditions affecting the matrix effect of Thioridazine 
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Figure 56 Different conditions affecting the matrix effect of Carbemazepine 
 
Figure 57 Different conditions affecting the matrix effect of Tamoxifen 
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Figure 58 Different conditions affecting the matrix effect of Indomethacine 
 
 
Figure 59 Different conditions affecting the matrix effect of Diclofenac 
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Figure 60 Different conditions affecting the matrix effect of Meclofenamic Acid 
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Table 14 Summary of Matrix Effect data on all target compounds 
 
It was observed from figures 52 to 60 that compound recovery had been significantly 
diminished under all conditions, with the smallest matrix effect observed using U 
extraction. For compounds Meb, Thio, Tamo, Indo and Meclo, ultrasonication 
significantly increased observed peak area for all concentrations possibly owing to 
agitation releasing a higher concentration of the target compound in the sediment 
sample. It must be noted that the sediment sample used may have already contained an 
unknown amount (although minimal) of target compounds. This was also the case for 
Meb tested using MAE, due to other physiochemical properties such as boiling and 
melting temperature. Table 14 gives full data information.  
Compound Extraction Method 10 50 100 200 500 1000 1500 2000
Ultrasonication 654335.6 1505998.2 5889040 6633493 13389999 16373719 19363265 28562990
No Matrix 232897 1704087.2 4187361 6959406 11912919 17796931 23346081 27885177
MAE 130457.9 531191.56 1057884 2014050 7068718 8917420 12047628 18682930
Microfuge 426531 534418.29 881446.2 1462755 3892074 5628995 7562895 11450468
Ultrasonication 5197.603 17669.843 257285.8 203343.1 726103.5 1933092 2486482 4730446
No Matrix 1944.691 10061.485 52170.57 189069.7 786275.8 2135699 3738977 4924089
MAE 4232.557 11476.187 43593.06 163576.6 1726292 2221110 2651249 3751246
Microfuge 3264 11210.225 35792.23 71008.34 588137.4 1155725 1842576 3386314
Ultrasonication 72168.05 176037.09 237341 246683.1 433032.4 578793.5 940594.9 2188634
No Matrix 57292.04 116283.1 161590.5 228208 360381.2 546589.5 665326.6 812134.3
MAE 34500.58 62481.677 94360.88 149192.6 377699.9 467568.3 521684 962154
Microfuge 43625 63155.348 85260.18 110009 233736.6 308309.5 403465.3 558672.5
Ultrasonication 8243437 15856814 23788117 26497016 38449646 42536067 42904816 46771376
No Matrix 5967521 11131669 15515082 20886195 31113333 38515228 43945808 44721469
MAE 1549628 4007290.1 7291371 12331959 34702108 40081180 44213268 47512365
Microfuge 2315486 4329846.5 6302520 9708877 22338814 29461855 35407181 44917979
Ultrasonication 261148.1 1532813.3 9703134 10604853 16529519 21288420 23650402 30955826
No Matrix 81596.27 923798.21 5749273 11182770 17866317 23839597 28201629 30984838
MAE 75977.76 360266.33 1624761 5060420 20117209 23493485 25315492 30945321
Microfuge 645213 351220.45 1291165 2870050 10500765 16187895 20827381 28704063
Ultrasonication 12252385 20517798 29966033 32948120 51565039 59727233 62011755 74778432
No Matrix 10760782 18882765 27413484 32580304 44814924 56274605 63656660 67214287
MAE 4273851 9910785.2 17501031 26789627 56645448 68933518 68952199 69314258
Microfuge 8512341 10349461 15238911 22072875 40246548 48371731 54830700 66821109
Ultrasonication 589547.2 1457637 3728475 3745315 5327826 7817558 7213059 9778408
No Matrix 224917.5 736715.27 1632753 2484964 3989310 5495329 6416809 8017631
MAE 112593.1 370805.11 699251.5 1012457 2713417 3151472 5362147 6214587
Microfuge 425319 282549 492561.1 842324.2 1769779 2250975 2792071 3461670
Ultrasonication 18313.98 59845.363 294989.8 287179.7 657118.1 1197502 1237739 1842226
No Matrix 5867.163 37318.9 133899.8 272285.9 657010.8 1172072 1546987 1964949
MAE 10309.16 25176.426 61212.13 144486.3 638343.9 772802.9 1136895 1421579
Microfuge 10945 19565.45 41395.58 83029.79 304912.7 490082.4 682596.3 1042737
Ultrasonication 29025.32 69533.376 250866.1 211276.1 493061.1 957174.6 852063 1199917
No Matrix 4363.477 15225.52 37073.96 77932.36 207728.9 452223.8 627758.4 878195.3
MAE 19618.83 35832.637 67618.57 162974 704383.4 844494.4 965472 1092444
Microfuge 10374 19994.517 38105.65 66458 260820.6 389566.5 576845.3 883452.7
Pro
Sulf
Meb
Thio
Carb
Tamo
Indo
Diclo
Meclo
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Microfugation caused the lowest compound peak area observations. During the micro 
filtration process compounds may become trapped in the sediment left behind, leaving 
only a small amount to pass through the filter film for analysis. For this reason 
microfugation was not tested at any further stage during method developent and 
analysis.  
 
Figure 61 Matrix of all compounds at 200ppm 
 
 
Figure 62 Normalization of 4 compounds at 200ppm 
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A concentration of 200ppm stock solution of pharmaceuticals was identified to be the 
most effective for sample testing and analysis. Illustrated in figure 61, it is evident that 
U produces overall best compound recovery, and outperforms a solvent only sample 
tested to illustrate the effect of no matrix. Sulf, Meb Indo, Diclo and Meclo although all 
producing conclusive results, were on a smaller scale and so a normalised results graph 
illustrates again how U outperforms any other extraction method (Figure 62), with 
microfugation, as for all compounds, producing poorest results. All compounds are 
successfully recovered at a good volume using 200ppm compound solutions with U, 
therefore the IS  stock solution of Diuron was produces at a concentration of 200ppm 
and used to spike all subsequent experiments. U was the extraction method of choice. 
Table 15 gives the peak area for the matrix effect of the method.  
 
  Ultrasonication No Matrix MAE Microfuge 
Pro 6633493.0 6959405.7 2014049.7 1462755.3 
Sulf 203343.1 189069.7 163576.6 71008.3 
Meb 246683.1 228208.0 149192.6 110009.0 
Thio 26497015.5 20886195.3 12331959.0 9708877.0 
Carb 10604853.0 11182770.0 5060419.9 2870050.0 
Tamo 32948119.5 32580304.0 26789626.8 22072875.0 
Indo 3745314.8 2484963.9 1012456.6 842324.2 
Diclo 287179.7 272285.9 144486.3 83029.8 
Meclo 211276.1 77932.4 162974.0 66458.0 
Table 15 Peak area for matrix effect of developed analytical method 
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3.5.10 Inter-day variability 
 
Figure 63 Inter-day variability over twelve days of all compounds 
 
A stock solution sample of 200ppm was run once a day for twelve days on the LC-
MS/MS to test variability of the equipment used, using a no matrix sample. In theory, 
the sample should remain at a constant level until there is none left. It can be seen in 
figure 45 that this is not true. Tamo, Carb and Thio recorded the highest peak areas, and 
the lowest recorded by Meb, Sulf and Meclo. Tamo showed the highest degradation 
between day 1 and 10, at which point the sample data reduces to a level below 
quantification due to degradation and evaporation.  
Degradation of samples plays a contributing factor in testing inter-day variability of the 
LC-MS/MS. Figure 63 clearly indicates that after day 10 the sample had degraded to 
such an extent that all compounds became almost undetectable, and the reality was that 
the sample had dried up after being stored at room temperature (or warmer) inside the 
LC-MS/MS. Storage under investigated optimum conditions of fridge temperature may 
significantly restore peak area and sample usefulness to a normal level and last a lot 
longer. It can be concluded here that samples stored at room temperature are only 
effective up to ten days before the peak area recorded is too low. Although there is 
preferred detection of up to 10 days, the sample is at its optimum for use up until day 4.   
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3.5.11 Intra-day variability 
Over a period of twelve days, intra-day variability was tested for LC-MS/MS equipment 
to analyse stability of the equipment. Results day by day are illustrated in Figure 64 to 
Figure 75 and a sample was taken and analysed over a three hour period on each day at 
the same time each day. It is noted that all results for compounds and days are stable 
and so as long as validation is carried out at the beginning of a set of samples this 
should be adequate. To ensure the highest accuracy, calibration was carried out once 
every 20 samples using the same stock standard solution each time to identify if there 
was and discrepancy and variability in results.  
 
 
Figure 64 Intra-day variability day 1 
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Figure 65 Intra-day variability day 2 
 
 
Figure 66 Intra-day variability day 3 
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Figure 67 Intra-day variability day 4 
 
 
Figure 68 Intra-day variability day 5 
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Figure 69 Intra-day variability day 6 
 
 
Figure 70 Intra-day variability day 7 
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Figure 71 Intra-day variability day 8 
 
 
Figure 72 Intra-day variability day 9 
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Figure 73 Intra-day variability day 10 
 
 
Figure 74 Intra-day variability day 11 
 
130 
 
 
Figure 75 Intra-day variability day 12 
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Chapter 4 - Validation of the developed method by application to environmental 
samples 
 
4.1 Introduction 
It is important to assess quality assurance (QA) at every step of method development, as 
highlighted in chapter 3. Following these, this chapter is a natural progression; method 
validation by application to real environmental samples. The analytical method 
developed based on ultrasonication was validated by the linear range, sensitivity, 
accuracy and precision as detailed in chapter 3. A series of injections of the target 
compounds in the concentration range from 1 μg/ml to 200 μg/ml and 1 μg/ml of 
internal standards were used to determine the linear concentration range of LC-MS/MS 
instrumentation. Repeated injections confirmed the linear range being between 1-100 
μg/ml with values of r2 > 0.92. 
The limits of detection (LOD), calculated as the concentration of three-times the 
standard deviation in 10 independent blank performance (Zhang and Zhou, 2007), are 
again given in chapter 3.5.5. The limits of quantification (LOQ) are the minimum 
concentrations of quantitative analysis, and determined as the analyte amount related to 
a signal/noise ratio of 10.  For all the compounds being analysed, their LOD values fell 
between 0.01 and 0.71 ng/g, and their LOQ values varied from 0.03 to 2.10 ng/g, all on 
dry weight basis. 
 
Full procedure recovery tests were performed for the validation of this method by 
spiking three different levels of standard mixture in sediment samples, and results 
presented in Table 3. Mean recoveries of all analytes except Meb and Thio in sediments 
ranged from 61.7 to 93.2 % at the spiking level of 5-50 ng/g, with RSD less than 22 %. 
Therefore, the results confirm that the method developed exhibits a satisfactory 
precision and reproducibility for the separation and determination of pharmaceutical 
compounds from sediment samples. 
 
Figure 76 gives a full process flow of experimentation and validation for this thesis.  
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Figure 76 Process flow of thesis and experimentation 
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4.2 Pilot Study - Analysis of environmental sediment samples in the River Ouse 
To test the analytical method developed in chapter 3 for the analysis of a range of 
PPCPs in sediment samples, this was applied to real environmental samples. Prior to the 
final sampling location being assessed, a small pilot study was conducted at a different 
location to further ensure that the method was applicable to real environmental samples 
rather than in a laboratory without using a real sample. However following matrix effect 
consideration experiments there should be no reason that the method would be any less 
effective.  
A small stretch of the River Ouse in East Sussex, UK, was selected for this purpose. 
This was chosen as a sampling location due to ease and close proximity to the 
laboratory, but more importantly the effluent site which could act as a source of the 
target pharmaceuticals into the river. Four sampling locations were selected; the effluent 
site, 100 m downstream from this, 10 m upstream, and 500 m upstream. This is 
proposed to give a good indication of how the effluent site affects the concentration of 
named PPCPs up and downstream from this.  
Figure 77 is a satellite image of the River Ouse which is clearly seen in the middle of 
the image. The sewage treatment works are also clearly identified just below the centre 
of the image. Figure 78 is a simple road map of the same location with the four 
sampling sites indicated by a circle at each. From left to right the sampling sites are as 
follows; 100 m downstream, effluent site, 10 m upstream, 500 m upstream.  
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Figure 77 Satellite image of sampling location at River Ouse (www.google.com, viewed 
on 14.04.2010). The outline of the river is seen in Figure 2. 
 
 
Figure 78 Four sampling sites at the River Ouse (www.google.com, viewed on 
14.04.2010) 
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4.2.1 River Ouse pilot study report  
After the preparation of samples using the Ultrasonication (U) method, samples were 
analysed using LC-MS/MS. It can be concluded from Figure 5 that the mean 
concentrations of pharmaceutical compounds are most dominant at the sewage effluent 
site (1.5 - 213.3 ng/g dry weight), as also seen in Table 16. This is all except Meb which 
had the highest concentration at the upstream site (23.59 ng/g). The concentrations of 
the target compounds became elevated at the effluent site, and also at downstream due 
to output at the effluent site. The most abundant and potentially persistent 
pharmaceutical compound identified was Tamo with concentrations between 63.9 ng/g 
and 213.3 ng/g, and the least being Thio with concentrations between < LOD and 1.5 
ng/g. 
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
500m Upstream 1.43 0.64 7.42 96.33 7.66 103.27 18.16 11.43 17.10 
Upstream 4.24 0.30 23.59 100.67 18.27 117.31 19.83 11.15 20.55 
Effluent Site 9.15 5.90 20.89 100.04 53.08 271.28 69.42 35.77 54.81 
Downstream 4.38 2.49 3.72 96.05 18.00 192.39 62.40 31.50 38.60 
 
Table 16 Concentration (ng/g) of pharmaceutical compounds found at the River Ouse 
(Sussex) in June 2009. 
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Figure 79 Concentration (ng/g) of pharmaceutical concentrations at sampling sites along 
the River Ouse (Sussex) in June 2009. 
 
When displayed graphically, it is apparent that the highest concentration of target 
PPCPs is identified at the effluent site (Figure 79). As expected, the concentrations of 
pharmaceuticals downstream from the effluent site are considerably raised to what were 
considered the normal (background) concentrations upstream. It can be argued that the 
concentration 10 m upstream may have some backflow PPCPs from the effluent site due 
to the natural tide flow of the river, however this does not appear to be significant 
statistically in this pilot study. As highlighted previously, Tamo not only has the highest 
concentration of all PPCPs analysed, but also the highest variability, shown in Figure 79 
by error bars. 
Compounds became increasingly concentrated as from 500 meters upstream to the 
effluent site, after which downstream the concentration remains significantly higher 
than before due to output at the effluent site. The most persistent pharmaceutical 
compound identified was Tamo with concentrations between 103.27 ng/g and 271.3 
ng/g, and the least being Sulf with concentrations between 0.30 ng/g and 5.90 ng/g. The 
concentrations of other compounds were as follows; Pro 1.43 – 9.15 ng/g, Meb 3.72 – 
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23.59 ng/g, Thio 96.05 – 100.67 ng/g, Carb 7.66 – 53.08 ng/g, Indo 18.16 – 69.24 ng/g, 
Diclo 11.15 – 35.77 ng/g and Meclo 17.10 – 54.81 ng/g.  
Analysis of a blank concluded no significant background concentration of target 
compounds (Table 17). Compounds Sulf, Thio, Indo, Diclo and Meclo produced zero 
concentrations in the blank sample. Only four compounds identified background 
concentrations, all below 0.80 ng/l; Pro 0.04 – 0.11 ng/l, Meb 0.26 – 0.79 ng/l, Carb 
0.02 – 0.05 ng/l and Tamo 0.01 – 0.03 ng/l. Average and variability values are also 
calculated. Although minimal background contamination, average blank values were 
deducted from sample validation analysis.  
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Blank1 0.11 0.01 0.26 0.01 0.05 0.01 0.01 0.01 0.01 
Blank2 0.04 0.01 0.79 0.01 0.02 0.01 0.01 0.01 0.01 
Blank3 0.07 0.01 0.34 0.01 0.02 0.03 0.01 0.01 0.01 
Average 0.07 0.01 0.46 0.01 0.03 0.02 0.01 0.01 0.01 
Stdev 0.04 1.69 0.29 1.69 0.02 0.01 1.69 1.69 1.69 
LOD 0.11 5.10 0.86 5.10 0.05 0.03 5.10 5.10 5.10 
Table 17 Analysis of a blank during River Ouse experiments (ng/l) 
 
The limit of detection (LOD) defined as the concentration that corresponds to three 
times the standard deviation of blanks (Zhang and Zhou, 2007), was measured by 
integrating blank peak area for each analyte in three independent performances with 
ultrapure water as a blank. LOD varied from 0.01 – 5.10 ng/l (Table 17). 
In comparison to data from other studies, the pharmaceutical concentrations in the River 
Ouse are similar in magnitude. For examples, 1.45 - 137 ng/g of Carb and 4.56 - 128 
ng/g of Diclo were detected in sediment samples from rivers and groundwater in the UK 
(Maskaoui and Zhou, 2010). Similar levels of Carb (49 ng/g) and Sulf (6.8 ng/g) have 
been reported by Stein et al. (Stein et al., 2008). Sanchez-Prado et al. recently collated 
information from different sources on the analysis of emerging pollutants in solid 
samples, including Pro in sediment samples (Sanchez-Prado et al., 2010), Carb in 
mollusk (Cueva-mestanza et al., 2008b) and Diclo in river sediment  (Antonic and 
138 
 
Heath, 2007) (Dobor et al., 2010). Cueva-Mestanza et al. concluded and evaluated that 
no real contaminated samples although recoveries of over 70 % were identified (Cueva-
mestanza et al., 2008a). Cueva-Mestanza et al. also could not determine the 
concentrations of pharmaceuticals in the mollusk samples, but reported a recovery of 
>85 % (Cueva-mestanza et al., 2008b). Although Diclo was being analysed in river 
sediments by Anatonic and Heath (2007), they did not report any concentration data but 
only a recovery of 46 %. Dobor et al. (2010) reported Diclo concentrations of 23 – 138 
ng/g in activated sludge samples and a recovery of 83 %, both of which are similar to 
what is being found in River Ouse sediment samples. 
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
500m Upstream 5.76 0.66 15.58 3.21 16.80 37.59 7.75 3.12 10.07 
Upstream 8.61 1.74 11.16 4.64 19.29 39.64 12.18 5.78 17.84 
Effluent Site 2.82 1.13 2.73 5.45 12.39 47.44 10.20 7.80 9.95 
Downstream 1.18 0.95 9.86 6.03 5.38 32.47 4.25 2.18 4.85 
Table 18 Standard deviation of pharmaceutical compounds found at the River Ouse 
(Sussex) in June 2009. 
 
It is interesting to assess the variability between replicate samples taken at the same 
location at the same sampling time. Table 18 highlights the standard deviation 
(variability) of replicate samples taken from River Ouse analysis. The lowest overall 
sample variability was identified from Sulf, with values between 0.66 to 1.74, compared 
to Tamo which displayed the highest variability between replicate samples between 
32.47 and 47.44. However, even Tamo has acceptable levels of variability for 
environmental samples.  
Table 19 details how in the laboratory (ex situ), subsamples vary between one another 
and how variable their retrievals are. There were 4 groups of samples (5up, up, eff and 
down) with three subsamples taken in the laboratory (ca, cb, cc etc). Most samples have 
a good precision of samples during the River Ouse analysis. Others showed a high 
variability, for example; Pro for 5up has results of 0.28, 1.53 and 15.47 and Tamo for 
eff has results of 4.36, 38.89 and 99.08.  
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Table 19 Precision of samples during River Ouse analysis 
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Bias Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
500m Upstream 6.14 0.24 9.65 2.41 29.42 93.06 18.99 16.98 27.46 
10m Upstream 14.15 9.76 18.04 2.78 89.91 206.81 81.93 39.22 62.00 
Effluent 1.81 3.42 3.41 0.43 15.76 272.90 91.15 42.52 38.11 
100m Down 0.85 0.50 3.14 2.90 7.52 83.61 15.29 14.35 19.73 
Table 20 Bias (+) of samples during River Ouse analysis. 
 
Between the same sites, Table 20 highlights how between the same sites, how variable 
the retrievals are in the form of bias. Overall, Tamo has the highest bias with results 
between 83.61 and 272.90, and Thio the lowest with a variability of 0.43 to 2.90. This 
means that Thio is by far the most stable (less varying between sites) compound. Pro 
and Sulf also have a good low bias.   
 
 
Figure 80 R squared value of Sulf and Pro concentrations at the River Ouse 
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To identify whether there is a relationship between compounds, a graph displaying the r 
squared value of one example is displayed in Figure 80 between Sulf and Pro, ie as one 
compound increases/decreases so does the other. Results for all compounds are given in 
Table 21. Pro and Sulf were chosen as they have the highest correlation coefficient of 
0.2396 %, which is still not overly significant so r
2
 was disregarded for any further 
analysis and assumed that compounds are independent of one another.  
 
Rsquared Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Pro - 0.2396 0.2189 0.0056 0.0057 0.0076 0.013 0.0254 0.0059 
 
Sulf - 0.2189 0.0056 0.0057 0.0076 0.013 0.0254 0.0059 
 
Meb - 0.0056 0.0057 0.0076 0.013 0.0254 0.0059 
 
Thio - 0.0057 0.0076 0.013 0.0254 0.0059 
 
Carb - 0.0076 0.013 0.0254 0.0059 
 
Tamo - 0.013 0.0254 0.0059 
 
Indo - 0.0254 0.0059 
 
Diclo - 0.0059 
  Meclo - 
Table 21 All R squared values from the River Ouse (%) 
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4.3 Further Method Validation and Temporal Variability; Report of the River 
Medway Sewage treatment works.  
 
4.3.1 Introduction 
A small part of the River Medway in North Kent, UK, was selected for the 
environmental analysis of sediment samples using the developed and tested method 
(Figure 81). Figure 81 is a satellite image of the specific part of the River Medway used 
for these sampling locations. The River Medway is a large tidal river and begins at the 
West Sussex border and continues until it ends in the Thames Estuary; stretching for 
over 70 miles. Man has had an increasing effect on this river for centuries. In recent 
years, activity surrounding the river on the banks includes two industrial plants, gas 
towers, a paper mill and many STWs and WTWs. Run off from these activities poses an 
increased risk of contamination into the river. Due to the previously highlighted 
occurrence of PPCPs through excretion by humans, particular focus was drawn to one 
particular STW located on Motney Hill, located towards the end of Motney Hill Road 
(Figure 82). Figure 82 is a simple road map of the same location with the three sampling 
sites indicated by a circle at each. Three sampling locations were selected; upstream 
from the effluent site, at the effluent site, and downstream from this (left to right on 
Figure 82). This is proposed to give a good indication of how the effluent site affects the 
concentration of named PPCPs up and downstream.  
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Figure 81 Satellite image of sampling site at the River Medway (www.google.com, 
viewed on 10.12.2009) 
 
Figure 82 Sampling locations at the River Medway (www.google.com, viewed on 
19.01.2010) 
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4.3.2 Spatial Variability 
4.3.2.1 December 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22 Concentration (ng/g) and standard deviation of target pharmaceuticals from 
River Medway samples from December 2009 
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Concentrations of pharmaceuticals at the River Medway in December ranged from 0.6 
ng/g to 1194.2 ng/g for Sulf upstream and Tamo at the effluent site respectively (Table 
22).  
Figure 82 clearly illustrates Tamo having the highest concentration at all three sample 
sites, with 283.7 ng/g upstream, 1194.2 ng/g at the effluent site and 715.6 ng/g 
downstream. 
 
Figure 83 displays the data as a bar chart where Tamo is clearly identified as the highest 
detected concentration of compound across all sampling locations. Standard deviation 
indicates that Sulf is the most reliable detected compound with results closest to the 
mean value (0.8 – 9.1), compared to Tamo which alongside its highest concentration 
values also has the highest standard deviation ranging from 20.4 to 1132.7. This is not 
surprising as for higher values there is the possibility of more room of variability. 
Although the concentration was high, the values have been averaged from replicated in 
and ex situ. Overall, variability is lowest downstream from the STW, with standard 
deviation ranging only from 0.8 to 22.8.  
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Figure 83 Total concentration of pharmaceuticals at River Medway sample locations for 
December 2009 
All compounds excluding Meb, Thio and Carb increase from the upstream to effluent 
sampling site, the largest increased being Diclo with an increase of 41.5 ng/g from 16.5 
– 58 ng/g. All compounds excluding Tamo, Indo and Meclo remain high or at increased 
levels after the effluent site, downstream. The largest increase from effluent to 
downstream sampling site being Carb (49.7 ng/g), from 39.3 – 89.0 ng/g.   
Due to the high concentration of Tamo at all sites, all compounds appear to recover 
small concentrations, which is not the case as normalization of results demonstrates 
(Figure 84). Aside from Thio, all compounds are highest at the sampling location 
downstream from the effluent site, which were significantly higher than concentrations 
observed upstream. Therefore as you travel downstream the concentration of target 
pharmaceutical compounds increases and remains this way due to the effluent site of the 
sewage treatment plant. This indicates that compounds released from the effluent site 
accumulate downstream as sediment containing target compounds settles on the river 
bed.  
Table 22 concludes individual data points used to create Figure 82 and Figure 83. 
Concentration of target compounds were as follows; Pro 18.5 – 43.9 ng/g, Sulf 0.6 – 9.0 
ng/g, Meb 6.5 – 13.6 ng/g, Thio 95.6 – 101.3 ng/g, Carb 39.3 – 89.0 ng/g, Tamo 283.7 – 
1194.2 ng/g, Indo 46.7 – 82.2 ng/g, Diclo 16.5 – 73.6 ng/g and Meclo 31.8 – 56.0 ng/g.  
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It is sometimes not considered good practice to normalize results but however removing 
one to three compounds from the group on graphical analysis simply enhances those 
with lower concentrations and makes them visibly easier to analyze. Absolute 
concentrations are shown in the data tables and first graphical representations. This is 
seen in Figure 8.  
 
 
 
 
 
 
Figure 84 Total concentration of pharmaceuticals at River Medway sample locations for 
December 2009. Normalization of results. 
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4.3.2.2 February 2010 
Pharmaceutical compounds at the chosen sampling locations in February ranged from 
0.47 ng/g for Sulf at the effluent site to 239.42 ng/g for Tamo downstream from the 
effluent site. Overall, Sulf once again had the lowest observed concentrations from 0.47 
to 1.06 ng/g, and Tamo the highest from 144.73 to 239.42 ng/g (Figure 85). There was 
an overall low variability (standard deviation) excluding one value for Tamp of 160.28. 
All others ranged from 0.25 for Pro to 63.33 for Carb. This suggests that the levels of 
pharmaceutical concentration during February were relatively stable.  
It is obvious that from upstream to effluent to downstream sampling sites the 
concentration overall for target pharmaceutical compounds increases Figure 85. This is 
also true for the precision of sampling, with the highest standard deviation results 
observed at the downstream site (0.30 – 160.28), in Table 23. For all compounds 
excluding Thio and Diclo, the downstream sampling location produced the highest 
concentration. Those to the exception were only lower by a small amount.  
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Figure 85 Total concentration of pharmaceuticals at River Medway sample locations for 
sediment samples in February 2010. 
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Table 23 Sediment sample data for February 2010 at the River Medway 
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4.3.2.3 April 2010 
 
  
Table 24 Concentration (ng/g) and standard deviation of target pharmaceuticals from 
River Medway samples from April 2010 
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Figure 86 Total concentration of pharmaceuticals at River Medway sample locations for 
April 2010 
Concentration of pharmaceutical compounds ranged from 11.03 ng/g (Sulf at the 
effluent site) to 2080.75 ng/g (Tamo at the downstream site) (Table 24). All compounds 
had a good recovery, in particular Tamo which had a range between 175.84 ng/g to 
2080.75 ng/g. The compound with the least concentration in sediment samples was Sulf, 
which had a maximum value of only 32.92 ng/g at the downstream sampling location. 
All target pharmaceutical compounds were recovered from all sampling sites. The site 
and compound with the best precision was Sulf at the effluent site, with a statistic of 
0.64. The most precise overall compound for recovery was Thio with values in the 
range of 1.60 to 2.69, with recoveries between 98.01 ng/g (downstream), 99.73 ng/g 
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(effluent) and 99.97 ng/g (upstream), in ascending order, 
 
Figure 86. Overall, compounds were identified with highest concentrations at the site 
downstream from the effluent outflow path, which is the case for all compounds except 
Thio, with a very slight increase of only 1.72 ng/g between the downstream and effluent 
site.  
The variability between samples is generally small for those taken in April, with the 
lowest being 0.64 for Sulf at the effluent site and highest for Meclo with 115.98 
downstream (Table 24). Minimum and maximum values of all target pharmaceutical 
compounds are as follows; 32.57 – 303.27 ng/g for Pro, 11.03 – 32.92 ng/g for Sulf, 
93.33 – 413.83 ng/g for Meb, 98.01 – 99.97 ng/g for Thio, 175.84 – 2080.75 ng/g for 
Tamo, 96.15 – 533.89 ng/g for Indo, 68.47 – 401.64 ng/g for Diclo and lastly 76.24 – 
459.90 ng/g for Meclo.  
4.3.2.4 June 2010 
Concentrations of pharmaceuticals at the River Medway in June ranged from 11.57 ng/g 
to 6156 ng/g for Sulf downstream and Diclo at the effluent site respectively (Table 25). 
Concentration of target compounds were as follows; Pro 328.42 – 590.05 ng/g, Sulf 
11.57 – 25.53 ng/g, Meb 51.96 – 136.93 ng/g, Thio 98.82 – 100.30 ng/g, Carb 251.50 – 
547.33 ng/g, Tamo 1058.48 – 1742.55 ng/g, Indo 176.47 – 425.51 ng/g, Diclo 2228.56 
– 5295.62 ng/g and Meclo 1599.31 – 6156.95 ng/g.  
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Figure 86 clearly illustrates that both Diclo and Meclo have the highest concentration at 
all three sample sites, with Diclo ranging from 2228.56 to 5295.62 ng/g, and Meclo 
ranging from 1599.31 to 6156.95 ng/g. Figure 87 displays the data as a bar chart where 
Meclo is identified as the highest detected concentration of compound at the sampling 
locations upstream and at the effluent site, whereas Diclo is the highest at the 
downstream sampling site. Standard deviation indicates that Thio is the most reliable 
detected compound with results closest to the mean value (2.88 – 5.01), compared to 
others including Tamo with up to 1507.94, Meclo with 1090.25 and Diclo with 1008.41. 
These also have high initial detected concentrations; this is not surprising as for higher 
values there is the possibility of more room of variability. Although the concentration 
was high, the values have been averaged from replicated in and ex situ.  
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Table 25 Concentration (ng/g) and standard deviation of target pharmaceuticals from 
River Medway samples from June 2010 
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Almost all compounds increase from the upstream to effluent sampling site, the largest 
increased being Diclo with an increase from 2995.14 ng/g to 5295.62 ng/g. Those which 
do not only have a very small increase, for example Tamo decreases from 1060.07 ng/g 
to 1058.48 ng/g. All compounds excluding Thio and Tamo decreased in concentration 
after the effluent site to downstream. The largest decrease from effluent to downstream 
sampling site being Meclo from 6156.95 – 1599.31 ng/g.   
 
 
Figure 87 Total concentration of pharmaceuticals at River Medway sample locations for 
June 2010 
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4.3.3 Soil Moisture Content (SMC) and Organic Matter Content (OMC) 
Table 26 highlights representative data collected when three samples were tested to 
analyze for SMC and OMC of the samples. The SMC ranged from 30.41 % to 31.08 % 
with an average of 30.79 %, and an excellent standard deviation of 0.35. The OMC 
ranged from 1.64 % to 2.43 %, with an average of 2.08 % and once again excellent 
standard deviation of 0.40 %. To conclude, approximately one third of the samples were 
soil moisture, and only an average of 2.08 % organic matter. This suggests that there 
may be a considerable concentration of pharmaceutical compounds present in the water 
part of the sample which could be lost during sample preparation (drying), which may 
pose an important significance when considering analysis. The organic matter however 
only makes up an average of 2.08 % of the sample and is not lost during sample 
preparation, simply dried as a solid part of the matrix, and subsequently included in 
analysis for target pharmaceutical compounds. The precision of both the SMC (2.26) 
and OMC (38.38) were within very good (<10%) and acceptable (<60%) limits.  
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Table 26 SMC (%) and OMC (%) of three samples taken from the River Medway 
during sample anaysis 
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4.3.4 Water samples 
Total target compound concentration in water sampling varied between 10.40 ng/l for 
Sulf downstream to 14573.12 ng/l for Diclo at the effluent sampling location (Table 27). 
Remaining concentrations were as follows; 61.81 - 261.63 for Pro, 10.40 - 31.54 ng/l 
for Sulf, 79.07 – 1583.28 ng/l for Meb, 70.50 – 140.90 ng/l for Thio, 850.82 – 4821.10 
ng/l for Carb, 57.93 – 260.21 ng/l for Tamo, 94.90 – 569.82 ng/l for Indo, 1131.45 – 
14573.12 ng/l for Diclo and finally 1743.84 – 3404.38 ng/l for Meclo. Seven out of the 
nine compounds were higher at the effluent site than downstream, but interestingly two 
compounds were higher at the upstream sampling location, before the effluent site. 
Also, seven of the nine compounds were found in a smaller concentration at the 
downstream site compared to the effluent site.  
With regards to the standard deviation (variability) of results, again some of the 
statistics are high, however when compared to the high concentration values of 
corresponding concentration data, are well within the acceptable limit (Table 27). This 
is displayed more clearly graphically in Figure 88 Total concentration (ng/l) of 
pharmaceuticals at River Medway sample locations for water samples in June  
In comparison to the sediment samples taken at the same time (June), there can be no 
assumption of a direct relationship, other than that if there is a high concentration 
detected in the sediment samples, there may be a higher concentration in the water due 
to agitation due to water movement, remobilizing PPCP compounds back into the water.  
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Table 27 Concentration (ng/l) and standard deviation of target pharmaceuticals from 
River Medway water samples from June 2010 
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Figure 88 Total concentration (ng/l) of pharmaceuticals at River Medway sample 
locations for water samples in June 2010 
 
4.3.5 Temporal Variability 
Data collected for the analysis of pharmaceutical compounds in the River Medway 
allowed for a second data set to be produced for temporal variability. This was 
conducted every other month for eight months between December to June (December, 
February, April and June). From this, a snapshot into variability of pharmaceuticals at 
the same site can be drawn for a period of eight months and spanning three seasons 
(Winter, Spring and Summer). Due to limitations of this project, an analysis for Autumn 
was unable to be conducted along with any further sampling.  
4.3.5.1 Upstream Site 
During the first three sampling instances, the concentration of target pharmaceutical 
compounds were significantly lower than the final in June, when there was a sudden 
increase; namely for Meclo (4490.11ng/g), Diclo (2995.14 ng/g), Tamo (1060.07 ng/g) 
and Pro (526.26 ng/g) (Figure 89). Whether or not there is a relation to it being the 
coldest month during which samples were taken, February was noticeably the time 
when target PPCP compounds were at their lowest concentration, ranging from 0.51 
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ng/g for Sulf to 144.73 ng.g for Tamo. December and April were also fairly low in 
terms of concentration observed at the upstream site across all compounds, with 
December results ranging from 0.64 ng/g for Sulf to 283.68 ng/g for Tamo, and April 
ranging from 14.83 ng/g for Sulf and 250.37 ng/g for Diclo (Table 28). There may have 
been a slight overall increase in compound concentration in April due to a slightly 
warmer temperature, however this is only an assumption. Another contributing factor to 
consider is rainfall, which I would typically expect to increase in autumn and winter 
months. This is not reflected at all sites tested for temporal variability.  
 
Upstream Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Dec 18.54 0.64 13.56 101.30 54.04 283.68 46.69 16.47 31.83 
Feb 4.60 0.51 13.75 98.95 12.71 144.73 35.84 17.85 10.29 
Apr 32.57 14.83 93.33 99.97 57.35 175.84 135.03 250.37 109.79 
Jun 526.26 25.53 69.98 98.82 410.97 1060.07 425.51 2995.14 4490.11 
Table 28 Concentration (ng/g) of target pharmaceuticals from River Medway water 
samples between December 2009 to June 2010 for the upstream sampling location. 
 
 
Figure 89 Temporal variability of all nine target pharmaceutical over seven month 
sampling period at upstream sampling location (Dec 2009 to Jun 2010) 
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4.3.5.2 Effluent Site 
Compared to the upstream sampling site, the effluent site has an increased concentration 
of target PPCP compounds, which is to be expected (Figure 90). In fact, the effluent 
sampling location had the highest of all three, which is again expected. Concentrations 
were the highest during June, with a range between 21.50 ng/g for Sulf to 6156.95 ng/g 
for Meclo (Table 29). Sampling during this month had the highest identified 
concentrations for eight of the nine compounds. The only exception being Meb, which 
had a concentration of 136.93 ng/g in June compared to 213.28 ng/g in April. As with 
the upstream sampling location, February had the overall lowest concentrations when 
compared to the others in December, April and June. Concentrations only ranged from 
0.47 ng/g for Sulf (also the lowest overall detected concentration at the effluent site) to 
165.33 ng/g for Tamo. Surprisingly, Tamo has the highest observed concentration at the 
effluent site during December, with a concentration of 1194.24 ng/g. April once again 
had a higher concentration than both December and February for all compounds except 
one (Tamo in Dec, previously discussed).  
 
Figure 90 Temporal variability of all nine target pharmaceutical over seven month 
sampling period between December 2009 to June 2010 at effluent sampling location 
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Effluent Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Dec 21.94 2.10 6.50 95.63 39.29 1194.24 82.20 57.98 55.95 
Feb 3.164 0.47 14.27 97.66 11.84 165.33 32.08 11.23 7.33 
Apr 39.22 11.03 213.28 99.73 65.44 710.54 96.15 68.47 76.24 
Jun 590.05 21.50 136.93 99.16 547.32 1058.48 413.38 5295.62 6156.95 
Table 29 Concentration (ng/g) of target pharmaceuticals from River Medway water 
samples across all months for the effluent site sampling location (Dec 2009 to Jun 
2010). 
 
4.3.5.3  Downstream Site 
At the downstream sampling location, concentrations were higher than at the upstream 
site, but lower than at the effluent site suggesting an increase following the effluent site 
discharge. As seen in Figure 91, there is a higher variability of target PPCP 
concentrations across all sites. In particular, Tamo has a noticeably higher concentration 
at the downstream site (following discharge from the STW at the effluent site), with a 
range between 690.04 ng/g to 2080.75 ng/g, also the highest observed concentration at 
the downstream location across all months (Table 30). During June, concentrations were 
again higher than the remaining times sampled. Aside from Tamo (1742.55 ng/g), the 
other two high compound concentrations observed were for Diclo and Meclo (2006.34 
ng/g and 1599.31 ng/g respectively) (Table 30). Disregarding one compound (Meb), 
February has the lowest observed concentrations compared to the other three months.  
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Figure 91 Temporal variability of all nine target pharmaceutical over seven month 
sampling period between December 2009 to June 2010 at downstream sampling 
location 
 
Downstream Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Dec 43.94 8.95 11.22 99.78 89.00 715.57 70.59 73.56 52.90 
Feb 21.44 4.53 78.02 97.67 38.86 690.04 70.15 45.90 46.51 
Apr 303.37 32.92 413.83 98.01 149.30 2080.75 533.90 401.64 459.90 
Jun 328.42 11.57 51.96 100.31 251.50 1742.55 176.47 2006.34 1599.31 
 
Table 30 Concentration (ng/g) of target pharmaceuticals from River Medway water 
samples across all months for the downstream sampling location (Dec 2009 to Jun 
2010). 
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4.4 Applications of the developed and validated method to different environmental 
matrices 
Following both successful development and validation, the methods were applied to 
different environmental sample matrices to further assess the fate of pharmaceutical 
compounds in the aquatic environment. A selection of different samples were taken on 
site at the River Medway during the final sampling period. They were then stored 
appropriately and prepared as the river sediment samples were, to ensure that the 
method was applied in the same way as to reduce bias.  
Eleven different sample matrices were tested to identify if the developed method could 
be applied to different samples other than sediment. These samples included seaweed, 
rosehip, grass root, lugworm, clamshell, crab, snails, grass shoots, buds, dandelions and 
leaves. These experiments are different to method validation in that it is applied to 
different matrices other than simply sediment from the River Medway. It is important to 
assess if the method has a wider use and variety of applications. Ultimately it would be 
preferable if the developed and validated method was applicable to different matrices 
(vegetation and biological) without sacrificing recovery or reliability levels. Recovery 
was calculated as a percentage, and reproducibility was analysed by taking replicates in 
and ex situ.   
Following collection, the samples were processed as in 3.2.6; stored at -18 °C, freeze 
dried and homogenized. The samples were then subjected to the same process as the 
sediment samples and analysed for the same selected PPCPs using LC-MS/MS. Each 
sample collected was spiked with 5 ng of 20 ppm pharmaceutical standard solution. The 
data in Figure 92 indicates that aside from this 100 ng/l spiked to each sample, there 
was already a high volume of existing pharmaceuticals in each sample. However it must 
be noted that the water compounds input may enhance the signal of the LCMS.  
All applications, proved to have both high recoveries and concentrations of PPCPs 
tested, with a range between 2.51 – 536.44 %. In particular Meb, with recoveries 
between 40.58 % and 520.37 %; the highest was found in the crab sample (Table 31). 
This would cause significant effects on the crustacean as detailed in the review of 
relevant literature. The minimum was observed for Sulf in the rosehip sample and the 
maximum for Tamo in dandelions. The concentration data in the samples is not given 
due to the recovery being so high; this is more significant as it shows the viability and 
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success of the method. The actual PPCP content itself is not so important as recovery in 
this instance.  
Figure 92 Application data from method development and validation for different 
matrices in 2009 
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Table 31 Recovery values for different sample matricies for the application of the 
developed pharmaceutical method 
 
4.4.1 Vegetation samples  
4.4.1.1 Seaweed 
Seaweed (Ascophyllum nodosum) samples produced recoveries between 4.22 % and 
332.14 % (Sulf and Meb respectively), with five out of nine target compounds over 
satisfactory recoveries (≥50 %); Pro (70.58 %), Meb (332.14 %), Thio (221.93 %), Carb 
(116.99 %) and Tamo (112.03 %).  
4.4.1.2 Grass root 
Grassroot sample followed trend with the highest recovery for Meb (446.62 %). The 
lowest observed recovery was 26.73 % for Diclo. All other eight compounds excluding 
Diclo produced acceptible recoveries above and beyond the accepted recovery value. 
Recoveries observed were as follows; Pro 240.86 %, Sulf 69.88 %, Thio 229.35 %, 
Carb 164.53 %, Tamo 144.14 %, Indo 113.41 % and Meclo 53.64 %.  
4.4.1.3 Grass shoot  
Meb far outperformed any other compound recovery on grass shoot matrix analysis 
with 417.65 %. The next highest recovery was for the analysis of Carb with 274.85 % 
recovery; the highest of all matrices analysed. The lowest compound recovery for grass 
 Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Seaweed 70.58 4.22 332.14 221.93 116.99 112.03 42.49 16.93 25.87 
Rosehip 236.53 2.51 491.69 229.35 107.10 162.22 181.42 40.77 88.88 
Grass Root 240.86 69.88 446.62 229.35 164.53 144.14 113.41 26.73 53.64 
Lugworm 299.86 69.74 123.42 229.63 188.86 91.10 18.12 4.92 39.84 
Clamshell 280.28 51.02 487.32 229.35 151.57 164.09 163.14 30.18 46.75 
Crab 118.53 13.03 520.37 229.35 50.15 144.20 160.98 13.25 16.23 
Snails 5.86 4.23 486.35 96.44 133.10 175.78 129.65 53.76 34.85 
Grass shoots 19.88 4.52 417.65 27.85 274.85 147.67 127.52 131.73 16.07 
Buds 92.16 34.15 116.38 21.03 404.33 158.33 396.55 430.11 461.22 
Dandelions 64.13 312.78 40.93 32.97 515.34 536.44 361.22 164.67 109.55 
Leaves 10.32 30.61 40.58 33.62 77.84 83.11 242.67 379.38 381.80 
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shoots was unsurprisingly Sulf (4.52 %). The next lowest recoveries were Meclo and 
Pro (19.88 % and 16.07 %). Other compounds analysed produced significant recoveries 
of 147.67 % (Tamo), 127.52 % (Indo) and 131.73 % (Diclo). The remaining compound 
below the acceptible recovery of ≥50 % and not yet mentioned was Thio, with 27.85 %.  
4.4.1.4 Rosehip 
The rosehip sample was taken from a rose bush on the side of the effluent site and so 
was in prime position to take up any contaminants into its system, providing the method 
application was sucessful to show this. Recoveries ranged from 2.51 % to 491.69 % 
(Sulf and Meb respectively), with seven out of nine target compounds producing 
acceptible recoveries over 50 %. Those which did not were Sulf (previously mentioned) 
and Diclo which gave a recovery of 40.77 %. 
4.4.1.5 Dandelion 
The dandelion sample (taraxacum) had a maximum recovery of 536.44 % as previously 
mentioned as the highest overall result for Tamo. This was closely followed by Carb 
(515.34 %). The lowest observed contaminant recovery for the dandelion samples was 
32.97 % and 40.93 % for Thio and Meb respectively. In ascending order, remaining 
compound recoveries were as follows; Pro (64.13 %), Meclo (109.55 %), Diclo (164.67 
%), Sulf (312.78 %), Indo (361.22 %).  
4.4.1.6 Sloe buds  
Sloe buds (Prunus spinosa), also commonly known as ‘blackthorn’, had significantly 
high recoveries for all compounds, in particular Indo, Diclo and Meclo which were the 
highest observed recoveries for all samples of 396.55, 430.11 and 461.22 %. Carb also 
had a high recovery of 404.33 %. The lowest recovery of 21.03 % was observed by 
Thio. 
4.4.1.7 Sloe leaves  
The target compound which obtained the highest recovery for slow leaves was Meclo, 
with 381.80 %, very closely followed by Diclo with 379.38 %. The minimum recovery 
identified was for Pro of only 10.32 %. Remaining compounds, in ascending order, 
obtained recoveries of 30.61 % (Sulf), 33.62 % (Thio), 40.58 % (Meb), 77.84 % (Carb), 
83.11 % (Tamo) and finally 242.67 % (Indo).  
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4.4.2 Biological (tissue) samples 
4.4.2.1 LugWorm 
Interestingly the lugworm (Arenicola marina) samples gave a highest recovery for the 
compound Prol (299.89 %), which suggests an interesting conclusion for biological 
uptake of this compound. The compound with the lowest observed recovery was 4.92 % 
for Diclo. Excluding this, Indo (18.12 %) and Meclo (39.84 %), all other compounds 
produced recoveries for target compounds far in excess of the minimum acceptible 
recovery.  
4.4.2.2 Crab 
The highest overall observed recovery in these sets of observations was in the crab; 
520.38 % for Meb. The lowest observed recovery for the crab was 13.03 % for Sulf, as 
with many other matrices for having low recorded recovery. Other recoveries below the 
accepted 50 % value were Diclo (13.25 %) and Meclo (16.23 %). All other compounds 
exceeded the minimum accepted value with recoveries of 118.53 % for Pro, 229.35 % 
for Thio, 50.15 % for Carb, 144.20 % for Tamo and 160.98 % for Indo.  
4.4.3 Crustacean samples 
4.4.3.1 Clamshell (bivalve mollusk) 
The clamshell again had a high recovery for Pro (280.28 %), but the highest recovery 
was afor Meb (487.32 %). The lowest recovery was observed for Diclo (30.18 %). 
Seven out of nine compounds produced recoveries above the threshold; Pro (280.28 %), 
Sulf (51.02 %), Meb (487.32 %), Thio (299.35%), Carb (151.57 %), Tamo (164.09 %) 
and Indo (163.14 %). Meclo had an observed recovery of 46.75 %, just below the 
accepted recovery value.  
4.4.3.2 Snails 
Following trend, Meb was the compound identified with the highest recovery of 486.35 
%. The next highest recovery was Tamo (175.78 %), closely followed by Carb and Indo 
(133.10 % and 129.65 % respectively). The lowest recovery of all compounds was Sulf 
with 4.23 % closely followed by Pro with 5.86 %. Remaining compounds were Thio, 
Diclo and Meclo with recoveries of 96.44 %, 53.76 % and 34.85 % in descending order.  
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4.5 Report of the River Medway Sewage treatment works – seaweed samples, 
following successful method application to different sample matrices. 
4.5.1 February 2010 
It is immediately obvious that concentration of pharmaceutical compounds in seaweed 
samples in the River Medway sampling sites increases as the samples proceed 
downstream from the upstream, effluent to downstream sampling location (Figure 93).  
The upstream sampling site has a range between 0.06 ng/g for Pro to 4.84 ng/g for 
Diclo. Remaining target compounds in ascending order were 0.11 ng/g for Sulf, 0.43 
ng/g for Thio, 1.02 ng/g for Meb, 3.11 ng/g for Indo, 3.15 ng/g for Carb, 3.99 ng/g for 
Meclo and 4.53 ng/g for Tamo (Table 32).  
 
 
Figure 93 Total concentration of pharmaceuticals at River Medway sample locations for 
seaweed samples in February 2010 
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Table 32 Seaweed sample data for February 2010 at the River Medway 
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Results for seaweed analysed from the downstream site at the River Medway sampling 
location were the highest observed in comparison to the other two sites. The maximum 
concentration observed was Diclo with 622.22 ng/g, also the highest overall result for 
seaweed in February. Lowest observed concentration of a pharmaceutical compound 
here was 14.14 ng/g for Pro. The standard deviation of results demonstrates that 
precision is fairly high for all compounds (between 4.98 and 29.82) with an exception 
of Sulf (52.18), demonstrated in Table 323. Concentrations for remaining compounds 
were as follows; Sulf 64.98 ng/g, Meb 51.21 ng/g, Thio 105.62 ng/g, Carb 329.62 ng/g, 
Tamo 430.76 ng/g, Indo 287.62 ng/g and Meclo 272.10 ng/g.  
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Table 33 Concentration (ng/g) and standard deviation of target pharmaceuticals from 
River Medway seaweed samples from April 2010 
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4.5.2 April 2010 
 
Figure 94 Total concentration of pharmaceuticals at River Medway sample locations for 
seaweed samples in April 2010 
 
It is clear that concentration of target pharmaceutical compounds increases as you travel 
downstream, with the overall lowest observations at the upstream sampling location and 
the highest downstream (Figure 94). This may be because the outfall may be a little 
further downstream than where samples were collected at the ‘effluent’ site. Also 
compounds may be carried in water samples and deposited further downstream, to then 
be taken up by other matrices as seaweed for an example here. Compound concentration 
ranged from 20.55 ng/g to 4712 ng/g at upstream and downstream sites respectively 
both for Indo. Therefore this compound has the highest variability in results. Excluding 
two compounds, Carb and Tamo, all sites observed an increase from upstream to 
effluent sampling sites. This is again the case between effluent and downstream 
sampling sites, with the exception of Meb and Thio. Figure 94 suggests that compounds 
Carb, Tamo, Indo and Meclo increased as a direct result of the effluent outfall. 
At the upstream sampling site, the lowest observed concentration was for Indo with 
20.55 ng/g and the highest for Tamo with 432.92 ng/g. At the effluent site, minimum 
concentration was observed for Carb of 77.00 ng/g and the maximum of 806.08 ng/g 
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for. At the downstream sampling location, the highest concentration calculated was for 
4712.55 ng/g for Indo and the lowest 98.59 ng/g for Thio.  
Range of concentration for each compound were as follows (4.5.2 April 2010 
); 50.46 – 1400.66 ng/g for Pro, 46.92 – 366.18 ng/g for Sulf, 78.44 – 735.10 ng/g for 
Meb, 95.32 – 111.73 ng/g for Thio, 77.00 – 2337.89 ng/g for Carb, 125.72 – 2089.51 
ng/g for Tamo,  20.55 – 4712.55 ng/g for Indo, 72.64 – 646.50 ng/g for Diclo and 
finally 122.40 – 2956.7 ng/g for Meclo.  
The standard deviation for seaweed samples in April ranged from very good (low 
variability) of 3.10 for Tamo at the effluent site, to extremely poor (high variability) of 
630.17 for Meclo at the effluent site.  
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4.5.3 June 2010 
It is immediately obvious that concentrations of pharmaceutical compounds in seaweed 
samples in the River Medway sampling sites from June are very high compared to 
previous analyses (Table 34). The upstream sampling site has a range between 102.51 
ng/g for Thio to 14206.81 ng/g for Meclo. At the effluent and downstream sampling 
sites the ranges were from 109.41 ng/g for Thio to 17704.05 ng/g for Diclo and 108.36 
to 43987.78 ng/g for Meclo respectively. Individual target compound ranges across the 
three sites were as follows; 1440.12 – 5739.89 ng/g for Pro, 366.97 – 450.47 ng/g for 
Sulf, 239.53 – 1296.50 ng/g for Meb, 102.51 – 109.41 ng/g for Thio, 4260.02 – 5241.70 
ng/g for Carb, 1155.20 – 8180.56 ng/g for Tamo, 698.39 – 3283.66 ng/g for Indo, 
12361.19 – 43866.78 ng/g for Diclo and lastly 14206.81 – 43987.78 ng/g for Meclo 
(Table 34).  
Results for seaweed analysed from the downstream site at the River Medway sampling 
location in June were the highest observed in comparison to the other two sites. The 
maximum concentration observed was Meclo with 43987.78 ng/g, also the highest 
overall result for seaweed in June. Lowest observed concentration of a pharmaceutical 
compound in June was 239.53 ng/g for Meb, which was surprisingly at the effluent site. 
The standard deviation of results demonstrates that precision is varied for all 
compounds, between a very good 4.53 for Tamo downstream to 5428.97 for Carb also 
at the downstream site, demonstrated in Table 34. A graphical analysis of seaweed 
sample concentrations is shown in Figure 95. Aside from Diclo and Meclo, it is no 
immediately obvious of any increasing trend at the effluent site or other. However going 
back to standard deviation; although statistically high, in comparison to the actual 
concentration results, they are of little significance as it is relative to the initial result, 
and as shown on Figure 95, all acceptable.   
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Table 34 Concentration (ng/g) and standard deviation of target pharmaceuticals from 
River Medway seaweed samples from June 2010 
179 
 
 
Figure 95 Total concentration of pharmaceuticals at River Medway sample locations for 
seaweed samples in June 2010 
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Chapter 5 - China Sample Analysis 
 
5.1 Project background 
A large study in China used a vast amount of samples to determine antibiotics in waters 
and surrounding environments. The samples were then sent for analysis of 
pharmaceuticals using the aforementioned developed method. As antibiotics are 
chemicals with the ability to inhibit the growth of microbes, a variety of antibiotics are 
currently been used to prevent and treat different diseases and infections in humans and 
animals. In addition, they are widely applied as growth promoter and feed additives in 
aquaculture and animal husbandry. Since antibiotics play a major role in medical 
treatment and modern livestock industries, they are used in large quantities worldwide. 
The global consumption of antibiotics is estimated to be 100,000-200,000 tons annually, 
of which approximately 13,000 tons were used in the EU countries and Switzerland, and 
16,200 tons in the USA. Similarly more than 25,000 tons of antibiotics are used in 
China every year. 
Due to the fact that most antibiotics are not completely metabolized by human and 
animal bodies, considerable fractions (about 25 ~ 75 %) of the administered doses are 
excreted directly with feces and ultimately enter the aquatic environment through 
various routes. Many antibiotics have been detected in different aquatic environments 
such as sewage effluents, surface water, groundwater and drinking water. Hence, 
aquatic organisms are subject to long-term exposure of antibiotics, with resulting 
chronic effects. For instance, the growth of Microcystis aeruginosa (freshwater 
cyanobacteria) was inhibited by exposure to chlortetracycline (CTC) or tetracycline 
(TC) at concentrations of less than 0.1 mg L
-1
. On the other hand, tetracyclines can bind 
to the ribosome and impair protein synthesis. In addition, it was reported that horizontal 
transfer of some resistance genes on plasmids could occur between different bacteria in 
the environment. Evidently, more and more concern is being raised on the potential 
risks of antibiotics to aquatic organisms. 
Till now, there have been limited studies investigating the environmental risks of 
antibiotics in China, e.g. in the Victoria Harbour and the Pearl River. In addition, 
studies of antibiotics tend to focus on rivers and harbors, with little attention to lakes. 
Ironically, lakes in China are generally abundant in biodiversity yet under intensive 
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pressure from human activities (e.g. aquaculture, agriculture). Thus, appropriate 
environmental risk assessment (ERA) on antibiotics in lakes plays a significant role in 
protecting aquatic organisms and ultimately human development. 
Guidelines for ERA of pharmaceuticals were introduced by the European Agency for 
the Evaluation of Medicinal Products and the US Food and Drug Administration. 
Currently, the risk quotient (RQ) approach is recommended to assess the environmental 
risk of medicines, by predicting the potential of many compounds to cause adverse 
environmental effects in aquatic organisms. In order to evaluate the environmental risk 
of antibiotics, their toxicity to aquatic organisms should be tested through different 
trophic levels, such as algae, flea and fish. However, a major obstacle in such risk 
assessment of antibiotics is the lack of appropriate toxicity data, there is therefore an 
urgent need for a reliable tool to predict acute and chronic toxicity. Consequently, the 
EcoSAR models, which were considered to be robust in predicting toxicity, are widely 
adopted in ERA. 
The aim of this study was to conduct the analysis pharmaceuticals in Baiyangdian 
(BYD) Lake, a major lake in North China, following analysis of antibiotics back in 
China. The seasonal variation of antibiotic concentrations were also investigated.  
 
5.2 Preliminary sample preparation 
5.2.1 Site description and sample collection 
As the largest freshwater lake (maximum depth was 3 m in 2007) in North China, BYD 
Lake is located about 200 km southwest of Beijing and covers more than 366 km
2
. It 
consists of more than 100 small and shallow lakes linked by thousands of ditches and 
large areas of reeds. Currently, there are more than 243,000 people living in 39 villages 
scattering in and around it. BYD Lake plays a key role in sustaining local aquaculture as 
well as poultry farming, which provides aquatic products and eggs for nearly seven 
million people in the cities of Baoding and Cangzhou. In the last two decades, the lake 
has become a semi-closed water body without any outflows, whilst receiving runoff 
from agricultural irrigation, and untreated wastewater and sewage effluents from 
villages and Baoding City. It is likely that various antibiotics commonly used by human 
and animals are discharged into the lake. 
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Ten sampling sites covering potential sources of antibiotic inputs, e.g. urban sewage, 
agricultural fields, were selected in BYD Lake. At each sampling site, surface water 
samples (0.5 m depth) were collected in three different time periods in July and 
November 2007 and April 2008, corresponding to summer, autumn and spring seasons, 
respectively. Samples could not be collected in winter due to ice coverage. Then, 
samples were transported in ice boxes to the laboratory and stored at -20 °C before 
treatment and analysis. 
 
5.2.2  Reagents and materials 
Reagents and materials followed the trialed and tested new methodology developed in 
chapter 3.2.  
The solvents used, including methanol and acetonitrile, were of distilled-in-glass grade, 
purchased from Rathrburn, Scotland. Formic acid was of HPLC grade. Internal standard 
(diuron-d6) was acquired from Cambridge Isotope Laboratories, USA. 
Unless otherwise indicated, the chemicals used in the study were of analytical grade 
without further purification. Separate stock solutions (1000 mg/L) of individual 
compounds and internal standard were prepared by dissolving an appropriate amount of 
each substance in methanol, which were then stored at -20°C, and further diluted before 
using. Solid-phase extraction (SPE) cartridges (Oasis HLB, 500 mg/mL) were obtained 
from Waters (Milford, MA, USA). Glass fiber filters (Millipore, 0.45 μm) were 
obtained from Waters (MA, USA). Ultrapure water was supplied by Maxima Unit from 
USF Elga, UK. 
 
5.2.3 LC-MS/MS analysis 
The LC-MS/MS analysis of samples  followed that used in the existing pharmaceutical  
experimentation in chapter 3.2.5.  
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5.3 Beijing sample analysis 
5.3.1 Biological Samples from Beijing 
 
Table 35 Average concentration and standard deviation of target pharmaceuticals from 
biological samples in Beijing 
 
 
Figure 96 Total concentration of pharmaceuticals at Beijing sampling locations (all) 
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Figure 97 Total concentration of pharmaceuticals at Beijing sampling locations 
(normalized results) 
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Figure 95 clearly illustrates that Tamo is the contaminant with the highest 
concentrations observed in Beijing biological samples at between 136.89 ng/g and 
567.00 ng/g (Screw and Narrow Leaves Waterweed, respectively) (Table 35). Samples 
were prepared in the same way as chapter 3 and 4. The samples of shrimp and catfish 
have low concentrations of Tamo of 195.04 ng/g and 145.52 ng/g . The lowest recorded 
concentration was 0.25 ng/g of Meb in the Shrip sample. Narrow waterweed leaves 
gave the highest recovery of compounds of all samples, indicating highest 
pharmaceutical contamination concentration up to 567.00 ng/g for Tamo. The lowest 
observed overall contaminant was Sulf with 0.81 ng/g at its lowest and only 10.85 ng/g 
as its highest concentration observed. The remaining compounds had concentration 
ranges as follows: Pro 3.58 – 39.69 ng/g, Meb 0.25 – 60.58 ng/g, Thio 2.53– 32.87 ng/g, 
Carb 16.49 – 222.96 ng/g, Indo 16.32 – 125.41 ng/g, Diclo 13.95 – 170.83 ng/g and 
finally Meclo 30.25 – 228.39 ng/g.  
Figure 97 shows normalized results for biological samples from Beijing, ie with Tamo 
removed. It is sometimes not considered good practice to normalize results but however 
removing one to three compounds from the group on graphical analysis simply 
enhances those with lower concentrations and makes them visibly easier to analyze. 
Absolute concentrations are shown in the data tables and first graphical representations. 
Data for all samples except ‘narrow leaves waterweed’ are still difficult to decipher 
visually from this. The narrow waterweed (Elodea) leaves samples had concentrations 
between 2.49 ng/g (Sulf) and 567.00 ng/g (Tamo). All compounds had significantly 
high recoveries in comparison to other sample matrices tested.  
Wide waterweed (Elodea) leaves also had good high concentrations of target 
compounds which range from 2.01 ng/g to 523.93 ng/g for Sulf and Tamo. Pro is 
similar in concentration to Sulf with only 3.58 ng/g. Two other compounds are low in 
comparison to the remaining four unmentioned compounds, which are Thio (7.62 ng/g) 
and Meb (10.90 ng/g). The remainder are 65.71 ng/g (Carb), 81.52 ng/g (Indo), 103.10 
ng/g (Diclo) and 111.41 ng/g (Meclo).  
In ascending order, reed root (Phragmites australis, or common reed) samples produced 
the following results for concentration of target compounds; 0.81 ng/g for Sulf, 4.09 
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ng/g for Pro, 4.72 ng/g for Meb, 5.86 ng/g for Thio, 24.72 ng/g for Carb, 56.03 ng/g for 
Meclo, 56.83 ng/g for Diclo, 60.46 ng/g for Indo and a large 427.32 ng/g for Tamo.  
Carp (Cyprinidae family) was the first fish sample tested and had the highest 
concentrations for Tamo, Indo, Diclo and Meclo (455.75 ng/g, 66.05 ng/g, 72.95 ng/g 
and 62.48 ng/g correspondingly). The lowest observed concentration was Sulf with 2.01 
ng/g quantified from sample analysis.  
As shown in Table 35, the concentrations of the target compounds are low for Caucian. 
The lowest observed concentration was 1.01 ng/g for Sulf. Tamo appears to be 
anomalous, with a concentration far exceeding the trend for this sample of 476.25 ng/g) 
(Figure 95) Other observed concentrations were as follows, in ascending order; 2.53 
ng/g (Thio), 4.53 ng/g (Prop), 17.22 ng/g (Carb), 21.71 ng/g (Meb), 58.41 ng/g (Meclo), 
68.33 ng/g (Indo) and 72.95 ng/g (Diclo).  
Silver carp (Hypophthalmichthys molitrix) had a highest observed concentration of 
467.13 ng/g, followed by Indo with 61.80 ng/g. The lowest observed concentration was 
for Meb with 1.79 ng/g. Other compounds with low observed concentrations were, in 
ascending order, Thio, Sulf and Pro (4.30 ng/g, 4.32 ng/g and 6.67 ng/g). Remaining 
compounds had higher amounts of pharmaceuticals ranging from 16.49 – 59.00 ng/g.  
Shrimp (Malacostraca) gave the lowest total concentrations observed in comparison to 
all other matrices analysed. Concentrations ranged from 0.25 ng/g for Meb to 195.04 
ng/g for Tamo. Other compounds with low concentrations were Pro (7.77 ng/g), Sulf 
(1.43 ng/g) and Thio (5.90 ng/g).  
Catfish (Siluriformes) gives the following observed concentrations for Pro at 31.83 
ng/g, Sulf at 10.85 ng/g, Thio at 6.20 ng/g, Carb at 49.84 ng/g, Tamo at 145.52 ng/g, 
Indo at 27.65 ng/g, Diclo at 36.85 ng/g and Meclo at 43.69 ng/g. The highest and lowest 
concentrations observed were Tamo, and Thio, respectively.  
Screw gave relatively low total concentrations compared to other matrices tested for the 
target pharmaceutical compounds. The highest concentration was recorded for Tamo 
(136.89 ng/g), which is the lowest recording for this compound of all sites. The same is 
true for Meclo and Indo.  
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5.3.2 Water samples from Beijing 
5.3.2.1 Haihe River 
 
Figure 98 Location of Haihe River in Beijing 
 
Figure 98 displays the location of the Haihe River in Beijing. Figure 99 and Figure 99 
highlight the 24 sampling locations (approximate) along the river.  
 
Figure 99 Location of sampling sites from the Haihe river 
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Figure 100 Location of sampling sites from the Haihe river 
 
Concentrations from the Haihe River in Beijing range from a low of 0.00 ng/l for Meb 
at thirteen sites and Meclo at site Dagu3 to 3486.1 ng/l for Carb at site Nancha. 
Excluding non-detected samples, the minimum observed concentration was identified 
for Meb at Majiacaivuan with 14.0 ng/l  (Table 36). Zero concentrations were identified 
for Meclo at Daliangdukou, Xihe, Dengshangu, Huangjiajuan, Tianjinzhan, 
Dongyangchang, Fengkoucun, Caizhuangzi, Nancha, Dagu1, 2, and 3 and Caoyinsi. A 
concentration of below LOD was also identified at Dagu3 for Meclo.  
Across all sites, Carb outperforms all other compounds as the highest concentration 
from a minimum of 984.8 ng/l at Haihe Bridge (Figure 102) to the maximum of 3486.1 
ng/l at Nancha (Figure 103). Figure 101 also displays results graphically. As a result, a 
second set of graphs (Figureure. 9-11) were drawn excluding Carb, as a measure of 
normalising results for analysis purposes which is spread over three separate graphs for 
ease. 
Two compounds regularly give high concentrations above all others (excluding Carb), 
Diclo and Tamo with ranges between 156.8 – 1598.5 ng/l and 140.2 – 1089.8 ng/l 
respectively; minimum and maximum values for these compounds was observed at 
Tianjinzhan & Beicha and Dagu2 & Dagu2.  
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Daliangdukou 99.2 170.0 0.0 206.4 1513.4 522.9 140.9 476.5 382.0 
Xihe 131.0 219.0 0.0 241.7 1625.0 551.7 213.6 526.2 496.8 
Dengshangu 155.8 297.5 0.0 231.6 3057.0 439.6 166.6 572.5 449.5 
Huangjiajuan 148.0 212.3 0.0 287.5 2480.1 932.5 152.7 469.2 748.0 
Jintanggaosu 116.2 390.6 14.6 301.7 2213.6 253.2 326.5 900.5 485.8 
Gegu 114.2 62.5 323.8 218.7 1545.5 810.9 195.6 507.0 445.7 
Tianjinzhan 110.3 176.2 14.7 208.2 2080.3 205.6 77.9 156.8 90.3 
Tianjinzhan 120.9 153.5 0.0 200.6 2643.8 219.0 146.2 322.9 120.4 
Haijin Brigge 194.7 155.7 223.0 283.2 2691.2 467.8 196.0 442.9 347.2 
Zhangguizhuang 123.8 141.9 145.3 114.8 1828.5 895.3 159.8 310.1 410.0 
Dongyangchang 128.8 173.6 0.0 312.7 2968.6 433.7 201.4 518.3 427.3 
Fengkoucun 113.2 228.6 0.0 287.9 1249.5 969.0 175.3 388.1 355.0 
Niwocun 97.6 139.3 309.7 212.6 1721.1 792.2 154.9 266.9 516.4 
Majiacaiyuan 164.2 224.7 14.0 195.5 2631.4 307.2 161.9 417.1 500.3 
Caizhuangzi 150.9 266.8 0.0 197.6 2100.1 729.9 262.2 553.2 504.5 
Chaqian 164.6 493.9 95.6 207.1 3431.1 311.8 177.3 895.9 381.0 
Beicha 113.1 332.8 1312.4 191.6 2102.4 264.0 202.4 1598.5 349.6 
Nancha 145.8 397.6 0.0 199.3 3486.1 241.9 230.5 649.4 370.6 
Pangu 201.2 486.0 9.5 224.4 2870.3 382.0 160.9 572.7 434.1 
Dagu1 87.4 518.9 0.0 264.6 2445.5 1089.8 693.1 791.3 765.5 
Dagu2 97.1 173.7 0.0 196.9 1157.6 140.2 133.8 537.3 108.2 
Dagu3 148.4 83.4 0.0 273.0 1045.3 263.6 142.8 288.4 0.0 
Haihe Bridge 148.8 88.8 22.6 212.0 984.8 943.1 246.7 381.2 343.7 
Caoyinsi 168.5 260.4 0.0 197.0 3475.8 429.4 243.5 624.3 424.5 
Table 36 Concentration (ng/l) of pharmaceutical compounds found in Haihe River 
surface water samples in June 2009 
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Figure 101 Target pharmaceutical compounds in surface water from Haihe River (ng/l) 
in June 2009 at the first 8 sampling locations 
 
Figure 102 Target pharmaceutical compounds in surface water from Haihe River (ng/l) 
in June 2009 at the next 8 sampling locations 
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Figure 103 Target pharmaceutical compounds in surface water from Haihe River (ng/l) 
in June 2009 at the last 8 sampling locations 
 
Site Dagu1 harbours the maximum value for four out of nine compounds across all 
sites, which is the highest number and suggests a high level of contamination. These are 
for Sulf (518.9 ng/g), Tamo (1089.8 ng/g), Indo (693.1 ng/g) and finally Meclo (765.5 
ng/g). The maximum value for Pro is identified at Pangu (201.2 ng/g), maximum for 
Meb at Beicha (1312.4 ng/g), Thio at Dongyangchang (312.7 ng/g), Carbemazepine at 
Nancha (3486.1 ng/g), and Diclo at Beicha (1598.5 ng/g) (Figure 100 – 102).  
For every site, the maximum identified concentration was for Carb with a range from 
984.8 ng/g to 3486.1 ng/g (Table 36). Normalised results are displayed in Figures 103 – 
105. 
Excluding non-detected samples, minimum concentrations identified were as follows; 
87.4 ng/g for Pro at Dagu1, 62.5 ng/g for Sulf at Gegu, 14.0 ng/g for Meb at 
Majiacaiyuan, 114.8 ng/g for Thio at Zhangguizhuang, 984.8 ng/g for Carb at the Haihe 
Bridge, 140.2 ng/g for Tamo at Dagu2, and finally 77.9 ng.g for Indo, 156.8 ng/g for 
Diclo and 90.3 ng/g for Meclo at Tianjinzhan1. This finding concludes that 
Tianjinzhan1 has the highest frequency of lowest concentrations identified suggesting it 
to be the least contaminated site sampled on the Haihe River in Beijing.   
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Figure 104 Target pharmaceutical compounds in surface water from Haihe River (ng/l) 
(Normalized results) in June 2009 at the first 8 sampling locations 
 
 
Figure 105 Target pharmaceutical compounds in surface water from Haihe River (ng/l) 
(Normalized results) in June 2009 at the next 8 sampling locations 
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Figure 106 Target pharmaceutical compounds in surface water from Haihe River  
(Normalized results) in June 2009 at the last 8 sampling locations 
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Daliangdukou 103.8 221.5 376.6 16.8 737.4 338.5 677.5 4149.4 3130.4 
Xihe 153.9 133.2 0.0 14.6 1090.8 351.9 1110.0 8476.1 5238.9 
Dengshangu 88.9 60.2 728.3 75.6 212.8 371.5 539.5 2988.3 3521.6 
Huangjiajuan 65.7 367.5 816.8 13.3 845.9 476.1 821.4 6146.1 4553.7 
Jintanggaosu 56.6 15.6 282.4 5.2 627.7 279.9 836.5 4055.2 3479.9 
Gegu 201.5 409.8 774.5 8.3 1620.1 451.4 981.0 3992.2 7006.8 
Tianjinzhan 74.6 68.7 117.1 10.5 272.9 259.6 475.6 2455.0 2983.4 
Tianjin 107.2 1092.5 2486.8 54.2 789.6 625.1 753.1 5871.3 6506.9 
Haijin Bridge 54.2 347.0 0.0 15.0 434.8 339.8 674.6 3356.1 4022.8 
Zhangguizhuang 173.3 281.3 0.0 10.3 775.3 528.6 745.7 5020.9 6472.7 
Dongyangchang 111.1 110.4 1058.9 13.6 795.8 465.6 875.5 3509.5 4583.4 
Fengkoucun 103.5 521.9 169.6 5.0 280.4 448.3 777.2 2687.4 2183.7 
Niwocun 160.8 442.3 38.8 9.7 1034.3 384.3 619.1 4285.3 4836.6 
Majiacaiyuan 71.9 7.2 0.0 11.5 498.7 279.0 611.7 3093.7 3214.7 
Caizhuangzi 93.1 445.8 121.6 15.8 774.7 492.8 750.9 3618.2 4820.1 
Chaqian 163.0 610.0 0.0 2.6 1735.8 505.7 988.2 5948.3 8106.9 
Beicha 84.7 3.8 195.1 9.5 164.0 311.9 405.8 2680.4 3765.9 
Nancha 211.3 3762.8 599.1 10.2 3102.1 629.6 2500.0 6503.0 4654.6 
Pangu 93.8 5.1 0.0 8.2 497.9 419.5 679.0 4985.3 3302.5 
Dagu1 686.2 4780.7 932.8 16.3 4962.7 302.7 5693.1 6508.4 7372.7 
Dagu2 392.2 3469.3 1142.2 7.4 3787.1 251.7 3967.0 3609.0 4071.9 
Dagu3 315.8 1872.2 293.3 1.5 3935.3 386.3 2472.7 3512.1 4350.6 
Haihe Bridge 147.5 197.4 344.4 11.3 427.7 389.7 545.4 3298.8 4386.5 
Caoyinsi 98.8 40.6 317.4 46.3 834.9 414.8 1165.8 5162.2 5768.3 
Table 37 Concentration (ng/l) of pharmaceutical compounds found in Haihe River 
surface water samples in November 2009 
 
During November 2009, the concentrations of pharmaceutical compounds  in the Haihe 
River surface water samples from the same locations as in Figure 106 - 108, are detailed 
in Table 37. The highest observed concentrations were for Meclo (8476.07 ng/l) and 
Diclo (8106.88 ng/l) at Xihe and Chaqian respectively. Meclo had the highest overall 
concentration of all compounds detected, with a range between 2454.98 ng/l at 
Tianjinzhan to the previously mentioned 8476.07 ng/l. The lowest observed 
concentrations were 0.00 ng/l, only observed for the compound Meb at a total of 6 
locations (Table 37). However the highest observed value for Meb was 2486.76 ng/l at 
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Tianjin. Other than zero values, sampling location Dagu3 had a very low concentration 
of 1.47 ng/l for Thio. Thio also had the lowest concentration range, between 1.47 ng/l 
and 75.62 ng/l at Dengshangu.  
Remaining target compound ranges were as follows; 54.17 ng/l to 686.18 ng/l for Pro, 
3.85 ng/l to 4780.67 ng/l for Sulf, 164.05 ng/l to 4962.65 ng/l for Carb, 251.70 ng/l to 
629.63 ng/l for Tamo, 405.78 ng/l to 5693.07 ng/l for Indo and 2183.73 ng/l to 8106.88 
ng/l for Diclo.  
For 17 of the total 24 sampling locations, Diclo is the highest observed compound 
concentration. The remaining 7 were identified for Meclo. Similarly, 15 out of a total 24 
sampling locations recorded Thio as the lowest observed compound concentration, 
which only excludes 6 zero concentrations identified for Meb and three for Sulf. 
Excluding zero concentrations, Thio would hold 19 of the total 24 sampling locations as 
having the lowest concentration.  
The sampling location with the highest observed concentration variation was Xihe, with 
a total range of 8476 ng/l. The lowest observed concentration variation was 
Fengkoucun, with a range of  2682 ng/l.  
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Figure 107 Target pharmaceutical compounds from the first 8 Haihe river surface water 
samples in November 2009 
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Figure 108 Target pharmaceutical compounds from the next 8 Haihe river surface water 
samples in November 2009 
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Figure 109 Target pharmaceutical compounds from the last 8 Haihe river surface water 
samples  in November 2009 
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5.3.2.2 Bohai Bay 
Below are two location maps for sampling in Bohai Bay, Beijing which was used on 
two occasions; June and November 2009. The first (Figure 109) is a general location 
map followed by Figure 110 which highlights the 18 sampling locations in more detail. 
Figure 110 Location of Bohai Bay in Beijing 
 
 
Figure 111 Location of sampling sites in Bohai Bay 
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Shagouzi 150.5 57.7 50.2 117.6 565.0 943.4 184.3 206.9 246.0 
Huangligang 237.1 115.3 34.0 154.9 851.8 659.9 305.9 462.8 258.8 
Xujiabao 170.2 79.7 215.8 187.0 607.8 1071.9 180.6 583.0 301.3 
Nanpaihe 175.3 69.7 44.5 45.2 541.6 1124.2 171.1 311.4 247.2 
Ziyaxinhe 146.6 73.8 171.9 65.8 764.0 1152.4 138.8 199.0 273.1 
Duliujianhe 135.8 97.0 92.3 200.1 1085.1 762.4 230.3 396.5 307.5 
Lvjugou 120.2 15.2 6.3 156.4 486.5 966.8 119.7 293.6 262.5 
Tianjinlingang 215.1 40.5 0.0 138.7 725.2 986.3 213.9 355.3 354.5 
Tianjinlgang 193.5 86.2 214.2 87.6 747.0 1225.8 215.8 291.0 306.4 
Tianjin Harbor 261.4 92.2 26.9 30.9 867.2 1052.5 233.4 373.4 401.8 
Dongjianggang 153.4 71.5 102.4 110.5 505.3 865.3 142.3 177.5 224.9 
Guanlanlu 201.9 2.4 0.0 100.8 1976.2 339.0 118.5 426.2 220.5 
Luanhekou 54.6 30.5 5.4 97.6 208.7 364.2 77.6 73.9 180.7 
Letinggongyeyuan 120.9 75.7 0.0 196.5 505.7 322.4 192.1 161.8 117.1 
Xihekou 56.4 106.9 0.0 59.6 1567.2 292.2 79.8 595.0 161.7 
Caofeidian 159.3 0.7 0.0 50.8 273.4 247.6 56.6 61.6 109.6 
Heiyanzi 55.6 45.1 138.4 88.4 469.8 459.9 69.0 98.4 285.4 
Beitangkou 61.6 136.4 0.0 102.6 1919.2 587.4 142.0 141.5 157.7 
Table 38 Concentration (ng/l) of pharmaceutical compounds found in Bohai Bay 
surface water samples in June 2009 
 
Table 38 details the surface water samples taken from 18 different sampling locations in 
Bohai Bay and the concentration (ng/l) observed at each. Minimum concentration 
values were identified for the compound Mebeverine at six sites; Tianjinlingang, 
Guanlanlu, Letinggongyeyuan, Xihekou, Caofeidian and Beitangkou. Excluding zero 
values, concentrations ranged from 0.7 ng/l to 1976.2 ng/l for Sulf at Caofeidian and 
Carb for Guanlanlu respectively. Tamo and Carb are by far the two compounds with the 
highest concentration identified across all sites.  
Graphs to represent sampling data were produced (Figure 111-113), where it is 
immediately obvious that Tamo and Carb far outperform other compounds in 
concentration identified. For ease of data analysis, a normalized set of graphs were 
produced (Figure 114 - 116) excluding these two compounds.  
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Figure 112 Target pharmaceutical compounds in surface water from Bohai Bay in June 
2009 at the first 6 sampling locations 
 
 
Figure 113 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
June 2009 at the next 6 sampling locations 
 
202 
 
 
Figure 114 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
June 2009 at the last 8 sampling locations 
 
In ascending order, maximum concentrations for each compound were as follows; 136.4 
ng/l for Sulf (Beitangkou), 200.1 ng/l for Thio (Duliujianhe), 215.8 ng/l for Meb 
(Xujiabao), 261.4 ng/l for Pro (Tianjin Harbour), 305.9 ng/l for Indo (Huangligang), 
401.9 ng/l for Meclo (Tianjin Harbor), 595.0 ng/l for Diclo (Xihekou), 1225.8 ng/l for 
Tamo (Tianjinlgang) and 1976.2 ng/l for Carb (Guanlanlu).  
In ascending order, minimum concentrations for each compound were as follows 
(excluding zero values); 0.7 ng/l for Sulf (Caofeidian), 5.4 ng/l for Meb (Luanhekou), 
30.9 ng/l for Thio (Tianjin Harbor), 54.6 ng/l for Pro (Luanhekou), 56.6 ng/l for Indo 
(Caofeidian), 61.6 ng/l for Diclo (Caofeidian), 109.6 ng/l for Meclo (Caofeidian), 208.8 
ng/l for Carb (Luanhekou) and 247.6 ng/l for Tamo (Caofeidian).  
No one site appears to be more highly contaminated than another, with only Tianjin 
Harbour having two of the nine maximum concentrations of target pharmaceutical 
compounds identified. Least contaminated site on the other hand is easier to identify, 
with Caofeidian having five out of nine (>50 %) of the observed minimum 
concentrations.  
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Figure 115 Target pharmaceutical compounds in surface water from Bohai Bay  (ng/l) 
in June 2009 at the first 6 sampling locations (Normalized results) 
 
 
 
Figure 116 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
June 2009 at the next 6 sampling locations (Normalized results) 
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Figure 117 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
June 2009 at the last 6 sampling locations (Normalized results) 
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Shagouzi 101.9 12.3 0.0 14.3 540.3 283.1 836.9 3064.4 2398.2 
Huangligang 172.1 7.6 0.0 5.3 228.9 325.1 921.0 3747.7 2715.0 
Xujiabao 121.9 4.4 39.5 8.7 202.7 304.9 719.5 2728.1 2636.8 
Nanpaihe 100.2 151.5 0.0 9.3 811.9 346.6 882.2 7838.9 3876.4 
Ziyaxinhe 125.1 1778.8 32.8 16.6 1143.4 319.1 1003.6 4776.3 4214.7 
Duliujianhe 157.6 208.2 0.0 17.4 739.0 460.1 904.9 3505.5 5908.5 
Lvjugou 103.6 54.8 46.3 22.4 251.6 346.4 648.5 2825.4 4184.8 
Tianjinlingang 135.1 99.8 0.0 23.7 372.2 352.4 977.6 4213.0 2560.8 
Tianjinlgang 110.3 54.1 26.3 10.3 210.4 375.6 701.6 3321.4 2942.7 
Tianjin Harbor 103.8 192.7 0.0 8.3 310.1 283.4 531.0 2623.7 3777.7 
Do ngjianggang 111.7 216.2 33.7 52.5 327.5 384.2 768.7 3399.9 3695.8 
Guanlanlu 106.6 15.8 0.0 13.8 505.1 421.8 890.9 4331.5 4498.8 
Luanhekou 138.0 398.6 0.0 46.2 198.5 419.9 568.4 2277.9 3053.3 
Letinggongyeyuan 154.3 15.4 148.0 14.6 211.5 436.3 832.3 4163.3 3266.5 
Xihekou 84.3 25.0 0.0 18.7 388.8 328.6 617.2 2916.0 4508.2 
Caofeidian 181.5 0.0 152.9 43.2 208.6 505.7 949.6 4980.6 6011.0 
Heiyanzi 76.2 186.1 103.8 16.9 615.1 307.1 460.9 2099.2 2803.4 
Beitangkou 126.4 11.0 0.0 8.4 217.5 261.6 655.6 2528.3 3899.6 
 
Table 39 Concentration (ng/l) of pharmaceutical compounds found in Bohai Bay 
surface water samples in November 2009 
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Figure 118 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
November 2009 at the first 6 sampling locations 
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Figure 119 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
November 2009 at the next 6 sampling locations 
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Figure 120 Target pharmaceutical compounds in surface water from Bohai Bay (ng/l) in 
November 2009 at the last 6 sampling locations 
 
During November 2009, the highest observed concentration from Bohai Bay surface 
water samples was identified as 7838.94 ng/l for Diclo at the site Nanpaihe. The lowest 
observed concentration was below LOD for both Sulf (Caofeidian) and Meb (Shagouzi, 
Huangligang, Nanpaihe, Duliujianhe, Tianjinlingang, Tianjin Harbor, Guanlanlu, 
Luanhekou, Xihekou and Beitangkou; 10 of the total 18 sample locations). Excluding 
zero concentrations, the lowest observed was at Xujiabao for Sulf, with only 4.40 ng/l. 
All results are displayed in Figure 118 - 119.  
The total range for each compound was as follows; 76.16 ng/l to 181.46 ng/l for Pro, 
0.00 ng/l to 1778.80 ng/l for Sulf, 0.00 ng/l to 152.95 ng/l for Meb, 5.32 ng/l to 52.46 
ng/l for Thio, 198.54 ng/l to 1143.37 ng/l for Carb, 261.64 ng/l to 505.69 ng/l for Tamo, 
460.87 ng/l to 1003.65 ng/l for Indo, 2099.23 ng/l to 7838.94 ng/l for Diclo and 2398.23 
ng/l to 6011.01 ng/l for Meclo (Table 39).  
Ten out of the 18 sampling locations identified Meclo as the higest observed 
concentration. The remaining eight were identified for Diclo. Zero concentrations were 
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listed previously, but are seen in Table 39. Remaining lowest identified concentrations 
were 4.40 ng/l for Sulf at Xujiabao, and the rest for Thio; 16.64 ng/l at Ziyaxinhe, 22.35 
ng/l at Lvjugou, 10.32 ng/l at Tianjinlgang, 14.64 ng/l at Letinggongyey and 16.85 ng/l 
at Heiyanzi.  
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6.3.2.3 Baiyangdian (BYD) Lake 
Figure 121 Location of sampling sites at BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 56.3 59.2 0.0 4.7 747.9 338.1 108.6 242.5 227.8 
Shaochedian 81.3 287.5 86.2 8.3 457.2 897.7 212.3 335.9 260.5 
Caiputai 35.8 12.1 14.0 3.6 354.4 359.2 63.8 97.9 169.8 
Duancun 45.9 27.4 0.0 7.0 701.6 325.8 62.9 179.7 94.5 
Beiliuzhuang 518.3 691.1 120.5 2.9 760.9 450.8 282.1 176.5 198.9 
Wangjiazhai 75.4 312.6 19.5 8.6 319.7 922.9 86.2 180.8 106.7 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 117.9 18.7 22.1 4.7 291.4 455.7 24.6 68.8 64.8 
Shaochedian 43.6 272.2 0.0 6.7 378.8 169.3 98.0 207.3 80.9 
Caiputai 45.2 37.6 0.0 16.5 895.1 343.9 106.7 249.8 159.7 
Duancun 94.9 46.8 0.0 19.8 156.4 186.5 124.4 331.2 220.7 
Beiliuzhuang 284.2 316.1 0.0 20.3 240.6 127.4 163.2 392.6 80.0 
Wangjiazhai 82.7 454.3 0.0 18.7 579.3 237.0 191.9 216.8 123.6 
P
o
re
 W
at
er
 
Zaolinzhuang 46.5 0.0 0.0 4.6 486.1 183.0 106.9 93.6 71.5 
Shaochedian 81.5 57.2 0.0 3.9 840.9 578.7 119.7 157.2 261.7 
Caiputai 81.2 34.8 389.3 13.5 307.8 198.9 58.8 96.7 39.7 
Duancun 62.3 41.0 0.0 18.9 264.8 287.0 61.6 159.1 134.3 
Beiliuzhuang 81.1 71.5 0.0 20.0 300.5 970.8 123.7 381.2 102.9 
Wangjiazhai 81.1 67.2 0.0 14.6 1305.7 1006.3 123.7 1381.0 200.8 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 35.2 69.6 485.2 18.3 546.0 112.9 80.7 82.2 104.4 
Shaochedian 51.6 56.7 0.0 4.6 390.2 234.5 82.4 153.0 101.2 
Caiputai 51.2 187.0 180.2 15.3 768.4 311.6 75.3 110.6 125.7 
Duancun 51.4 40.7 60.8 17.2 196.9 405.8 93.6 158.1 54.5 
Beiliuzhuang 57.4 98.6 0.0 8.5 397.6 361.9 92.0 120.1 159.7 
Wangjiazhai 125.2 90.3 0.0 9.6 245.8 609.9 882.2 203.2 267.6 
 
Table 40 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
surface water samples in March 2009 
 
Sampling locations are displayed in Figure 120. All concentrations of target 
pharmaceutical compounds found in BYD Lake surface water samples from March are 
listed in Table 40 and displayed in Figure 122 - 124.  
The range of target compounds for surface water samples was <LOD for Meb at 
Zaolinzhuang and Duancun to 923 for Tamo at Wangjiazhai. For overlying water 
samples the range was between <LOD for Meb at 5 of 6 sampling locations (all but 
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Zaolinzhuang) to 895 ng/l for Carb at Caiputai. For pore water samples, the lowest 
identified concentration was for Meb at 5 out of 6 sampling locations excluding 
Caiputai of <LOD  to 1381 ng/l for Diclo at Wangjiazhai. For the last sample group of 
water-release test samples, the lowest observed concentration was once again <LOD for 
Meb at Shaochedian, Beiliuzhuang and Wangjiazhai to 882 ng/l for Indo at 
Wangjiazhai.   
 
 
Figure 122 Concentration  of target pharmaceutical compounds for March 2009 in 
Surface water samples for BYD Lake 
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Figure 123 Concentration of target pharmaceutical compounds for March 2009 in 
Overlying water samples for BYD Lake 
 
 
Figure 124 Concentration of target pharmaceutical compounds for March 2009 in Pore 
water samples for BYD Lake 
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Figure 125 Concentration of target pharmaceutical compounds for March 2009 in 
Water-release test samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 90.1 192.6 46.6 8.2 1091.9 410.0 94.8 154.2 152.6 
Shaochedian 1092.5 98.2 935.6 13.2 271.3 204.0 57.2 191.0 203.7 
Caiputai 27.3 206.0 107.5 14.2 239.8 287.7 65.7 116.7 168.7 
Duancun 12.1 45.6 0.0 16.2 641.6 157.4 71.2 101.2 90.9 
Beiliuzhuang 33.4 133.9 71.6 21.2 568.6 283.9 79.8 78.6 45.3 
Wangjiazhai 56.5 191.8 0.0 10.2 566.9 220.6 342.3 915.2 82.9 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 23.4 194.4 418.2 4.1 486.2 255.5 32.1 159.3 64.4 
Shaochedian 20.5 6.3 0.0 9.2 618.4 117.6 0.0 171.7 68.1 
Caiputai 13.6 116.4 0.0 18.2 422.5 149.4 66.5 218.7 57.2 
Duancun 23.4 52.7 25.0 6.2 838.6 533.7 215.7 216.5 72.1 
Beiliuzhuang 10.8 59.9 791.9 23.2 578.6 147.3 94.6 152.3 266.5 
Wangjiazhai 75.9 212.7 139.4 19.5 105.7 384.8 313.4 1009.1 191.7 
P
o
re
 W
at
er
 
Zaolinzhuang 21.6 154.3 7.5 13.2 308.4 296.5 23.8 60.1 68.9 
Shaochedian 21.6 154.3 7.5 13.2 381.4 300.1 23.8 60.1 68.9 
Caiputai 34.8 62.2 95.1 18.0 200.0 151.1 61.6 51.8 58.9 
Duancun 26.8 56.1 22.7 21.2 390.5 217.7 49.3 59.2 92.7 
Beiliuzhuang 23.7 0.0 16.3 19.2 271.9 235.9 51.4 63.0 52.8 
Wangjiazhai 21.0 0.0 56.2 16.2 209.7 545.0 37.7 32.3 81.5 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 33.2 558.9 0.0 1.1 232.3 578.2 102.8 984.0 60.3 
Shaochedian 15.7 1.2 725.8 15.2 500.6 293.1 41.3 170.3 41.8 
Caiputai 29.1 38.8 0.0 12.1 229.4 190.5 58.2 51.4 102.4 
Duancun 30.0 199.2 0.0 2.3 841.8 540.6 55.7 45.5 8.2 
Beiliuzhuang 38.5 16.1 0.0 16.2 308.8 649.1 52.9 79.0 68.8 
Wangjiazhai 28.3 20.0 0.0 12.2 220.5 1051.5 49.8 58.7 0.0 
 
Table 41 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
surface water samples in April 2009  
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from April are listed in Table 41 and displayed in Figure 126 - 128.  
The highest observed concentration for surface water samples was 1092 ng/l at 
Shaochedian for Pro, closely followed by Carb at Zaolinzhuang with 1092 ng/l. The 
lowest observed concentration for this group of samples was <LOD for Meb at Duancun 
and Wangjiazhai. For overlying water samples, the lowest observed concentration was 
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once again <LOD for Meb (Shaochedian and Caiputai) and Indo (Shaochedian). The 
highest observed concentration for this group of samples was of 1009 ng/l for Diclo at 
Wangjiazhai. For pore water samples, the minimum concentration identified was once 
again <LOD for Meb at Beiliuzhuang and Wangjiazhai and the highest was for Tamo at 
545 ng/l at Wangjiazhai. The concentration range for the water-release test sample 
group was between <LOD for Meb at all locations except Shaochedian and Meclo at 
Wangjiazhai to 1052 ng/l for Tamo at Wangjiazhai.  
 
 
Figure 126 Concentration  of target pharmaceutical compounds for April 2009 in 
Surface water samples for BYD Lake 
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Figure 127 Concentration of target pharmaceutical compounds for April 2009 in 
Overlying water samples for BYD Lake 
 
Figure 128 Concentration of target pharmaceutical compounds for April 2009 in Pore 
water samples for BYD Lake 
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Figure 129 Concentration of target pharmaceutical compounds for April 2009 in Water-
release test samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 51.8 825.3 0.0 4.7 433.4 504.5 85.8 774.9 12.6 
Shaochedian 28.3 113.1 0.0 15.2 794.4 456.2 385.7 0.0 85.3 
Caiputai 11.8 6.2 215.2 14.2 336.8 255.0 182.2 37.8 8.0 
Duancun 35.0 16.9 41.2 9.1 357.8 325.5 233.9 149.3 365.0 
Beiliuzhuang 9.5 24.3 0.0 7.2 662.6 201.6 41.8 193.4 10.3 
Wangjiazhai 24.4 428.9 118.0 4.3 106.2 388.7 0.0 0.0 159.5 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 6.6 215.5 776.4 6.2 333.0 448.8 94.2 0.0 131.7 
Shaochedian 19.4 45.9 119.6 15.2 361.8 139.5 101.9 0.0 13.1 
Caiputai 34.3 151.6 0.0 4.2 367.1 412.6 25.3 79.2 190.9 
Duancun 11.7 12.7 61.9 16.2 42.9 106.6 23.4 0.0 16.9 
Beiliuzhuang 18.9 24.4 258.5 13.0 567.3 508.3 133.9 175.5 110.6 
Wangjiazhai 112.1 1106.8 168.7 11.2 1056.8 98.2 207.9 1330.2 100.0 
P
o
re
 W
at
er
 
Zaolinzhuang 3.7 215.8 1276.2 10.2 475.8 120.6 83.7 31.2 101.5 
Shaochedian 6.4 23.9 704.4 5.2 180.1 314.0 31.7 37.3 108.5 
Caiputai 27.4 6.8 0.0 6.1 179.0 346.5 35.5 221.7 8.3 
Duancun 13.8 0.0 9.4 8.1 88.3 693.6 31.8 36.3 61.7 
Beiliuzhuang 8.1 2.0 0.0 14.2 227.2 350.9 41.5 27.0 80.7 
Wangjiazhai 9.7 129.7 0.0 5.1 1160.5 987.0 31.6 411.9 23.7 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 14.1 7.8 114.6 6.2 522.2 187.8 88.2 220.0 145.0 
Shaochedian 19.9 8.3 41.3 5.2 263.0 333.9 86.6 0.0 125.6 
Caiputai 12.2 1.6 339.2 1.2 1217.4 977.4 86.8 94.4 127.3 
Duancun 19.0 73.4 0.0 13.2 229.8 339.6 66.2 164.6 8.8 
Beiliuzhuang 10.4 4.5 88.4 9.1 254.9 249.1 23.6 89.8 4.6 
Wangjiazhai 15.3 315.5 0.0 5.1 413.6 225.9 34.7 695.6 122.1 
 
Table 42 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
surface water samples in May 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from May are listen in Table 42 and displayed graphically in Figure 130 - 
132.  
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In the sample group of surface water samples, the highest observed concentration was 
for Sulf of 825 ng/l at Zaolinzhuang, and the lowest observed concentration was <LOD  
for Meb at Zaolinzhuang, Shaochedian and Beiliuzhuang, Indo at Wangjiazhai and 
Diclo at Shaochedian. For overlying water samples, the lowest observed concentration 
was once again <LOD at Caiputai for Meb and at Zaolinzhuang, Shaochedian and 
Duancun for Diclo. The highest observed concentration was of 1330 ng/l for Diclo at 
Wangjiazhai, closely followed by Sulf and Carb for the same location with 1107 ng/l 
and 1057 ng/l respectively. For pore water samples, concentrations identified ranged 
from <LOD to 1276 ng/l. The lowest was observes at 4 locations; Duancun for Sulf and 
at Caiputai, Beilizhuang and Wangjiazhai for Meb. The highest was observed at 
Zaolinzhuang for Meb. Lastly, the highest and lowest observed concentrations for 
water-release test samples were <LOD and 1217 ng/l. The lowest was recorded for both 
Duancun and Wangjiazhai for Meb and Shaochedian for Diclo and the highest was 
observed at Caiputai for Carb.  
 
 
Figure 130 Concentration (ng/l) of target pharmaceutical compounds for May in Water-
release test samples for BYD Lake 
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Figure 131 Concentration of target pharmaceutical compounds for May 2009 in Pore 
water samples for BYD Lake 
 
Figure 132 Concentration of target pharmaceutical compounds for May 2009 in 
Overlying water samples for BYD Lake 
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Figure 133 Concentration of target pharmaceutical compounds for May 2009 in Surface 
water samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 23.4 84.8 66.2 14.2 1155.2 170.6 50.2 52.3 0.0 
Shaochedian 0.0 1.4 134.8 6.2 497.9 577.6 0.0 272.9 104.6 
Caiputai 0.0 9.0 71.6 14.2 506.8 117.9 16.9 339.9 96.4 
Duancun 12.7 297.8 37.8 4.2 1030.5 193.9 178.1 324.0 148.1 
Beiliuzhuang 27.2 678.3 211.1 6.1 123.7 137.5 0.0 207.8 7.2 
Wangjiazhai 21.6 577.3 0.0 13.2 441.8 273.7 77.2 285.5 166.4 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 7.5 41.6 0.0 10.2 336.3 888.8 2.0 154.5 171.9 
Shaochedian 26.6 42.4 875.3 8.2 1712.6 215.2 74.1 102.2 148.3 
Caiputai 4.9 0.0 166.6 4.2 395.3 184.9 0.0 36.6 19.4 
Duancun 25.7 99.7 0.0 6.2 491.6 813.6 144.3 403.8 431.2 
Beiliuzhuang 83.9 1712.2 0.0 13.2 798.1 392.3 301.8 1904.0 0.0 
Wangjiazhai 103.7 685.5 85.0 10.2 687.3 737.6 69.7 940.7 255.3 
P
o
re
 W
at
er
 
Zaolinzhuang 42.3 77.0 273.1 11.0 730.2 1324.2 6.0 127.0 89.2 
Shaochedian 13.9 29.7 0.0 16.2 324.7 334.6 33.5 55.6 182.0 
Caiputai 57.3 4.6 0.0 3.1 73.5 338.6 46.8 343.1 307.5 
Duancun 65.3 9.3 54.8 13.2 28.0 1344.3 18.3 32.6 38.0 
Beiliuzhuang 112.0 853.9 269.7 17.2 369.2 899.9 157.4 179.2 309.0 
Wangjiazhai 21.8 21.2 26.6 11.2 656.6 191.8 0.0 174.8 58.6 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 13.4 40.5 52.7 3.1 298.2 189.1 51.9 73.4 29.6 
Shaochedian 5.9 84.9 0.0 5.2 488.4 180.4 82.7 16.6 115.4 
Caiputai 0.7 7.7 97.2 8.2 126.9 118.5 36.8 76.7 10.4 
Duancun 35.6 8.3 1144.5 5.2 160.5 167.9 63.5 0.0 121.1 
Beiliuzhuang 2.4 1200.0 0.0 5.2 315.3 156.6 6.8 91.7 146.1 
Wangjiazhai 907.5 197.8 815.9 1.2 204.1 453.2 429.6 798.7 1716.3 
           
Table 43 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
surface water samples in June 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from June are listed in Table 43 and displayed graphically in Figure 134-
136.  
Starting with the group of 6 surface water samples, the highest observed concentration 
was 1155 ng/l for Carb at Zaolinzhuang and the lowest was for 60. ng/l values found at 
Zaolinzhuang for Meclo, Shaochedian for Pro and Indo, Caiputai for Pro, Beiliuzhuang 
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for Indo and Wangjiazhai for Meb. The highest identified concentration for the group of 
overlying water samples was 1904 ng/l at Beiliuzhuang for Diclo. Other high identified 
compounds were Sulf at Beiliuzhuang and Carb at Shaochedian with 1712 ng/l and 
1713 ng/l respectively. For the pore water samples, non detection was once again 
identified three times as the lowest value for Meb at Shaochedian and Caiputai and for 
Indo at Wangjiazhai. For the water-release test samples the highest observed 
concentration was 1200 ng/g at Beiliuzhuang for Sulf and the lowest of <LOD at 
Shaochedian and Beiliuzhuang for Meb and Duancun for Diclo. A low concentration of 
0.7 ng/l was also identified at Caiputai for Pro.  
 
 
Figure 134 Concentration (ng/l) of target pharmaceutical compounds for June in Water-
release test samples for BYD Lake 
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Figure 135 Concentration  of target pharmaceutical compounds for June 2009 in Pore 
water samples for BYD Lake 
 
Figure 136 Concentration of target pharmaceutical compounds for June 2009 in 
Overlying water samples for BYD Lake 
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Figure 137 Concentration  of target pharmaceutical compounds for June 2009 in 
Surface water samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 1.7 636.0 1597.8 16.2 398.2 491.8 446.1 330.2 234.1 
Shaochedian 0.9 126.2 249.7 22.2 725.9 110.6 63.9 33.0 59.0 
Caiputai 0.0 28.6 0.0 15.2 1346.1 97.3 0.0 0.0 142.3 
Duancun 12.3 78.0 0.0 16.2 1218.4 461.2 59.2 511.5 373.9 
Beiliuzhuang 124.4 209.5 217.6 19.2 529.4 131.6 591.0 360.5 331.9 
Wangjiazhai 101.8 1194.7 27.7 8.2 136.9 230.0 628.1 1148.1 434.3 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 5.9 157.7 516.9 3.2 988.3 177.3 111.9 191.8 474.1 
Shaochedian 26.7 80.2 1004.3 14.0 167.0 232.3 222.7 405.3 91.6 
Caiputai 264.5 0.0 1292.1 10.2 200.3 133.9 293.6 472.1 518.8 
Duancun 49.4 90.8 1089.0 14.2 1093.2 216.1 0.0 678.5 233.4 
Beiliuzhuang 164.7 263.7 0.0 5.2 466.1 78.0 667.1 632.8 134.1 
Wangjiazhai 278.6 1084.5 1491.5 11.2 540.6 380.2 355.2 1718.5 471.9 
P
o
re
 W
at
er
 
Zaolinzhuang 29.9 73.0 0.0 9.2 357.8 390.5 44.6 490.5 168.3 
Shaochedian 117.1 132.2 0.0 6.2 611.9 433.8 356.5 439.0 244.4 
Caiputai 1.4 0.0 154.3 12.3 258.7 67.7 31.9 107.3 73.2 
Duancun 0.0 0.0 0.0 13.2 503.3 226.8 52.6 277.8 224.2 
Beiliuzhuang 119.8 108.8 239.6 11.2 243.8 563.9 511.1 368.6 404.8 
Wangjiazhai 18.8 0.0 0.0 15.2 114.9 161.4 17.1 457.6 211.4 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 24.6 80.2 211.8 4.2 334.4 176.1 48.3 92.5 62.7 
Shaochedian 284.0 62.1 568.4 5.2 519.5 909.2 128.3 79.0 380.5 
Caiputai 157.7 15.6 0.0 8.2 272.7 1304.6 102.4 204.8 62.8 
Duancun 26.4 150.7 0.0 2.1 301.3 247.5 78.5 103.6 78.3 
Beiliuzhuang 49.8 969.3 0.0 3.3 258.2 110.2 235.9 1287.1 141.9 
Wangjiazhai 22.2 687.1 0.0 5.2 216.8 282.4 117.7 263.5 211.0 
 
Table 44 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
surface water samples in July 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from July are listed in Table 44 and are displayed graphically in Figure 
138 - 140.  
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For samples in July, the higest observed concentration of target compound identified in 
surface water samples was 1598 ng/l at Zaolinzhuang for Meb and the lowest was for 
<LOD for Pro at Caiputai, Meb for Caiputai and Duancun, Indo for Caiputai and Diclo 
for Caiputai. For overlying water samples, the highest observed concentration was 1718 
ng/l for Diclo at Wangjiazhai. There were also other very high concentrations; 1084 ng/l 
for Sulf at Wangjiazhai, 1492 ng/l for Meb at Wangjiazhai and 1093 ng/l for Carb at 
Duancun. The highest observed concentration for pore water samples was 611.9 ng/l for 
Carb at Shaochedian. The lowest were <LOD identified at Duancun for Pro, Sulf and 
Meb, Wangjiazhai for Sulf and Meb, Caiputai for Sulf, and Shaochedian and 
Zaolinzhuang for Meb. Low concentrations were also identified of 1.4 ng/l for Pro at 
Caiputai and 6.2 ng/l for Thio. Thio generally has a low concentration through out the 
sampling in July 2009 , with a range from 2.1 ng/l to 22.2 ng/l. For water-release test 
samples, the highest observed concentration was of 1305 ng/l for Tamo at Caiputai, and 
the lowest of <LOD for all sites excluding Shaochedian and Zaolinzhuang for Meb.  
 
Figure 138 Concentration of target pharmaceutical compounds for July 2009 in Water-
release test samples for BYD Lake 
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Figure 139 Concentration of target pharmaceutical compounds for July 2009 in Pore 
water samples for BYD Lake 
 
Figure 140 Concentration of target pharmaceutical compounds for July 2009 in 
Overlying water samples for BYD Lake 
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Figure 141 Concentration of target pharmaceutical compounds for July 2009 in water 
release test samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 93.8 718.1 20961.5 4.7 660.6 4961.7 4679.0 1828.1 3577.9 
Shaochedian 8.6 195.5 8384.2 15.3 1113.0 737.5 2469.2 3928.9 234.1 
Caiputai 33588.1 97358.6 24385.9 12.4 24590.4 57124.6 107137.0 43706.6 84160.9 
Duancun 176.9 359.2 1638.9 7.2 641.9 2865.6 3869.8 1079.7 6566.1 
Beiliuzhuang 261.3 1219.2 2979.7 6.3 1709.6 4354.8 10753.3 1442.5 2159.3 
Wangjiazhai 140.1 291.1 2505.7 19.3 12681.3 5006.9 10119.7 11219.5 26962.6 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 158.8 238.7 301.8 45.7 873.1 664.4 2363.6 1054.7 107.1 
Shaochedian 109.6 0.0 194.8 12.6 0.0 1015.8 2072.5 0.0 434.4 
Caiputai 39.5 63.8 0.0 10.2 960.0 1441.9 1665.3 3480.3 3061.6 
Duancun 159.3 203.7 2953.3 6.4 578.2 1371.0 7165.4 30524.0 0.0 
Beiliuzhuang 652.7 8121.1 68438.3 9.6 44078.2 24356.9 37485.0 59631.1 43439.4 
Wangjiazhai 0.0 10806.6 9467.3 45.2 5339.2 8490.1 24026.5 0.0 3384.2 
P
o
re
 W
at
er
 
Zaolinzhuang 0.0 0.0 8786.1 32.5 1444.5 14495.4 17871.5 4406.5 1521.2 
Shaochedian 0.0 134.9 2229.8 6.2 259.0 727.1 968.7 536.5 0.0 
Caiputai 1821.6 4285.9 18030.3 15.3 0.0 6238.8 49350.9 36499.4 12835.9 
Duancun 298.4 13.9 221.5 18.2 109.0 1225.4 1528.1 1242.6 60997.1 
Beiliuzhuang 670.7 1901.4 0.0 7.2 336.5 641.7 769.6 1958.0 1350.1 
Wangjiazhai 138.2 592.0 1550.6 11.3 67.0 1188.5 5202.8 6820.9 46470.5 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 5.1 9627.7 1383.9 3.2 149.5 591.5 1050.3 3611.1 1287.3 
Shaochedian 8.6 25.1 33.5 63.2 7.2 285.8 285.8 156.3 0.0 
Caiputai 335.1 27820.7 2235.6 12.4 161.5 1450.8 3183.3 0.0 2948.0 
Duancun 61.3 446.7 0.0 7.2 389.6 1294.0 2530.8 2652.1 4332.6 
Beiliuzhuang 63.5 0.0 678.9 14.3 342.9 181.2 1272.1 485.5 449.0 
Wangjiazhai 160.0 1119.2 14767.2 5.6 803.1 2302.8 1566.7 1753.1 0.0 
 
Table 45 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples in September 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from September are listed in Table 45 and are displayed graphically in 
Figure 142 - 144.  
It is immediately obvious when looking at Figure 142 that the sampling location with 
the highest identified concentrations for surface water samples in September is Caiputai. 
This is also the case for Beiliuzuang for overlying water samples Figure 143.  
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The concentration of target pharmaceutical compounds in samples from September 
measured much higher concentrations than identified before. The maximum 
concentration identified in surface water samples was 107137 ng/l for Indo at Caiputai. 
The minimum was a very small 2.7 ng/l in comparison for Thio at Zaolinzhuang. Thio 
had overall the lowest identified concentration with a range between 4.7 ng/l and 19.3 
ng/l (Wangjiazhai), which is also the case across all sample groups during this month 
with a range between 3.2 ng/l (at Zaolinzhuang during the water-release test) and 63.2 
ng/l (at Shaochedian during the water-release test).  The highest identified concentration 
for the overlying water sample group was 68438.3 ng/l at Beiliuzhang for Meb. The 
lowest was a value of <LOD on seven occasions for Pro, Sulf, Meb, Carb, Diclo and 
Meclo. For pore water samples, the highest identified concentration for target 
pharmaceutical compounds was 60997 ng/l for Meclo at Duancun. The lowest 
(excluding six 0.00 ng/l values) was 6.2 ng/l for Thio at Shaochedian. The maximum 
concentration identified during the water-release test sample group was 27821 ng/l for 
Sulf at Caiputai, and the lowest (once again excluding <LOD values) was 3.2 ng/l for 
Thio at Zaolinzhuang.  
 
 
Figure 142 Concentration  of target pharmaceutical compounds for September 2009 in 
Surface water samples for BYD Lake 
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Figure 143 Concentration of target pharmaceutical compounds for September 2009 in 
Overlying water samples for BYD Lake 
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Figure 144 Concentration  of target pharmaceutical compounds for September 2009 in 
Pore water samples for BYD Lake 
 
 
Figure 145 Concentration  of target pharmaceutical compounds for September 2009 in 
water-release test samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 878.4 633.9 0.0 16.3 4732.2 0.0 14311.9 6215.7 8665.2 
Shaochedian 8.2 0.0 10248.9 4.3 7734.5 1360.3 24901.0 0.0 2483.9 
Caiputai 2769.5 1899.1 0.0 11.4 234.0 67.7 817.2 3803.6 573.6 
Duancun 4.6 62.8 1409.9 9.3 1.4 37.2 143.5 453.4 2480.6 
Beiliuzhuang 101.8 259.4 2830.3 8.7 3161.6 467.4 2357.2 7204.2 0.0 
Wangjiazhai 4.8 4.1 0.0 12.3 539.3 34.3 74.5 274.1 142.9 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 0.0 0.0 212.0 10.2 497.5 169.0 3344.4 1935.6 1917.6 
Shaochedian 23.2 114.6 212.2 6.3 2402.0 1943.8 2234.6 4723.6 0.0 
Caiputai 101.9 598.3 0.0 8.7 265.2 208.3 929.0 4310.5 7087.1 
Duancun 54.2 3543.6 6272.3 19.2 0.0 361.9 8072.0 359.3 2494.9 
Beiliuzhuang 2398.3 5249.0 0.0 11.7 6177.1 1913.5 8666.8 3895.8 4188.7 
Wangjiazhai 33.2 372.2 0.0 10.3 4499.5 7270.2 3729.7 0.0 0.0 
P
o
re
 W
at
er
 
Zaolinzhuang 5.5 0.0 7799.3 7.2 120.3 26.5 512.4 5269.5 6237.8 
Shaochedian 71.5 1215.2 201.6 86.2 14.9 112.4 695.9 7014.0 86.8 
Caiputai 288.1 2475.6 8041.7 86.3 129.6 2552.4 1563.2 0.0 5677.0 
Duancun 29.3 1090.8 3750.9 53.2 144.6 1013.2 4746.4 183.2 7669.7 
Beiliuzhuang 0.0 26.4 8654.9 26.6 0.0 875.0 2838.5 2219.3 0.0 
Wangjiazhai 4931.6 1140.3 4764.7 7.2 0.0 1560.7 5719.4 6757.5 0.0 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 723.4 0.0 6246.1 16.4 378.1 1039.3 2048.4 3594.4 157.1 
Shaochedian 518.5 6616.6 6247.3 2.7 278.4 629.5 0.0 0.0 1508.5 
Caiputai 33.7 0.0 0.0 10.6 0.0 1391.5 7727.9 4152.3 4130.3 
Duancun 902.4 2270.7 0.0 14.5 1223.8 7283.3 1382.0 0.0 4464.7 
Beiliuzhuang 63.2 3978.1 2733.5 60.0 4920.8 3767.4 7196.8 3502.9 7764.6 
Wangjiazhai 106.2 0.0 0.0 53.2 0.0 1803.5 7902.3 1427.7 0.0 
Table 46 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples in October 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from October are listed in Table 46, displayed graphically in Figure 146 - 
148.  
During October, the target pharmaceutical compound with the overall lowest observed 
concentrations was Thio, with a range between 2.7 ng/l (Shaochedian during water-
release tests) and only 86.3 ng/l (Caiputai during pore water sampling). The highest 
overall observed compound concentration was 24901 ng/l for Indo at Shaochedian 
during surface water sampling. This compound along with Meclo gave very high 
concentration results. <LOD were identified across a variety of sites and sample groups 
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at all compounds excluding Thio on at least one occasion. The minimum observed 
concentration for surface water samples excluding <LOD values, was 1.4 ng/l for Carb 
at Duancan. Other minimum values for sample groups were as follows (excluding zero 
values); 6.3 ng/l for Thio at Caiputai (overlying water), 5.5 ng/l for Pro at Zaolinzhuang 
(pore water) and 2.7 ng/l for Thio at Shaochedian (water-release tests). Remaining 
maximum sample concentrations observed at all sites (excluding aforementioned 
maximum overall concentration) were as follows; 8667 ng/l for Indo at Beiliuzhuang 
(overlying water), 8655 ng/l ng/l for Meb at Caiputai (pore water) and 7902 ng/l for 
Tamo at Wangjiazhai (water-release test samples).   
 
 
Figure 146 Concentration  of target pharmaceutical compounds for October 2009 in 
Surface water samples for BYD Lake 
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Figure 147 Concentration  of target pharmaceutical compounds for October 2009 in 
Overlying water samples for BYD Lake 
 
 
Figure 148 Concentration (ng/l) of target pharmaceutical compounds for October 2009 
in Pore water samples for BYD Lake 
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Figure 149 Concentration (ng/l) of target pharmaceutical compounds for October 2009 
in water-release test samples for BYD Lake 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
u
rf
ac
e 
W
at
er
 
Zaolinzhuang 179.4 8314.5 0.0 4.7 435.6 4537.3 4273.0 0.0 2481.0 
Shaochedian 1806.2 12584.8 13151.2 23.4 1093.7 1698.3 3479.0 0.0 0.0 
Caiputai 23.2 1565.5 0.0 52.4 450.6 234.5 3066.9 477.2 0.0 
Duancun 2773.0 0.0 0.0 48.6 412.8 502.7 1167.1 6275.7 439.7 
Beiliuzhuang 0.0 1701.3 0.0 16.3 12015.3 3612.7 12675.3 12827.5 12351.1 
Wangjiazhai 0.0 769.8 6626.4 97.4 2427.4 1779.0 284.2 0.0 6878.5 
O
v
er
ly
in
g
 W
at
er
 
Zaolinzhuang 81.6 0.0 1698.6 46.3 0.0 2642.4 0.0 6988.6 3132.7 
Shaochedian 286.1 0.0 8996.5 31.2 5195.2 1080.2 1434.5 0.0 3129.4 
Caiputai 3788.6 3063.4 0.0 10.3 0.0 3793.4 5682.0 0.0 0.0 
Duancun 77.6 0.0 7027.9 52.2 389.2 61.4 9578.7 5261.4 11610.0 
Beiliuzhuang 201.0 4608.9 3807.0 86.4 10529.7 288.1 6669.5 6194.4 4871.7 
Wangjiazhai 296.6 5866.9 12628.4 94.3 1497.1 34.5 765.3 4591.2 744.2 
P
o
re
 W
at
er
 Zaolinzhuang 311.6 2534.8 12588.8 43.3 619.8 2678.1 769.0 897.6 6176.5 
Shaochedian 0.0 2119.0 0.0 15.3 513.8 5729.0 2172.5 2962.2 0.0 
Wangjiazhai 70.7 2688.9 4239.1 16.3 1259.3 7057.5 8931.4 927.8 0.0 
W
at
er
-r
el
ea
se
 t
es
t 
Zaolinzhuang 456.2 607.5 7562.3 72.3 847.2 1436.3 1882.5 0.0 847.4 
Shaochedian 238.7 77.2 0.0 38.0 716.0 2614.9 1787.9 490.9 3604.5 
Caiputai 0.0 0.0 0.8 46.3 15.9 165.6 116.0 406.6 484.5 
Duancun 44.1 2.4 0.7 95.2 92.1 55.2 201.1 774.3 580.8 
Beiliuzhuang 62.5 55.7 7.7 18.4 225.5 75.0 309.3 2698.1 671.5 
Wangjiazhai 46.8 6.8 0.0 45.2 115.9 81.8 232.9 782.4 533.4 
 
Table 47 Concentration (ng/l) of pharmaceutical compounds found in BYD Lake 
sediment samples in November 2009 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from November are listed in Table 47 are displayed graphically in Figure 
150 - 152.  
 
The overall highest concentration observed during sample analysis in November from 
BYD lake water samples was 13151 ng/l for Meb at Shaochedian (surface water 
samples). Meb also had the overall highest concentrations observed. Seven out of nine 
compounds observed <LOD concentrations on at least one occasion exclusing Thio and 
Tamo. Surface water samples had a lowest concentration (excluding zero 
concentrations) of 4.7 ng/l for Thio at Zaolinzhuang. Thio was also the lowest observed 
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concentration (excluding <LOD) for overlying water samples and pore water samples 
for Caiputai (10.3 ng/l) and Shaochedian (13.3 ng/l) respectively. The lowest observed 
for water-release test samples excluding zero concentrations was for Meb with a 
concentration of 0.7 ng/l at Duancan, closely followed by 0.8 ng/l at Caiputai. 
Maximum concentrations for each sample group were as follows (excluding 
aforementioned highest overall observed); 12628 ng/l for Meb at Wangliazhai 
(overlying water samples), 12589 ng/l for Meb at Zaolinzhuang (pore water samples) 
and 7562 ng/l for Meb at Zaolinzhuang (water-release test samples). Only three 
sampling locations were collected for pore water samples as opposed to the regular six; 
Zaolinzhuang, Shaochedian and Wangjiazhai, for logistical and access reasons.  
 
 
 
Figure 150 Concentration (ng/l) of target pharmaceutical compounds for November 
2009 in Surface water samples for BYD Lake 
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Figure 151 Concentration (ng/l) of target pharmaceutical compounds for November 
2009 in Overlying water samples for BYD Lake 
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Figure 152 Concentration (ng/l) of target pharmaceutical compounds for November 
2009 in Pore water samples for BYD Lake 
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Figure 153 Concentration (ng/l) of target pharmaceutical compounds for November 
2009 in water-release test samples for BYD Lake 
 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Zaolinzhuang 115.0 18.4 0.0 200.0 231.9 317.0 510.0 2983.3 1884.7 
Duancun 232.2 102.2 5.0 326.2 882.3 430.7 1325.0 5443.5 3319.5 
Beiliuzhuang 86.6 1.2 0.0 200.0 184.0 268.9 797.4 3102.7 2411.1 
Table 48 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples in February 2010 
 
All concentrations of target pharmaceutical compounds found in BYD Lake surface 
water samples from February are listed in Table 48. These are displayed graphically in 
Figure 154.  
During February, a total of only three samples were collected for surface water samples 
only; Zaolinzhuang, Duancun and Beiliuzhuang. Out of these, there were two zero 
concentrations observed for Meb at the first and last location. The lowest observed 
concentration overall was 1.2 ng/l for Sulf at Beiliuzhuang. The highest overall 
observed concentration was 3319 ng/l for Meclo at Duancun.  
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Figure 154 Concentration (ng/l) of target pharmaceutical compounds for February 2010 
in Surface water samples for BYD Lake 
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5.3.3 Sediment samples from Beijing 
5.3.3.1 Haihe River 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Daliangdukou 6.6 4.2 27.7 14.7 25.0 433.6 107.4 23.7 100.9 
Xihe 10.5 27.6 177.6 12.2 20.1 452.2 114.4 44.0 8.0 
Dengshangu 3.2 1.4 58.0 15.2 31.7 465.5 191.4 35.8 41.4 
Jintanggaosu 5.2 4.5 3.4 8.2 20.4 482.9 176.5 29.5 26.6 
Gegu 8.5 6.8 38.5 16.2 27.2 466.3 174.4 61.2 31.9 
Tianjinzhan 12.7 1.0 25.2 10.2 34.2 547.2 169.7 61.9 45.7 
Haijin Bridge 6.4 5.0 81.3 13.3 51.0 414.8 168.4 71.8 9.9 
Zhangguizhuang 16.0 6.5 75.8 8.1 40.6 548.3 162.1 53.1 10.9 
Dongyangchang 16.1 7.7 8.8 6.0 69.0 497.1 180.2 48.8 22.5 
Fengkoucun 17.2 6.5 102.8 10.2 55.6 383.7 172.1 46.1 21.5 
Niwocun 10.0 10.9 2.2 15.2 48.9 320.5 162.0 38.1 51.6 
Majiacaiyuan 15.0 5.5 59.1 16.2 27.0 434.8 151.4 0.0 629.2 
Caizhuangzi 13.9 3.3 81.4 12.0 31.8 341.2 95.9 3.1 5.2 
Chaqian 12.1 2.5 59.4 12.3 27.0 420.9 128.3 62.0 79.2 
Beicha 11.1 3.2 60.6 7.2 27.6 406.8 107.4 30.6 56.8 
Nancha 13.8 7.5 155.5 14.2 56.5 387.8 108.2 13.7 27.0 
Pangu 20.3 7.6 76.2 10.2 41.1 322.5 65.1 32.7 45.4 
Dagu1 31.3 0.4 77.1 16.2 61.7 236.0 118.7 25.5 31.2 
Dagu2 20.0 3.7 129.6 15.0 58.9 349.8 185.5 18.9 101.6 
Dagu3 15.2 21.4 48.9 13.3 60.3 291.4 105.4 54.8 114.8 
Haihe Bridge 32.0 4.0 155.6 9.3 53.6 267.0 150.4 39.8 0.0 
Table 49 Concentration (ng/g) of pharmaceutical compounds found in Haihe River 
sediment samples in June 2009 
 
During June 2009, 21 sample locations were analysed for the concentration of 9 target 
pharmaceutical compounds in sediment samples from Haihe River. These data are 
found in Table 49. Following data analysis, these were presented graphically in Figure 
155 - 156. Due to the nature of these data for Tamo and Meclo, graphs were made 
giving a more normalized representation in Figure 157 - 159. 
The maximum overall concentration was observed for Meclo at Majiacaiyuan with a 
concentration of 629 ng/g. There were two zero concentrations observed; one for Diclo 
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and the other for Meclo. Disregarding these, the lowest overall observed concentration 
was for Sulf at Dagu1 with a concentration of only 0.4 ng/g. Both Sulf and Thio had 
low overall concentrations of only 0.4 ng/g to 27.6 ng/g and 6.0 ng/g and 16.2 ng/g 
respectively. Remaining sample range concentrations were as follows; 3.2 ng/g to 32.0 
ng/g for Pro, 2.2 ng/g to 177.6 ng/g for Meb, 20.1 ng/g to 69.0 ng/g for Carb, 236.0 ng/g 
to 548.3 ng/g for Tamo, 65.1 ng/g to 191.4 ng/g for Indo, 3.1 ng/g to 71.8 ng/g 
(excluding 0.0 ng/g concentration) for Diclo and 5.2 ng/g to 629.2 ng/g for Meclo 
(again, excluding <LOD).  
 
 
Figure 155 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the first seven sites in June 2009 
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Figure 156 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the next seven sites in June 2009 
 
 Figure 157 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the last seven sites in June 2009 
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Figure 158 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the first seven sites in June 2009 (normalized results) 
 
Figure 159 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the next seven sites in June 2009 (normalized results) 
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Figure 160 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the last seven sites in June 2009 (normalized results) 
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Daliangdukou 55.3 3.1 68.7 10.3 71.9 341.0 93.9 75.2 0.0 
Xihe 28.9 3.3 1276.9 14.2 34.6 234.9 82.3 27.8 0.0 
Dengshangu 35.6 68.5 22.6 5.3 94.9 413.2 218.1 21.3 41.1 
Jintanggaosu 84.2 0.0 39.4 6.2 130.0 483.0 173.1 183.1 225.5 
Gegu 27.0 1.4 288.8 18.2 140.3 430.6 265.9 181.4 48.4 
Tianjinzhan 49.8 1.9 7.3 13.3 55.5 291.7 92.3 102.2 29.2 
Haijin Bridge 46.4 0.0 842.1 4.2 75.6 332.1 245.2 0.0 7.0 
Zhangguizhuang 38.7 5.4 163.0 23.3 61.6 262.8 176.6 38.5 0.0 
Dongyangchang 67.5 12.8 277.7 34.3 51.9 396.3 237.0 91.2 27.3 
Fengkoucun 83.1 10.6 363.7 6.2 131.9 260.0 94.4 151.7 219.0 
Niwocun 23.0 0.0 1975.0 4.2 97.2 270.3 122.4 0.0 2.2 
Majiacaiyuan 109.9 3.8 1279.8 11.0 218.9 667.9 253.8 0.0 41.6 
Caizhuangzi 56.0 0.0 3594.7 10.2 108.2 663.2 199.1 0.0 291.3 
Chaqian 11.8 40.1 7.8 7.2 73.0 221.1 111.6 8.4 2.6 
Beicha 77.7 20.8 370.4 13.2 178.0 387.9 266.6 12.2 0.0 
Nancha 6.3 0.0 386.8 39.3 54.8 469.6 145.1 55.8 16.6 
Pangu 19.3 570.8 60.1 12.4 86.0 268.5 96.4 62.9 497.8 
Dagu1 16.0 0.0 29.6 41.2 69.0 382.9 425.9 102.0 0.0 
Dagu2 20.0 0.0 305.7 12.4 139.5 578.7 379.4 919.0 0.0 
Dagu3 15.7 85.7 11.9 4.3 76.6 396.0 176.7 141.0 57.6 
Haihe Bridge 80.1 0.8 74.8 6.2 72.1 380.6 237.1 39.1 126.8 
Table 50 Concentration (ng/g) of pharmaceutical compounds found in Haihe River 
sediment samples in November 2009 
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Table 50 details the concentration of pharmaceutical compounds found in sediment 
samples from the Haihe River in November 2009. Figure 160, figure 161 and figure 162 
graphically show these data from Table 50. Due to the high concentration nature of Meb 
and Tamo, these were removed for normalisation purposes of results shown graphically, 
in Figure 163 – 165. Meb and Tamo have the highest overall concentrations observed, 
with a range of 7.3 ng/g to 3595 ng/g and 221.1 ng/g to 667.9 ng/g respectively. Meb 
has the highest overall observed value of 3595 ng/g at Caizhuangzi. A zero 
concentration was observed on 16 occasions for compounds Sulf, Diclo and Meclo. 
Aside from these, the lowest recorded concentration was observed at the sample 
location Haihe Bridge for Sulf of 0.8 ng/g.  
 
 
 
 
 
 
 
 
 
252 
 
 
 
Figure 161 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the first seven sites in November 2009 
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Figure 162 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the next seven sites in November 2009 
 
 
 Figure 163 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the last seven sites in November 2009 
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Figure 164 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the first seven sites in November 2009 (normalized results) 
 
Figure 165 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the next seven sites in November 2009 (normalized results) 
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Figure 166 Concentration (ng/g) of target pharmaceutical compounds from Haihe river 
sediment samples for the last seven sites in November 2009 (normalized results) 
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5.3.3.2 Bohai Bay 
  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Shagouzi 37.7 5.9 139.7 4.3 135.6 245.5 99.3 68.5 39.1 
Huangligang 92.9 9.5 42.6 5.2 92.7 222.3 104.9 72.6 58.7 
Xujiabao 64.7 8.9 113.3 9.2 49.0 255.9 216.2 35.6 244.6 
Nanpaihe 41.2 2.3 139.7 7.2 52.6 262.5 98.1 19.7 52.1 
Ziyaxinhe 82.3 28.5 111.3 10.2 78.0 324.1 153.2 32.9 17.1 
Duliujianhe 82.2 10.4 11.7 15.2 58.5 297.3 350.6 35.0 118.6 
Lvjugou 46.9 30.1 529.3 13.2 53.3 284.9 118.2 1.1 8.2 
Tianjinlingang 72.8 41.9 86.3 16.2 116.1 423.5 224.5 0.0 19.1 
Tianjinlgang 52.8 7.7 121.4 18.2 66.6 224.5 98.5 17.7 15.1 
Tianjin Harbor 66.2 18.0 35.2 21.2 74.6 317.1 144.8 0.0 25.7 
Do ngjianggang 126.4 0.0 78.0 20.5 109.8 417.0 77.1 2.7 62.4 
Guanlanlu 39.7 0.0 95.9 4.3 77.4 383.3 60.9 39.7 9.6 
Luanhekou 48.9 8.2 79.0 5.2 155.4 257.7 90.8 4.4 0.0 
Letinggongyeyuan 32.7 84.4 49.2 6.2 89.0 314.2 43.4 23.2 19.2 
Xihekou 15.1 0.0 75.0 4.2 65.2 288.7 215.5 94.1 94.5 
Caofeidian 15.5 16.5 24.3 11.2 82.4 286.0 110.7 14.9 37.3 
Heiyanzi 67.2 5.4 5.8 17.2 81.3 271.4 123.0 28.7 4.0 
Beitangkou 31.6 0.0 70.8 13.2 76.7 480.6 147.8 41.6 326.5 
Table 51 Concentration (ng/g) of pharmaceutical compounds found in Bohai Bay 
sediment samples in June 2009 
 
All eighteen sample locations from Bohai Bay analysed for sediment samples in June 
2009 are detailed in Table 51. These are displayed graphically in Figure 167 - 168. 
257 
 
Tamo and Indo were removed for 
 
Figure 170 – 171 for the normalisation of results. The maximum observed concentration 
was observed for Meb at Lvjugou with 529.3 ng/g. Zero values were identified for three 
compounds; Sulf, Diclo and Meclo on five occasions. Other than these, the lowest 
observed concentration identified was 1.1 ng/l for Diclo at Lvjugou. Thio gave the 
lowest overall concentrations with a range between 4.2 ng/g and 21.2 ng/g, only a 
difference of 17.0 ng/g. The highest overall range observed was for Meb of 523.5 ng/g, 
with concentrations ranging between 5.8 ng/g and 529.3 ng/g.  
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Figure 167 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the first six sites in June 2009
Figure 168 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the next six sites in June 2009 
259 
 
 
 
Figure 169 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the last six sites in June 2009 
 
Figure 170 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the first six sites in June 2009 (normalized results) 
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Figure 171 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the next six sites in June 2009 (normalized results) 
 
 
 Figure 172 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the last six sites in June 2009 (normalized results) 
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  Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
Shagouzi 33.5 30.5 47.9 8.4 61.3 359.3 130.2 155.4 365.8 
Huangligang 27.1 1.2 79.5 13.1 92.0 276.4 152.0 381.5 27.6 
Xujiabao 106.9 8.9 311.9 15.2 137.2 340.5 108.2 0.0 0.0 
Nanpaihe 74.0 65.7 76.5 21.2 81.1 301.6 176.9 10.4 49.6 
Ziyaxinhe 42.5 58.5 1275.0 3.2 150.6 412.4 189.5 19.5 11.5 
Duliujianhe 97.9 189.4 742.8 16.2 128.5 412.6 342.5 0.0 37.9 
Lvjugou 51.8 730.0 550.7 53.2 176.2 363.6 225.7 7.1 78.8 
Tianjinlingang 76.7 1.7 7.9 8.2 179.1 370.9 102.2 0.0 38.3 
Tianjinlgang 180.5 30.8 0.0 9.2 378.2 258.7 387.7 1069.1 797.2 
Tianjin Harbor 195.3 12.6 248.7 16.3 138.5 300.1 361.8 253.2 116.8 
Do ngjianggang 102.8 3.6 351.6 12.3 101.8 191.0 157.4 6.9 29.8 
Guanlanlu 46.4 42.2 318.9 13.2 79.5 273.5 120.3 50.4 0.0 
Luanhekou 72.4 0.0 51.8 10.2 114.9 212.2 89.5 77.1 8.5 
Letinggongyeyuan 85.6 7.6 1959.9 7.5 138.0 349.4 106.9 15.6 0.0 
Xihekou 110.3 154.3 650.0 22.2 215.3 544.6 191.5 212.3 28.0 
Caofeidian 76.9 17.9 4647.7 21.4 124.8 285.5 143.9 95.9 76.1 
Heiyanzi 49.2 27.8 44.4 8.5 122.6 247.4 72.1 5.2 30.7 
Beitangkou 93.2 3.0 535.1 5.2 80.3 522.2 185.9 77.7 33.9 
Table 52 Concentration (ng/g) of pharmaceutical compounds found in Bohai Bay 
sediment samples in November 2009 
 
Sediment samples taken from Bohai Bay in November are listed in Table 52 and 
displayed in Figure 173 - 174. The compound with concentrations of the highest overall 
range was Meb, with a range from <LOD to 1960 ng/g. The compound with the lowest 
range was Thio with only 50.0 ng/g, with the minimum and maximum values of 3.2 
ng/g and 53.2 ng/g. The highest observed concentration for Meb was also the highest 
overall for this data set and was found at the location Latinggongyeyuang. <LOD were 
found for the compounds Sulf, Meb, Diclo and Meclo for a total of seven occasions. 
Other than these, the lowest observed concentration was for Suld at Huangligang with 
1.2 ng/g. Normalised results are given in Figures 175 – 177. 
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Figure 173 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the first six sites in November 2009 
 
Figure 174 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the next six sites in November 2009 
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 Figure 175 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the last six sites in November 2009 
 
 
Figure 176 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the first six sites in November 2009 (normalized results) 
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Figure 177 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the next six sites in November 2009 (normalized results) 
 
 
Figure 178 Concentration (ng/g) of target pharmaceutical compounds from Bohai Bay 
sediment samples for the last six sites in November 2009 (normalized results) 
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5.3.3.3 BYD Lake 
    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
M
ar
ch
 
Zaolinzhuang 66.6 1.1 117.1 323.9 105.0 395.8 96.4 55.0 50.7 
Shaochedian 22.4 24.1 9.8 235.2 53.4 192.1 62.3 0.0 410.5 
Caiputai 99.8 677.5 11.6 153.2 109.6 406.4 274.7 12.6 20.9 
Duancun 58.8 1.3 30.1 432.2 79.5 287.5 150.0 59.9 76.2 
Beiliuzhuang 38.8 0.0 116.0 296.5 139.4 420.8 227.7 1.2 8.1 
Wangjiazhai 24.4 34.2 317.7 313.9 117.2 394.5 181.3 0.0 0.0 
A
p
ri
l 
Zaolinzhuang 38.7 10.7 882.6 298.5 100.9 331.3 175.7 3.2 40.1 
Shaochedian 38.2 0.0 20.3 165.2 72.1 566.3 574.7 50.4 1093.0 
Caiputai 74.8 4.1 0.0 356.5 62.0 558.3 516.6 379.6 0.0 
Duancun 14.3 13.9 199.1 215.2 11.7 257.7 234.3 126.7 1081.5 
Beiliuzhuang 80.0 234.8 1054.5 175.2 177.2 667.7 452.3 414.4 32.8 
Wangjiazhai 41.9 0.0 33.6 291.1 118.3 501.5 252.9 82.4 69.3 
M
ay
 
Zaolinzhuang 4.1 49.4 0.0 223.7 63.3 328.3 199.1 0.0 69.7 
Shaochedian 48.4 0.0 333.9 204.2 175.2 779.7 629.8 378.0 760.9 
Caiputai 14.5 16.3 224.5 185.2 51.0 609.9 361.9 66.6 1593.1 
Duancun 73.9 16.2 141.9 143.2 83.3 334.0 167.2 0.0 276.7 
Beiliuzhuang 14.4 159.3 3352.7 196.3 80.0 533.5 250.3 203.7 1792.1 
Wangjiazhai 32.7 12.3 834.9 200.7 110.7 340.9 258.0 0.0 48.0 
Ju
n
e 
Zaolinzhuang 0.0 22.8 539.7 163.2 122.4 210.9 326.5 0.0 54.8 
Shaochedian 36.2 1362.4 514.6 95.6 125.1 290.6 155.5 85.7 0.0 
Caiputai 1.4 46.5 24.9 128.2 139.8 349.5 336.9 466.2 2055.2 
Duancun 1.8 28.1 454.2 108.3 103.3 296.9 270.9 18.9 10.9 
Beiliuzhuang 72.5 46.5 0.0 268.3 46.0 313.2 99.1 53.2 19.3 
Wangjiazhai 5.8 4.0 0.0 342.3 62.9 387.8 130.9 0.0 73.9 
Ju
ly
 
Zaolinzhuang 10.2 0.0 10.6 196.3 43.3 413.2 329.3 279.3 17.3 
Shaochedian 36.4 581.4 442.0 172.0 180.5 253.3 423.9 1616.1 234.2 
Caiputai 70.3 47.1 105.4 196.3 64.1 361.5 209.8 12.9 574.8 
Duancun 6.4 2.3 1194.0 365.3 34.1 205.3 152.4 59.2 88.3 
Beiliuzhuang 1.5 207.4 1067.3 265.2 201.3 439.5 446.6 1996.6 1162.0 
Wangjiazhai 108.9 350.1 699.9 185.2 46.4 369.7 206.4 86.4 1907.0 
S
ep
te
m
b
er
 
Zaolinzhuang 2.0 7.2 3414.6 285.3 211.7 340.3 127.8 79.8 1217.8 
Shaochedian 17.6 37.5 633.7 149.2 42.3 185.8 139.2 314.3 3625.6 
Caiputai 4.1 571.3 4447.7 235.6 22.5 324.2 251.9 0.0 0.0 
Duancun 54.7 43.1 1794.7 168.3 87.5 451.1 291.5 3050.7 82.2 
Beiliuzhuang 29.8 11.5 172.2 326.4 34.0 403.1 320.6 59.1 134.7 
Wangjiazhai 28.3 6.2 759.4 126.3 61.2 348.4 214.1 3295.2 0.0 
O
ct
o
b
e
r Zaolinzhuang 3.4 8.1 0.0 75.3 25.7 493.8 247.0 136.6 99.4 
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Shaochedian 3.7 2.9 11.7 120.2 25.5 502.2 177.7 0.0 3730.3 
Caiputai 23.1 165.6 4355.2 86.3 27.2 643.3 157.7 28.3 89.0 
Duancun 17.3 0.0 0.0 96.2 7.9 600.7 489.7 167.9 52.8 
Beiliuzhuang 0.4 0.0 455.4 43.2 31.2 374.0 348.4 72.8 0.0 
Wangjiazhai 2.0 0.0 5.8 161.2 0.5 604.4 279.5 0.0 429.2 
N
o
v
em
b
er
 
Zaolinzhuang 66.6 3.6 3152.9 152.245. 65.3 569.0 325.2 41.7 88.7 
Shaochedian 17.4 18.1 76.7 85.3 53.4 692.6 297.5 84.2 2534.9 
Caiputai 14.1 0.3 10.0 76.3 1.8 578.3 364.2 70.3 1797.9 
Duancun 0.5 0.5 622.2 101.0 30.4 721.3 306.3 138.2 147.6 
Beiliuzhuang 0.9 0.0 367.7 146.3 3.4 910.0 547.0 65.5 0.0 
Wangjiazhai 4.4 9.2 31.6 136.2 22.1 458.6 205.1 20.0 163.0 
D
ec
 
Zaolinzhuang 22.4 9.7 60.5 143.2 35.6 461.0 222.2 3.5 21.6 
Duancun 8.6 96.1 229.7 63.2 40.0 539.6 226.2 128.5 0.0 
Wangjiazhai 5.1 7.6 630.9 166.2 57.6 656.8 281.7 4.0 22.6 
Table 53 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples between March to December 2009 (excluding August) 
 
Table 53 details all concentrations of target pharmaceutical compounds from sediment 
samples of BYD Lake between March to December, excluding August as this month 
was not investigated due to logistical reasons.  
 
During March, concentrations of pharmaceuticals were fairly low in comparison to 
other months in this set of observations (Figure 179). The maximum observed 
concentration was 677.5 ng/g for Sulf at Caiputai, and the lowest (excluding zero 
concentrations) was 1.1 ng/g for Sulf at Zaolinzhuang. Duancan also had a low 
concentration for Sulf of 1.3 ng/g. Beiliuzhuang had a concentration of only 1.2 ng/g for 
Diclo. <LOD were observed on four occasions; one for Sulf, two for Diclo and one for 
Meclo.  
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Figure 179 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during March 2009 
 
 
Figure 180 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during April 2009 
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The maximum observed concentration during April was 1093 ng/g for Meclo at 
Shaochedian. This was closely followed by 1081.5 at Duancun for the same compound. 
<LOD were observed on three occasions; Shaochedian and Wangjiazhai for Sulf, and 
Caiputai for Meb. Excluding these, the lowest observed concentration was for Diclo of 
3.2 ng/g at Zaolinzhuang (Figure 180).  
 
 
Figure 181 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during May 2009 
 
The sample ranges for each site during May 2009 sediment samples for BYD lake were 
as follows; <LOD  (Meb and Diclo) to 328.3 ng/g (Tamo) for Zaolinzhuang, <LOD 
(Sulf) to 779.7 ng/g (Tamo) for Shaochedian, 16.3 ng/g (Sulf) to 1593 ng/g (Meclo) for 
Caiputai, <LOD (Diclo) to 334 ng/g (Tamo) for Duancun, 14.4 ng/g (Pro) to 3352.7 
ng/g (Meb) for Beiliuzhuang and <LOD (Diclo) to 835 ng/g (Meb) at Wangjiazhai 
(Figure 181). Concentrations were generally high during May 2009.  
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Figure 182 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during June 2009 
 
It is immediately apparent that the highest concentration observed for BYD Lake 
sediment samples during June 2009 is at Caiputai for Meclo, with a value of 2055 ng/g. 
The second highest is at Shaochedian for Sulf with a concentration of 1362 ng/g (Figure 
182). <LOD were observed on six occasions for the compounds Pro, Meb, Diclo and 
Meclo.   
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Figure 183 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during July 2009 
 
During July, the compound Diclo presented two instances of high observed 
concentrations at Shaochedian and Beiliuzhuang of 1616 ng.g and 1997 ng/g 
respectively (Figure 183). High concentrations were also observed for Meclo at 
Wangjiazhai and Beiliuzhuang with values of 1907 ng/g and 1162 ng/g respectively. 
Meb also gave relatively high concentrations on three occasions at Duancun (1194 
ng/g), Beiliuzhuang (1067 ng/g) and Wangjiazhai (700 ng/g). The lowest observed 
concentration was 1.5 ng/g at Beiliuzhuang for Pro.  
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Figure 184 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during September 2009 
 
The concentration of target pharmaceutical compounds observed at BYD Lake in 
September 2009 are illustrated in Figure 184. Some concentrations during September 
are considerably high; Meb at Caiputai is the highest overall observed with 4448 ng/g. 
The next being Meclo at Shaochedian with a concentration of 3626 ng/g, Pro at 
Zaolinzhuang with 3414 ng/g, Diclo at Wangjiazhai with a concentration of 3295 ng/g 
and lastly at Duancun of 3051 ng/g. Excluding these, concentrations ranged from <LOD 
on three occasions to 1795 ng/g (Meb at Duancun).  
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Figure 185 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during October 2009 
 
Figure 184 displays the concentration of target pharmaceutical compounds found in 
BYD Lake sediment samples during October 2009. These concentrations are fairly low 
across all compounds excluding two; Meclo at Shaochedian with a concentration of 
3730 ng/g and Meb at Caiputai with 4355.2 ng/g, also being the highest overall 
observed. The lowest concentration excluding <LOD was for 0.4 ng/g at Beiliuzhuang 
for Pro, closely followed by 0.5 ng/g at Wangjiazhai for Carb. <LOD concentrations 
were identified on eight different occasions. Pro gave the lowest overall concentration 
range of only 22.7 ng/g, with values ranging between 0.4 ng/g and 23.1 ng/g.  
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Figure 186 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during November 2009 
 
 
The highest overall concentration observed during November 2009 for sediment 
samples at BYD Lake was 3153 ng/g for Meb at Zaolinzhuang (Figure 186). Excluding 
this and two other significantly high concentrations observed for Meclo at Shaochedian 
and Caiputai of 2535 ng/g and 1798 ng/g respectively, concentrations were fairly stable 
and all below 910 ng/g (Tamo at Beiliuzhuang). On more than one occasion 
concentrations below 1.0 ng/g were observed; 0.5 ng/g and 0.9 ng/g for Pro, 0.3 ng/g 
and 0.5 ng/g for Sulf, and zero concentrations at Sulf and Meclo.  
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Figure 187 Concentration (ng/g) of pharmaceutical compounds found in BYD Lake 
sediment samples during December 2009 
 
Figure 187 is the last in this series of sediment sampling results from BYD Lake in 
2009. Only three sampling locations were investigated due to logistical reasons. A 
concentration of <LOD was only observed on one occasion for Meclo at Duancun. The 
highest concentration observed was for Indo of 657 ng/g for Tamo at Wangjiazhai. This 
was closely followed with a concentration of 631 ng/g for Meb at the same sampling 
location. Two other relatively high concentrations were observed during December; 461 
ng/g and 540 ng/g both for Tamo at Zaolinzhuang and Duancun respectively.  
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5.4 Shanghai sample analysis 
5.4.1 Sampling location 
 
Figure 188 Map detailing sampling locations of onshore locations from the Huangpu 
River in Shanghai 
 
The sampling locations of those from the Huangpu River in Shanghai are detailed in 
Figure 188. Due to incomplete information from the sampling locations related to the 
samples sent from Shanghai, it was not possible to match samples to their exact 
locations seen in figures to follow.  
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
P
M
 E
D
C
s 
n
g
/g
 
0.82 6.45 55.03 283.00 10.88 177.56 387.16 2.96 296.01 
0.60 0.00 59.11 248.25 7.05 131.52 173.54 12.34 67.48 
0.42 1.65 137.99 282.90 0.00 126.39 174.77 0.00 62.76 
0.99 4.69 0.00 268.30 0.00 116.70 175.03 0.00 173.10 
51.73 1.34 430.89 285.75 45.10 612.94 639.14 98.35 573.32 
2.47 0.00 346.14 261.50 3.35 621.81 15.02 0.00 0.00 
S
ed
im
en
ts
 
0.43 0.06 93.12 99.40 1.18 84.11 54.31 5.00 24.49 
0.36 0.22 91.77 55.40 0.83 67.39 46.60 6.31 33.80 
0.02 0.00 89.08 30.80 0.01 112.19 26.76 1.50 14.64 
0.18 0.13 44.40 32.90 0.07 59.98 29.26 0.00 16.63 
4.72 0.14 231.70 75.62 6.81 45.20 123.76 11.91 67.68 
0.13 0.51 153.06 68.30 1.08 207.40 57.01 3.56 35.68 
O
n
sh
o
re
 l
o
ca
ti
o
n
s 
0.37 0.48 58.44 15.90 2.46 249.59 163.85 15.09 99.19 
0.06 0.00 40.45 25.22 1.52 430.97 12.41 2.06 0.00 
0.25 0.15 63.07 53.85 0.90 258.23 130.34 18.39 63.89 
0.14 0.22 62.06 3.00 0.55 290.48 71.92 0.00 24.90 
2.04 0.10 414.66 18.95 0.56 287.96 114.69 0.00 52.64 
0.20 1.00 18.60 7.85 0.59 323.94 61.89 2.26 30.38 
0.95 0.39 67.40 18.14 3.93 372.60 135.36 35.12 75.58 
0.77 0.01 126.87 1.39 0.00 212.03 105.61 0.00 43.90 
IS
 
0.02 0.11 2.10 3.05 0.00 1.30 2.90 0.00 2.66 
 
 Table 54 Concentration data for the analysis of pharmaceutical compounds in samples 
from Shanghai 
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    Pro Sulf Meb Thio Carb Tamo Indo Diclo Meclo 
S
P
M
 E
D
C
s 
n
g
/g
 
1.16 0.77 3.07 20.51 0.40 16.05 76.79 0.23 7.90 
0.24 0.00 79.91 54.94 0.91 7.87 4.07 0.96 2.57 
0.59 2.34 73.01 0.71 0.00 1.25 28.51 0.00 69.34 
0.14 0.55 0.00 13.72 0.00 26.44 6.06 0.00 25.51 
14.43 0.20 36.79 19.30 17.67 32.89 13.40 15.77 10.50 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
S
ed
im
en
ts
 
0.26 0.08 15.37 0.57 0.79 4.08 5.57 1.27 8.18 
0.31 0.32 3.23 5.23 0.04 0.21 6.53 0.57 6.93 
0.03 0.00 1.33 1.84 0.01 25.30 1.04 0.42 2.60 
0.19 0.19 10.28 12.45 0.05 4.38 11.14 0.00 2.30 
0.74 0.20 14.57 6.17 1.28 11.74 7.41 2.14 0.74 
0.13 0.00 19.16 4.10 0.29 2.83 0.88 0.94 18.70 
O
n
sh
o
re
 l
o
ca
ti
o
n
s 
0.53 0.20 12.88 4.67 0.53 35.16 6.99 3.24 3.89 
0.09 0.00 7.56 5.49 0.45 80.51 0.60 0.93 0.00 
0.01 0.21 2.99 21.00 0.33 58.00 15.99 1.68 7.18 
0.15 0.32 4.76 0.14 0.25 28.25 16.60 0.00 2.54 
0.24 0.14 11.93 1.06 0.26 90.96 14.69 0.00 7.84 
0.28 0.23 2.13 2.05 0.41 87.19 5.68 0.22 4.21 
0.12 0.16 4.95 4.47 1.03 76.31 63.83 3.42 4.92 
0.61 0.02 3.58 0.22 0.00 22.66 26.47 0.00 28.78 
IS
 
0.03 0.07 0.85 0.07 0.00 0.28 1.27 0.00 0.05 
 
Table 55 Standard deviation for the analysis of pharmaceutical compounds in samples 
from Shanghai 
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5.4.2 Sediment Samples 
 
Figure 189 Concentration of pharmaceutical compounds in SPM samples from 
Shanghai 
 
Testing samples for SPM EDCs still showed surprisingly high concentrations of 
pharmaceuticals (Figure 189). Nine recordings of zero concentrations were identified 
for compounds Sulf, Carb, Diclo and Meclo, shown in Table 54 and 55. Location fq had 
the highest overall contamination with values ranging from a minimum of 1.34 ng/g for 
Sulf and 639.14 ng/l for Indo, also the highest overall identified concentration value. 
Thio gave relatively similar values for all sites, with a range of only 262 – 286 ng/g.  
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Figure 190 Concentration of pharmaceutical compounds in sediment samples from 
Shanghai 
 
Figure 190 represents the concentration of selected pharmaceutical compounds 
identified in sediment samples from Shanghai. Concentrations ranged from <LOD to 
232 ng/g (Table 54). Concentration range for each compound was as follows, with the 
minimum and maximum site noted respectively; Pro 0.02 – 4.72 ng/g (fu anf fw), Sulf 
<LOD – 0.51 ng/g (fu and fx), Meb 44.40 – 232 ng/g (fv and fw), Thio 30.80 – 99.40 
ng/g (fu and fs), Carb 0.01 – 6.81 ng/g (fu and fw), Tamo 45.20 – 207 ng/g (fw and fx), 
Indo 26.76 – 124 ng/g (fu and fw), Diclo <LOD  – 11.91 ng/g (fv and fw), and Meclo 
14.64 – 67.68 ng/g (fu and fw). Fw harbours the highest concentration for six of the 
nine compounds. The opposite is true for fu, which records the lowest for six of the nine 
compounds.  
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Figure 191 Concentration of pharmaceutical compounds from onshore locations in 
Shanghai 
 
Eight onshore locations in Shanghai were analyzed for the concentration of 
pharmaceutical compounds (Figure 191). Excluding gc, Tamo is the highest 
concentration identified for all sites with a range between 212. – 431 ng/g (gf and fz 
respectively). At gc, the highest concentration identified was for Meb with 415 ng/g. 
Concentration range for each site was as follows; fy 0.37 – 250 ng/g, fz <LOD – 431 
ng/g , ga 0.15 – 258 ng/g, gb 0.00 – 291 ng/g, gc <LOD – 415 ng/g, gd 0.20 – 324 ng/g, 
ge 0.39 – 373 ng/g, and finally gf <LOD – 212. ng/g.  
 
5.5 Conclusion 
Overall, pharmaceutical concentrations of samples from Shanghai were higher in water 
than sediment samples, with results regularly over 10,000 ng/l. This is particularly the 
case for concentrated fluid samples. Maximum concentration for sediment samples 
rarely exceeded 300 ng/g, with maximum results just over 600 ng/g for just three 
individual cases. Some <LOD concentrations were observed, but this is perfectly viable.  
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In comparison to Chapter 4, samples from Shanghai demonstrated the same patterns; 
higher in water than sediment as a comparison. The maximum concentration of 
pharmaceuticals in the River Medway water samples was 14,573.12 ng/l. Perhaps more 
surprising, is the concentration of pharmaceutical compounds in sediment comparison. 
Throughout the sampling of sediment between December 2009 and June 2010, the 
minimum and maximum concentrations observed from the River Medway were 0.47 
ng/g and 6156 ng/g, compared to a maximum of just over 600 ng/g in Shanghai, with 
most concentrations rarely exceeding 300 ng/g.  
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Chapter 6 - Conclusions 
 
6.1 Development of an LC-MS/MS method for the extraction of pharmaceutical 
compounds from sediment samples 
Through a series of method development, a method of sediment extraction for 
pharmaceuticals was successfully developed. The developed method used a dry and 
homogenized sample mass of 2 g, followed by the use of methanol as the solvent of 
choice. Extraction using Ultrasonication (U) was then used followed by Waters Oasis 
SPE cartridges for the clean-up process. Standard practice reduction of samples using 
N2 blow down followed, and then finally analysis with a previously tried and tested 
method using LC-MS/MS for final quantification.  
Experiments were conducted at each stage of the method development process and gave 
excellent results. A sample mass of 2 g was concluded to be the optimal to use 
following recovery results (%) of these and sample masses of 1 g and 5 g. The recovery 
range for the sample masses were as follows; 0.01 – 58.37 % for 1g, 4.54 – 78.28 % for 
2 g and 0.02 – 25.30 % for 5 g (Figure 14). The sample mass of 2 g had the highest 
overall recovery average of 52.67 % compared to 13.48 % for 1 g and 13.71 % for 5 g 
(Figure 15). 
Among the various solvents tested including Methanol, Acetonitrile, Hexane and Ethyl 
Acetate, it was concluded that methanol was the best solvent to use for the extraction 
process. Overall methanol produced the highest recoveries for the majority of 
compounds, with the majority over 70 % (Figure 16). It is fair to say that other solvents 
out performed methanol on some occasions for a few compounds, however this was a 
fair and accepted trade-off to be able to use one solvent for the extraction process, as all 
compounds tested using methanol had good recoveries. Figure 17 clearly highlights that 
methanol is the best overall solvent to use with a recovery average (%) outperforming 
any other solvent or solvent mixture.  
Although there was extensive testing of the use of MAE for method development, this 
was also compared to using U (Figure 11). MAE produced the best recoveries at 110 °C 
for 15 min using methanol with results between 4.5 % (Thio) to 84.6 % (Pro), however 
U for 30 mins at room temperature outperformed the MAE method with results between 
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19.3 % (Thio) to 97.6 % (Pro), with seven out of nine compounds achieving a recovery 
above 60 %. Therefore, U was selected for further method development and testing.  
The effect of changing the cleanup method on extraction was considered to enhance the 
sensitivity and overall quality of analysis for pharmaceuticals. Tested were laboratory 
made columns of silica, alumina, silica: alumina (1:1), silica: alumina (1:3), silica: 
alumina (3:1), SPE Oasis and SPE Supelco, with results illustrated in 
Figure 10. It is clearly noticeable that SPE Oasis far outperforms any other cleanup 
method with results between 50.99 % (Indo) to 98.35 % (Carb) and so was chosen for 
continued use in this method development process.  
A flow diagram to illustrate the new developed method for the simultaneous 
determination of nine pharmaceutical compounds is displayed in Figure 18.  
 
6.2 Validation of the developed method by application to environmental samples 
Following a successful pilot study on samples from the River Ouse (East Sussex, UK), 
the developed method was then used to conduct a formal spatial and temporal 
variability report of the nine target pharmaceutical compounds in the River Medway 
(Kent, UK) at locations at and around Motney Hill sewage treatment works.  
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Temporal variability was recorded across 7 seasons for a total of 4 occasions; December 
2009, February 2010, April 2010 and June 2010. Concentrations of pharmaceuticals at 
the River Medway during December 2009 ranged from 0.6 ng/g to 1194.2 ng/g for Sulf 
upstream and Tamo at the effluent site respectively (Table 22). During February 2010, 
pharmaceutical compounds at the chosen sampling locations ranged from 0.47 ng/g for 
Sulf at the effluent site to 239.42 ng/g for Tamo downstream from the effluent site. 
During April the concentration range across all sites and compounds was between 11.03 
ng/g for Sulf and 2080.75 ng/g for Tamo. Concentrations of pharmaceuticals at the 
River Medway in June 2010 ranged from 11.57 ng/g for Sulf downstream and 6165 
ng/g for Diclo at the effluent site. For all observed months Sulf had the lowest observed 
concentrations. 
The month of February in 2009 showed the overall lowest target pharmaceutical 
concentration whereas the month of June in 2010 saw the highest concentration 
(concentrations previously stated). This suggests that this is due to seasonal variability 
of water temperature having an effect on the remobilization and presence of compounds 
remaining in the sediment. However the discharge of pharmaceutical compounds from 
STWs is also expected to be seasonal. During Summer (warmer) months, the water is 
more likely to be less agitated and therefore more of the target pharmaceutical 
compounds remain in the sediment. For example it is proposed that in Winter months 
when waters are more agitated due to bad weather and winds that there may be a higher 
remobilization of the compounds from the sediments into the water and therefore 
leaving the sediment with a lower compound concentration than in the surrounding 
waters. There may also be an increased concentration of pharmaceutical compounds in 
the sediment at this time of year as there may be an increase in these compounds 
released into the water (and subsequently becomes dormant in the sediment) due to 
increased river activity (ie recreational boating) in these warmer Summer months. 
Another contributing factor may be the effect of water dilution with rainfall and 
increased mobilization between solids and water.  
 
6.3 Application of the developed and validated method to different environmental 
matrices.  
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The developed method was successfully applied to a variety of different matrices 
including samples of water, vegetation (seaweed, grass root, grass shoot, rosehip, 
dandelion, slow buds and sloe leaves), biological (tissue) samples (lug worm and crab) 
and crustacean samples (clam shell and snails).  
The method was very successful and confirmed the further assessment of fate of 
pharmaceutical compounds in the aquatic environment by giving a snap shot into the 
scale of the concentrations. Success in this instance is the recovery of spiked 
compounds; at this stage of the method development, any recovery for these set of 
experiments is deemed successful. All samples were treated the same as sediment 
samples previously and then subjected to the same developed analytical method. 
Recoveries ranged from 2.51 % (Sulf for rosehip) to 536.44 % (Tamo for dandelion). 
Overall Meb had particularly high recoveries, with the highest of 520.37 % found in the 
crab sample. Results suggest a high degree of bio accumulation and magnification 
through the food chain, which is considered in 6.5. In the instance of these experiments 
however, it is the recovery (%) which is of more importance than the target 
pharmaceutical content (ng/g).  
During sampling at locations aforementioned in the River Medway, seaweed samples 
were taken for the months of February, April and June of 2010 and so analysed using 
the developed method to give an indication of pharmaceutical concentration, temporal 
variability and bioaccumulation. Seaweed was chosen as it was the only available 
sample to be collected on all occasions. Other examples such as crabs were available, 
however they may not have always originated at these locations.  
The seaweed samples had increasingly high concentrations as you travel from the 
upstream to effluent to downstream sampling locations, in particular for February and 
April. The concentrations did not show this pattern as strongly in June for all 
compounds, although the maximum concentrations during this month were almost ten 
fold greater than the previous observations. February 2010 was by far the month where 
seaweed concentrations were the overall lowest ranging between 0.06 ng/g for Pro at the 
upstream site and 622.22 ng/g for Diclo at the downstream site. For April 2010 the 
concentration range was between 20.55 ng/g to 4712 ng/g at upstream and downstream 
sites respectively both for Indo. The concentrations in June 2010 were significantly 
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higher with a range bwtween 239.53 ng/g for Meb at the effluent site and 43987.78 ng/g 
for Meclo.  
 
 
 
 
 
 
 
 
 
 
6.4 Completion of aims and objectives 
6.4.1 Aim 1 – Pharmaceutical analysis and monitoring 
6.4.1.1 Objective 1 – Extraction and clean-up method 
It was proposed to identify the best extraction and cleanup method of pharmaceutical 
compounds from a solid sample matrix. This included selecting the optimum solvent, 
sample size, extraction conditions and cleanup method.  
This aim was successfully completed as a method was developed and tested with 
excellent results. It was concluded that the best solvent to use is methanol with a (dry) 
sample size of 2 g. The extraction method of choice is U for 30 mins at room 
temperature followed by cleanup using SPE Oasis columns.  
6.4.1.2 Objective 2 – LC-MS/MS method 
Objective 2 described how a LC-MS/MS method would be used for the simultaneous 
extraction, separation and quantitative analysis of a group of nine pharmaceutical 
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compounds from river sediment samples. After initial investigations it was concluded 
that an existing tried and tested (and published) analytical LC-MS/MS technique was to 
be used as described by Zhang and Zhou (2007).  
6.4.1.3 Objective 3 – Environmental samples 
As described in objective three, the developed method from objectives one and two 
were used to quantify the concentration of target pharmaceuticals in the River Ouse and 
River Medway. The samples were taken at locations which would determine spatial 
analysis as required. Using samples from the River Medway, a temporal and spatial 
variability report was successfully conducted as well as finally applying the successful 
method to samples from China.  
 
6.4.2 Aim 2 – Assessing the quality of analysis 
6.4.2.1 Objective 4 – Precision and bias of sampling 
To assess the precision and bias of sampling, triplicate sampling was conducted ex situ 
(in the field). Once back in the laboratory, each replicate sample was processed in 
triplicate once again to further increase precision and bias. At the final stage of analysis, 
LC-MS/MS, each sample was analysed three times (triple injection). Therefore 
objective four was fulfilled successfully at every possible opportunity.  
To further assess quality of the results, experiments were conducted to analyse the inter- 
and intra-day variability of the LC-MS/MS equipment. Although there was slight 
variation in results taken from the same sample, these were not significant to analysis 
and so continued as normal.  
6.4.2.2 Objective 5 – Analysis of blank samples 
As required by objective five, a blank sample was analysed to minimize any effect of 
background concentration of the nine target pharmaceutical compounds. It was 
concluded that there was no significant effect as concentrations were either below the 
LOD or very low and close to this.  
6.4.2.3 Objective 6 – Sample storage 
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To be able to identify the best possible way to store samples and elucidate any 
significant differences in doing so, four different conditions were tested; in a freezer, in 
a fridge, at room temperature and at room temperature uncovered. Results for each 
compound were conclusive over a six week period that storing the samples in a fridge 
was the best option.  
6.4.2.4 Objective 7 - Matrix effect 
It was important to consider if there was any bias once the validated method was 
successful and applied to environmental samples with a solid matrix. To assess this, the 
extraction method was tested on samples with no matrix and a solid soil matrix. Results 
were conclusive across all compounds that there was no significant matrix effect from 
the use of ultrasonication (U), and that MAE experiments showing extracts had 
significant interference in the response of compounds upon analysis. Similar results 
were found for the other compounds, suggesting that MAE is more destructive than U in 
causing the dislodging of sediment compounds.  
 
 
6.4.3 Aim 3 – Applications of the developed method 
6.4.3.1 Objective 8 – Biological samples 
A variety of different biological samples were taken from the River Medway as stated in 
objective eight and the recovery of pharmaceuticals following spiking experiments were 
determined. It can be concluded that the method is extremely successful in application 
to all of the biological samples tested and is applicable to a wider variety of matrices. 
This makes the method more widely useable. On reflection, non-spiked as well as 
spiked samples should have been analysed to further validate the developed 
methodology, however time and sample volume constraints prohibited this.  
6.4.3.2 Objective 9 – Water samples 
To test whether the developed method can be applied successfully to water samples, 
they were taken from the River Medway for analysis. Target pharmaceuticals were 
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successfully identified in samples rendering the developed method suitable for both 
sediment and water sample analysis with good high recoveries.  
6.4.3.3 Objective 10 – Geochemistry of contaminants 
It was proposed that the pH, salinity and dissolved Oxygen were to be analysed from 
water samples used in objective nine to assess the geochemistry of contaminants of the 
nine selected pharmaceutical compound concentrations. This unfortunately was the only 
objective which was not conducted due to logistical and practical reasons concerning 
the equipment. However after consideration post experimentation, this objective was 
not entirely relevant to the rest of the studies as it only assessed these from water 
samples and the  work was predominantly focused on sediment samples.  
 
6.5 Further work 
Although my work has shown the successful development, validation and application of 
a simultaneous and reliable method to detect a group of nine selected pharmaceutical 
compounds, and my original objectives have all been achieved, there are still areas for 
consideration, concern and further remediation as follows; 
 Organisms in water and sediment at certain levels and selected compounds will 
be affected 
 There is no immediate or direct threat to human health 
 Concentrations found are relatively high; bioaccumulation in sea life through 
recreational activities is of indirect dancer to human health 
 Water should be treated before use by humans and as a general rule should be 
avoided by consumption even after treatment as a safety precaution.  
 PPCPs found in sediment are less of a threat to humans. However sediment of 
this nature (busy river) are likely to be significantly high due to remobilization 
of PPCPs from sediment due to activity on and in the waters which will disturb 
the sediment.  
 PPCP levels should be routinely monitored as a precautionary measure due to 
the potential threats.  
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Sampling was collected once a month for four months over a total of seven. These were 
in December, February, April and June. In future work, more continuous monitoring 
should be practiced to include a more detailed insight into seasonal variability and 
increased temporal monitoring to minimize limitations of point sampling.  
Comparisons of total PPCP concentrations from different studies should be treated with 
caution as different numbers of parent PPCP compounds were analysed from different 
studies and so compounds measured may differ. Different methods are likely to have 
been used as this project focuses on a new methodology, and also variables such as time 
of year mean that comparisons cannot be made directly without considerations. This is 
especially true as it appears that PPCPs show a tendency to be higher in Winter 
compared to Summer months. The simple numeric predicament of altering units must 
be treated with caution.  
Further data collection could include particle size analysis routinely of each of the 
original samples before analysis. This may determine how well sediments retain 
contaminants and prove a vital variable for consideration. It may also determine how 
easily these contaminants are decomposed or remobilized and even have an effect on 
sediment pH and salinity.  
It is important to assess the pH and salinity of samples which was an objective which 
was unable to be considered in this study for logistical reasons. These were that the 
equipment were not available at the time I required and it was needed for these to be 
collected at each sampling opportunity. This is something that must be considered in 
further work.  
Measuring water turbidity may prove beneficial as there may be a relationship for 
example; in Summer months there is an increased water turbidity due to increased 
recreational activity on the river and therefore leads to increased PPCP concentration in 
water samples compared to sediment samples at this time of year. Installing a flow 
meter at each sampling location to measure constantly which would increase temporal 
variation in results. Higher flow data collection will increase knowledge of how PPCPs 
move through the water column and how easily they move within a small area.  
Processes which affect the distribution of PPCPs should be considered. For example 
how easily degradable they are in sediment once settled. It would be interesting to 
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conduct a study of the selected pharmaceutical compounds on a sample core from each 
of the sample sites. Sedimentation rate would determine the timescale of this deposition 
with an insight further into temporal variability.  
Future concentrations in sediment (and water) in the locations considered in this 
investigation cannot be inferred. They are dynamic in nature and a considerable number 
of variables determine their distribution and fate.  
Lastly but most importantly, if the study were to take one further direction for this work, 
I would consider developing a method for the successful removal of these nine target 
pharmaceutical compounds simultaneously from sediment samples. I feel that now these 
can be successfully and reliably detected and measured in sediment samples, the next 
logical step would be to develop a way to effectively remove these from the 
environment. This would in turn ensure and enable certain aquatic areas to be deemed 
safe for activities such as aquaculture and not pose a threat to marine (or in turn human) 
life.  
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Chapter 8 - Appendices 
 
8.1 Appendix 1  
Particle size analysis of River Ouse samples using a HORIBA particle size analyzer. 
These begin on the following page.  
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8.2 Appendix 2 
Temperature and relative humidity for three sample storage conditions. 
  
Room Freezer Fridge 
Temperature 
(°C) 
Humidity 
(%RH) 
Temperature 
(°C) 
Humidity 
(%RH) 
Temperature 
(°C) 
Humidity 
(%RH) 
17/02/2010 21.8 21.9 -18.6 23.4 5.5 19.8 
18/02/2010 21.6 29.6 -19.5 32.3 5.4 26.9 
19/02/2010 21.4 24.5 -19.4 26.7 5.4 22.2 
20/02/2010 20.3 24.3 -20.0 26.5 5.3 21.9 
21/02/2010 20.5 30.8 -20.3 33.9 5.3 27.9 
22/02/2010 21.7 31.5 -19.1 34.5 5.4 28.1 
23/02/2010 22.2 28.4 -18.7 31.1 5.4 25.8 
24/02/2010 22.6 35.7 -19.3 39.6 5.9 32.8 
25/02/2010 22.8 36.2 -20.5 40.9 5.7 33.5 
26/02/2010 22.9 28.9 -20.4 32.1 5.6 26.5 
27/02/2010 23.0 32.4 -20.4 36.4 5.7 30.1 
28/02/2010 23.2 28.9 -20.4 32.3 5.7 26.6 
01/03/2010 22.7 25.2 -20.7 28.0 5.8 23.0 
02/03/2010 22.6 24.5 -20.9 27.3 5.8 22.5 
03/03/2010 22.7 20.9 -20.8 23.0 5.7 18.9 
04/03/2010 23.2 19.8 -20.5 21.6 5.7 17.7 
05/03/2010 22.4 18.8 -20.8 20.7 5.8 16.9 
06/03/2010 22.9 20.5 -20.8 22.6 5.8 18.6 
07/03/2010 20.8 16.1 -21.5 17.5 5.7 14.3 
08/03/2010 22.1 17.9 -21.2 19.8 5.7 16.2 
09/03/2010 22.7 22.1 -20.9 24.4 5.7 20.4 
10/03/2010 22.7 21.4 -20.7 23.7 6.0 19.8 
11/03/2010 22.5 20.8 -20.8 22.8 5.7 18.9 
12/03/2010 22.4 24.3 -21.0 27.0 5.7 22.8 
13/03/2010 22.2 26.9 -21.1 29.7 5.7 25.1 
14/03/2010 22.7 24.1 -21.0 26.5 5.7 22.9 
15/03/2010 22.9 25.7 -20.7 28.5 5.7 23.9 
16/03/2010 23.0 22.5 -20.4 24.7 5.7 20.4 
17/03/2010 23.0 30.1 -20.5 33.5 5.7 28.4 
18/03/2010 22.8 30.5 -20.5 33.7 5.7 28.0 
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19/03/2010 23.3 40.2 -20.1 45.2 6.1 37.5 
20/03/2010 23.5 40.0 -19.9 45.2 6.2 36.8 
21/03/2010 23.1 33.4 -20.0 37.0 6.0 30.4 
22/03/2010 23.0 32.5 -20.1 36.1 6.0 30.3 
23/03/2010 22.3 34.1 -20.3 37.9 6.0 33.0 
24/03/2010 22.4 38.6 -20.3 43.4 5.9 38.1 
25/03/2010 22.9 41.9 -20.0 47.3 6.2 40.1 
26/03/2010 23.2 33.1 -20.1 37.2 6.3 30.4 
27/03/2010 22.9 34.4 -20.3 38.4 6.2 31.6 
28/03/2010 22.8 34.6 -20.3 38.7 6.2 31.7 
29/03/2010 22.9 39.8 -20.0 44.5 6.2 36.6 
30/03/2010 23.0 34.1 -20.0 38.0 6.2 31.1 
31/03/2010 23.0 26.3 -20.3 28.9 6.2 23.7 
01/04/2010 22.7 24.0 -20.6 26.4 6.2 21.5 
02/04/2010 22.6 31.3 -20.5 34.9 6.2 28.8 
03/04/2010 22.7 31.2 -20.4 35.3 6.2 29.9 
04/04/2010 22.6 27.9 -20.6 30.8 6.2 26.5 
05/04/2010 22.6 30.8 -20.7 34.4 6.1 29.7 
06/04/2010 22.7 31.1 -20.5 34.4 6.2 28.9 
07/04/2010 22.9 34.6 -20.5 38.8 6.2 31.6 
08/04/2010 23.4 26.6 -20.3 29.4 6.4 24.1 
09/04/2010 23.4 27.9 -20.3 31.1 6.6 25.5 
10/04/2010 23.4 28.7 -20.3 31.9 6.5 26.2 
11/04/2010 23.4 25.5 -20.3 28.3 6.4 23.2 
12/04/2010 23.3 27.3 -20.3 30.4 6.5 25.0 
13/04/2010 23.0 26.4 -20.4 29.3 6.2 24.0 
14/04/2010 23.0 25.9 -20.6 28.8 5.5 23.7 
15/04/2010 23.1 26.6 -20.6 29.6 5.5 24.4 
16/04/2010 23.0 26.1 -20.5 28.9 5.5 23.8 
17/04/2010 22.7 26.4 -20.6 29.4 5.6 24.1 
18/04/2010 22.7 26.3 -20.5 29.2 5.5 24.0 
19/04/2010 23.0 28.6 -20.3 31.9 5.5 26.3 
20/04/2010 23.2 25.7 -20.0 28.2 5.6 23.2 
21/04/2010 22.2 22.9 -20.8 25.2 5.6 20.4 
22/04/2010 22.9 23.9 -20.7 26.5 5.5 20.9 
23/04/2010 22.9 24.6 -20.7 27.4 5.5 21.5 
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8.3 Appendix 3 
Standard deviation of temperature and humidity data collected. 
  
Room Freezer Fridge 
Temperature 
(°C) 
Humidity 
(%RH) 
Temperature 
(°C) 
Humidity 
(%RH) 
Temperature 
(°C) 
Humidity 
(%RH) 
17/02/2010 0.3 0.6 0.6 1.1 1.2 1.2 
18/02/2010 1.2 3.3 0.5 3.7 0.9 3.4 
19/02/2010 1.0 2.4 0.4 2.8 0.9 2.5 
20/02/2010 1.1 1.5 0.4 1.9 0.8 1.9 
21/02/2010 1.4 3.7 0.6 4.0 0.9 3.5 
22/02/2010 1.1 3.7 0.8 4.6 0.9 4.2 
23/02/2010 0.8 1.8 1.1 2.3 0.9 2.2 
24/02/2010 0.4 1.2 0.7 1.9 1.8 1.9 
25/02/2010 0.2 1.1 0.4 1.5 0.9 1.8 
26/02/2010 0.2 4.4 0.4 5.1 1.0 4.5 
27/02/2010 0.1 0.7 0.3 1.0 0.8 1.5 
28/02/2010 0.2 1.8 0.3 2.2 0.8 2.3 
01/03/2010 0.5 0.8 0.4 1.0 0.8 1.2 
02/03/2010 0.8 1.6 0.4 2.0 0.7 1.8 
03/03/2010 0.8 2.8 0.4 3.5 0.8 3.0 
04/03/2010 0.5 2.7 0.4 3.2 0.8 2.8 
05/03/2010 1.0 1.2 0.5 1.7 0.9 1.6 
06/03/2010 0.4 4.1 0.4 4.8 0.7 4.0 
07/03/2010 1.7 1.0 0.7 1.3 0.7 1.3 
08/03/2010 1.2 2.4 0.5 2.9 0.8 2.5 
09/03/2010 0.8 1.2 0.5 1.4 0.9 1.7 
10/03/2010 0.7 1.1 0.4 1.4 1.2 1.8 
11/03/2010 0.4 1.4 0.3 1.7 0.9 1.4 
12/03/2010 0.6 4.0 0.3 4.7 0.8 3.5 
13/03/2010 0.6 1.8 0.3 2.2 0.8 1.7 
14/03/2010 0.3 1.6 0.2 1.9 0.8 1.8 
15/03/2010 0.2 1.7 0.4 2.0 0.8 1.8 
16/03/2010 0.2 1.5 0.3 2.0 0.8 1.9 
17/03/2010 0.2 3.2 0.3 3.7 0.9 3.2 
18/03/2010 0.4 3.6 0.3 4.2 0.8 3.7 
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19/03/2010 0.3 1.2 0.4 1.8 0.9 2.1 
20/03/2010 0.2 1.5 0.3 2.0 0.6 2.1 
21/03/2010 0.2 2.0 0.3 2.3 0.8 2.2 
22/03/2010 0.1 2.0 0.4 2.6 0.8 2.6 
23/03/2010 0.7 4.4 0.4 5.3 0.8 4.9 
24/03/2010 0.6 2.9 0.5 3.6 0.8 3.1 
25/03/2010 0.3 4.3 0.4 5.0 0.8 4.9 
26/03/2010 0.2 0.6 0.4 0.9 0.7 1.3 
27/03/2010 0.2 2.4 0.2 2.9 0.7 2.7 
28/03/2010 0.2 3.0 0.1 3.6 0.7 3.2 
29/03/2010 0.2 1.4 0.4 1.7 0.7 1.8 
30/03/2010 0.2 4.3 0.4 5.1 0.7 4.3 
31/03/2010 0.2 2.2 0.3 2.6 0.7 2.4 
01/04/2010 0.2 1.8 0.4 2.2 0.7 2.0 
02/04/2010 0.1 1.8 0.3 2.2 0.7 2.0 
03/04/2010 0.1 1.4 0.4 2.4 0.7 1.6 
04/04/2010 0.1 4.3 0.4 5.1 0.7 4.4 
05/04/2010 0.2 4.9 0.4 5.8 0.7 5.1 
06/04/2010 0.2 1.7 0.4 2.2 0.7 2.8 
07/04/2010 0.6 1.9 0.4 2.3 0.6 1.9 
08/04/2010 0.2 2.5 0.3 3.0 0.6 2.5 
09/04/2010 0.1 1.4 0.3 1.6 0.6 1.6 
10/04/2010 0.1 1.6 0.2 2.0 0.6 1.9 
11/04/2010 0.1 1.3 0.3 1.6 0.6 1.5 
12/04/2010 0.2 0.8 0.3 0.9 0.7 1.1 
13/04/2010 0.1 1.8 0.3 2.1 0.8 2.0 
14/04/2010 0.2 1.4 0.4 1.7 0.9 1.8 
15/04/2010 0.1 2.5 0.4 3.1 1.0 2.8 
16/04/2010 0.1 1.1 0.3 1.4 0.9 1.6 
17/04/2010 0.2 1.5 0.4 1.7 1.0 1.8 
18/04/2010 0.1 1.1 0.3 1.3 1.0 1.6 
19/04/2010 0.2 3.0 0.3 3.6 0.9 3.3 
20/04/2010 0.2 4.3 0.3 5.0 0.9 4.6 
21/04/2010 1.0 2.2 0.4 2.6 1.0 2.4 
22/04/2010 0.2 2.1 0.4 2.6 1.2 2.9 
23/04/2010 0.2 2.0 0.4 2.5 1.0 2.3 
 
